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Thesis summary 
Over 50% of clinically-marketed drugs target membrane proteins; in particular G protein-
coupled receptors (GPCRs). GPCRs are vital to living cells, performing an active role in many 
processes, making them integral to drug development.  In nature, GPCRs are not sufficiently 
abundant for research and their structural integrity is often lost during extraction from cell 
membranes.  
The objectives of this thesis were to increase recombinant yield of the GPCR, human adenosine 
A2A receptor (hA2AR) by investigating bioprocess conditions in large-scale Pichia pastoris and 
small-scale Saccharomyces cerevisiae cultivations. Extraction of hA2AR from membranes using 
novel polymers was also investigated. 
An increased yield of hA2AR from P. pastoris was achieved by investigating the methanol 
feeding regime.  Slow, exponential feed during induction (µlow) was compared to a faster, 
exponential feed (µhigh) in 35 L pilot-scale bioreactors. Overall hA2AR yields were increased for 
the µlow cultivation (536.4pmol g
-1
)
 
compared to the µhigh148.1 pmol g
-1
. hA2AR levels were 
maintained in cytotoxic methanol conditions and unexpectedly, pre-induction levels of hA2AR 
were detected. Small-scale bioreactor work showed that Design of Experiments (DoE) could be 
applied to screen for bioprocess conditions to give optimal hA2AR yields. Optimal conditions 
were retrieved for S. cerevisiae using a d-optimal screen and response surface methodology. 
The conditions were 22°C, pH 6.0, 30% DO without dimethyl sulphoxide. A polynomial 
equation was generated to predict hA2AR yields if conditions varied.  
Regarding the extraction, poly (maleic anhydride-styrene) or PMAS was successful in 
solubilising hA2AR from P. pastoris membranes compared with dodcecyl-β-D-maltoside 
(DDM) detergent. Variants of PMAS worked well as solubilising agents with either 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) or cholesteryl hemisuccinate (CHS). 
Moreover, esterification of PMAS improved solubilisation, suggesting that increased 
hydrophobicity stabilises hA2AR during extraction. 
Overall, hA2AR yields were improved in both, P. pastoris and S. cerevisiae and the use of novel 
polymers for efficient extraction was achieved. 
 
Keywords: Yeast; human adenosine A2A receptor, methanol-induction, poly (maleic anhydride-
styrene), Design of Experiments 
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A2AR  Adenosine A2A receptor 
APS  Ammoniun persulphate 
BCA   Bicinchoninic acid 
Bmax   Maximum binding capacity 
BMGY  Buffered complex glycerol medium 
BMMY  Buffered complex methanol medium 
BSA  Bovine serum albumin 
BSM  Basal salts medium 
FM22  Fermentation Medium 22 
PTM  Pichia trace metals 
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DMEM  Dulbecco‘s Modified Eagle‘s medium 
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DMSO   Dimethyl sulphoxide 
DNA   Deoxyribonucleic acid 
DO   Dissolved oxygen concentration 
DO   Drop out solution 
DTT   Dithiothreitol 
E. coli   Escherichia coli 
EC50  Half the effective concentration  
ECL   Extracellular loop   
GC  Gas chromatography 
GFP   Green fluorescent protein 
GPCR   Guanine nucleotide-binding protein coupled receptor 
3
H  Tritium 
hA2AR  Human adenosine A2A receptor 
HEK  Human embryonic kidney cells 
HEPES  (2-[4-(2-hydroxyethyl) piperazin-1-yl]ethanesulfonic acid) 
ICL   Intracellular loop 
Kd   Concentration of ligand required to bind half of the receptors 
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Ki  Concentration of competing ligand required to bind half of the receptors 
LB   Luria-Bertani 
MEK  Methyl ethyl ketone 
MFC   Mass flow controller 
NECA  5'-N-Ethylcarboxamidoadenosine 
Ni-NTA  Nickel nitrilotriacetic acid  
OD   Optical density 
PAGE   Polyacrylamide gel electrophoresis 
PBS   Phosphate buffered saline 
PBST   Phosphate buffered saline Tween 20 
PEI  Poly(ethylenimine) 
pH   Negative logarithm of the hydrogen ion concentration 
PID  Proportional – integral - deriviative 
pKd  - log10 of Kd 
pKi  - log10 of Ki 
PMAS  Poly (maleic anhydride-styrene) 
P. pastoris  Pichia pastoris 
PTFE  Polytetrafluoroethylene 
S. cerevisiae  Saccharomyces cerevisiae 
SCADA Supervisory control and data acquisition software 
SDS   Sodium dodecyl sulphate 
SMA  Styrene maleic anhydride co-polymer 
SMALP Styrene maleic acid lipid particle 
T   Time 
TAE  Tris acetate EDTA 
TEMED  N,N,N',N'-tetramethyl- ethane-1,2-diamine 
TEV   Tobacco etch virus 
TM   Transmembrane domain 
Tris   Tris(hydroxymethyl)aminoethane 
Tween 20  Polyoxyethylene sorbitan monolaurate 
UPS  Uninterruptable power supply 
v/v   Volume/volume 
WT   Wild type 
w/v   Weight/volume 
XAC  Xanthine amine congener 
YPD   Yeast peptone dextrose 
YPDS   Yeast peptone dextrose sorbitol 
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YNB   Yeast nitrogen base 
ZM241385 4-(2-(7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5- 
  ylamino)ethyl)phenol 
µ  Specific growth rate 
λexe  Excitation wavelength 
λem  Emission wavelength 
Units 
°C  Celsius 
fmol  Femtomole  
g  Gram 
g  Gravitational force 
Hz  Hertz 
h   Hour 
kDa   Kilo Dalton 
Kg  Kilogram 
L   Litre 
mg   Milligram 
min   Minute 
mL   Millilitre 
mmol  Millimole 
mol   Mole 
ms  Millisecond 
nM   Nanomolar 
nm  Nanometre 
Nm  Newton metre 
nmol  Nanomole 
pmol  Picomole 
psi  Pounds per square inch 
RCF  Reactive centrifugal force 
RFU  Relative fluorescence units 
rpm   Revolutions per minute 
s   Second 
U  Units 
V  Volts 
vvm  Volume per volume per  minute 
µL  Microlitre 
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µg  Microgram 
µM  Micromolar 
Amino acids 
Table 1 Standard amino acid abbreviations. Standard amino acid abbreviations used 
interchangeably throughout text. 
Amino acid 3-letter 1-letter Amino acid 3-letter 1-letter 
Alanine Ala A Leucine Leu L 
Arginine Arg R Lysine Lys K 
Asparagine Asn N Methionine Met M 
Aspartic acid Asp D Phenylalanine Phe F 
Cysteine Cys C Proline Pro P 
Glutamic acid Glu E Serine Ser S 
Glutamine Gln Q Threonine Thr T 
Glycine Gly G Tryptophan Trp W 
Histidine His H Tyrosine Tyr Y 
Isoleucine Ile I Valine Val V 
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Chapter 1: Introduction 
1.1. Overview  
Over 50% of clinically marketed drugs target membrane proteins; in particular G-protein 
coupled receptors (GPCRs) (Gudermann et al., 1995). GPCRs are vital to living cells due to 
their active role in many cellular processes, including signal transmission. Many diseases centre 
on the action of these GPCRs, making an understanding of their structures and functions 
integral to drug design (Flower, 1999). In nature, GPCRs are not sufficiently abundant for such 
studies and their structural integrity is often lost during extraction from the cell membrane. 
Therefore, a major challenge pharmaceutical industries face is to reproducibly produce high 
yields of structurally stable recombinant GPCRs (Baker, 2010, Flower, 1999). 
This thesis is concerned with a specific GPCR - recombinant human adenosine A2A receptor 
(hA2AR) - and aims to improve the tractability of its production in yeast. The research focussed 
on two main areas: the bioprocess of yeast cultures and the extraction of hA2AR from yeast cell 
membranes. For the bioprocess aspect, the work was further divided into two areas: an 
examination of feeding regimes and their impact on hA2AR production in the yeast, Pichia 
pastoris, and an investigation into optimising hA2AR production conditions in the yeast, 
Saccharomyces cerevisiae via a statistical Design of Experiments (DoE) approach. For the 
extraction aspect, novel polymers called poly (maleic anhydride-styrene) (PMAS) were used to 
solubilise recombinant hA2AR from P. pastoris membranes to investigate an alternative to 
detergent solubilisations.  
1.2. Recombinant protein production in a commercial environment 
Sir Alexander Fleming‘s discovery of penicillin from a common mold in 1928 and its 
subsequent development for use in World War II for treatment of injured soldiers prompted the 
need to produce the organism in large quantities in tanks of broth, thereby signifying the 
beginnings of pharmaceutical biotechnology (Rhodes, 1985). Several decades later, in the 
1970s, gene cloning and recombinant DNA technology were developed and define modern day 
pharmaceutical biotechnology (Doran, 1995). Recombinant DNA technology provides a 
solution to producing proteins in non-native host cells. In general, recombinant protein 
production is performed if the native protein of interest is present low quantities, if the protein 
of interest is innately unstable or if mutant forms of the protein are required for in vitro studies 
(Schmidt, 2004, Doran, 1995).  In terms of clinical and pharmaceutical use, recombinant 
proteins are essential for the development of drugs (either as drugs or drug targets), the 
engineering of antibodies and enzymes as well as other therapeutic protein production e.g. 
insulin, human growth hormone. In fact, in the U. S. market alone, the volume of recombinant 
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protein products on sale recently is more than $ 50-60 billion (Schmidt, 2004). Also, it is not 
only the large pharmaceutical companies that develop, produce and market recombinant protein 
products, but many small and medium enterprises (SMEs) follow the recombinant protein 
production business model (Repasi, 2013). SMEs tend to focus on a single disease area and 
develop therapies and drugs. Their popularity is increasing since the world financial crisis 
started in the late 2000s and big pharmaceutical companies began outsourcing and downsizing 
(Repasi, 2013). Notable recombinant protein products include erythropoietin (developed by 
Janssen), insulin (developed by Novo-Nordisk) and Hepatitis B vaccine (developed by Glaxo 
Smith Kline) (Doran, 1995, Schmidt, 2004, Demain and Vaishnav, 2009).  
Typically, recombinant protein production involves amplifying a DNA sequence which encodes 
a protein of interest. It is inserted into an appropriate vector and then transformed or transfected 
into the chosen host cell. The combination of the DNA encoding the gene of interest, usually 
from another organism, and the vector DNA results in a recombinant DNA product and hence 
the protein that is produced by the cells is termed a recombinant protein (Doran, 1995).   
1.2.1. Challenges in recombinant protein production for commercial use 
 The demand for therapeutic and prophylactic recombinant protein treatment continues to 
increase (Schmidt, 2004). Yet, new challenges present themselves with regards to recombinant 
protein production using current technologies. On a commercial stance, many applications 
would benefit from higher production efficiencies with a better quality of product whilst 
lowering the costs of the final product (Doran, 1995).  
Common issues encountered with recombinant protein production include loss of expression 
caused by structural changes or disappearance of the recombinant gene; issues in post-
translational processing including protein mis-folding, protein aggregation, proteolytic 
processing and glycosylation, depending on the host system used (Mattanovich, 2012). 
Strategies are usually in place to minimise these unwanted effects of recombinant protein 
production in a commercial setting in order to maximise quality product at a low cost whilst 
increasing yield (Schmidt, 2005). These include optimising bioreactor operations such as 
controlling the temperature, pH and aeration delivered to the host organism which is producing 
the recombinant protein (section 1.3.3.); (Schmidt, 2004, Schmidt, 2005, Doran, 1995). In this 
thesis, Chapter 3 investigates this approach by applying it to recombinant hA2AR production in 
yeast. Another strategy routinely employed to overcome issues in recombinant protein 
production in a commercial setting are by applying induction strategies and controlling growth 
of the host organism (section 1.2.2.2. and 1.3.4.); (Potvin et al., 2012). This is addressed in 
Chapter 4 of this thesis where controlling the induction feeding regimes of yeast producing 
hA2AR are examined.  
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20-30% of all open reading frames encode for membrane proteins (Wallin and Heijne, 1998). 
The largest family of membrane proteins,  GPCRs,  transduce extracellular stimuli into 
intracellular signals and are therefore vital drug targets when implicated in disease making them 
attractive proteins for pharmaceuticals to study (Gudermann et al., 1995, Flower, 1999). Since 
membrane proteins are not secreted out of the cell and are embedded in the cell membrane, 
extraction of the recombinant protein must be performed in order for further study to be carried 
out; this comes with its own challenges (section 1.4.); (Seddon et al., 2004). Chapter  5 studies 
the use of a novel compound to improve extraction of recombinant hA2AR from yeast 
membranes.  
1.2.2. Yeast as a host system for recombinant protein production - Saccharomyces 
cerevisiae and Pichia pastoris 
S. cerevisiae (Figure 1.1) is more commonly referred to as Bakers‘ or Brewers‘ yeast and its 
uses span beer, wine and bread making (Lodolo et al., 2008), being a model organism in 
molecular biology (Botstein, 1997), being a biological tool for studying aging (Longo et al., 
2012) and as a host system for recombinant protein production (Mattanovich, 2012). It has been 
classified as ‗Generally Regarded As Safe‘ or GRAS by the FDA in the U.S.A. and is regularly 
used in food stuff production (Mattanovich, 2012).  
P. pastoris (Figure 1.2) was first reported along with other yeast species, Candida, Hansenula 
and Torulopsis by Koichi Ogata and colleagues in 1969 to utilise methanol as a sole carbon 
source (Ogata, 1969) . They coined the term ‗methylotroph‘ to describe these types of yeast.  At 
the beginning of the 1970s, acquiring methanol from methane was a cheap process; therefore 
these species were an attractive source of single cell protein (SCP) for animal feed (Cregg, 
1985).  However, later in the 1970s a global oil crisis occurred and the cost of methane 
increased and the use of SCP was abandoned. Phillips Petroleum, USA subsequently developed 
the first recognised methods and protocols for culturing P. pastoris to high cell densities using 
methanol (Wegner, 1990) and it has since been utilised as a popular host system (available from 
Life Technologies Corporation) for recombinant protein production due to its regulated alcohol 
oxidase (AOX) promoter (Cereghino and Cregg, 2000) .  
31 
 
 
Figure 1.1 Confocal microscopy image of S. cerevisiae cells. The cells shown are producing a 
membrane protein tagged with recombinant green fluorescent protein and are actively budding. 
The cells are approximately 5-10 µm in size and were taken on a Leica TCS SP5 confocal 
microscope at 100× magnification (Image provided by Dr. Debasmita Sarkar, Aston 
University). 
 
Figure 1.2 Confocal microscopy image of P. pastoris cells. Cells are secreting recombinant 
green fluorescent protein, are actively budding and are approximately 5-10 µm in size and were 
taken on a Leica TCS SP5 confocal microscope at 100× magnification (Image provided by Dr. 
Sarah Routledge, Aston University). 
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1.2.2.1. The microbiology of S. cerevisiae and P. pastoris 
Saccharomyces cerevisiae and Pichia pastoris are eukaryotic organisms belonging to the Fungi 
kingdom, the Ascomycota phylum and the Saccharomycetaceae family. S. cerevisiae belongs to 
the Saccharomyces genus and P. pastoris belongs to the Komagatella genus (Dujon, 2010). This 
was originally the Pichia genus but was re-classified after phylogenetic sequencing was 
performed (Mikata and Yamada, 1995) but is still frequently referred to as Pichia.  
S. cerevisiae and P. pastoris are between 5-10 µm in size and can reproduce sexually and 
asexually(Herskowitz, 1988). It is more common for the cells to reproduce asexually which is 
known as ‗budding‘(Herskowitz, 1988). There are three cell types for S. cerevisiae and P. 
pastoris, a type, α type and a/α type and all of them are capable of undergoing mitotic cell 
division or budding. The haploid cells (a and α) can however mate giving rise to diploid cells 
and these diploid cells can undergo meiosis and yield haploid cells via the production of spores 
(Herskowitz, 1988). For both, it is known that if nitrogen is limited when the cells are under 
stress, sexual reproduction can occur (Shen et al., 1998). 
Yeast has a three component cell envelope comprising the cell wall, the periplasmic space and 
the plasma membrane (Walker, 1998). The function of this envelope is to keep the yeast cell 
intact and to protect the cell. It also regulates and enables transport of material in and out of the 
cell. The yeast periplasmic space is very thin (~ 35-45 Å) with the cell wall residing externally 
to it and the plasma membrane internally to it. The space contains secreted proteins called 
mannoproteins. These are unable to permeate the cell wall but perform functions such as 
hydrolysis of substrates (Walker, 1998). 
The cell wall is present in yeast, which is a major difference between yeast and mammalian 
cells. The cell wall needs to be removed before any membrane protein extraction can take place. 
Methods include enzymatic removal with zymolase, lyticase or helicase. These resulting 
structures are termed spheroplasts or protoplasts and are useful for whole cell immunological 
studies. For example, Bonander and colleagues in 2013 used protoplasts of P. pastoris cells 
expressing the recombinant tetraspanin CD81 (Bonander et al., 2013). In some instances, the 
enzymatic removal of the cell wall is not appropriate as the enzyme can interfere with 
extracellular loops of GPCR structures (Salazar and Asenjo, 2007). Therefore the cell wall is 
removed by mechanical means by either glass bead agitation or high pressure homogenisation 
(Darby et al., 2012). The cell wall is 100-200 nm thick and consists of glucans, mannans or 
mannoproteins and less so, chitins. The β-(1,6) and β-(1,3)-glucans give strength to the cell wall 
by forming a microfibrillar network. The mannans include α-1,6 linked inner core with α-1,2 
and α-1,3 side chains. The chitin, which is a polymer of N-acetylglucosamine is mainly located 
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in the bud scars and only found in 2-4% of the cell wall (Zinser and Daum, 1995). Figure 1.3 
shows a representation of a yeast cell wall. 
 
 
Figure 1.3 Yeast cell wall. Picture shows a representation of a yeast cell wall with the glucan, 
mannan or mannoproteins and chitin constituents. Image also shows the periplasmic space and 
plasma membrane. Adapted from Zinser & Daum, 1995. 
S. cerevisiae has a respiro-fermentative metabolism if in the presence of a fermentable carbon 
source such as glucose (ethanol is the by-product). Once the glucose has been consumed, a 
diauxic shift occurs where the respiro-fermentative metabolism switches to respiration and the 
cells start to consume the ethanol (Al-mhanna, 2010, Werner‐Washburne et al., 1996). S. 
cerevisiae is a Crabtree positive yeast (De Deken, 1966, Díaz-Ruiz et al., 2008) since it can 
ferment glucose in the presence of oxygen. P. pastoris is Crabtree negative and is strictly 
aerobic, utilising glucose or glycerol as a carbon source, which is metabolised via the glycolytic 
pathway; glycerol is phosphorylated by a cytosolic glycerol kinase to 3-phosphoglycerol. This is 
then oxidised to dihydroxyacetone by FAD-dependent glycerol phosphate ubiquitone 
oxidoreductase and is then used in pyruvate synthesis and gluconeogenesis. In recombinant 
protein production, glycerol is typically chosen for biomass generation since P. pastoris has a 
high glycerol uptake rate (Cereghino and Cregg, 2000).  
In addition to glycerol and glucose, as mentioned earlier, P. pastoris has the capacity to 
metabolise methanol. Two AOX genes encode enzymes that metabolise methanol. AOX1 
accounts for more than 85% of the methanol metabolism activity. AOX2 possesses the same 
specific activity as AOX1 but has a much lower expression level and is therefore the weaker 
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Mannoprotein
β-Glucan
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Mannoprotein
Periplasmic space
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promoter (Daly and Hearn, 2005). The methanol utilisation pathway for P. pastoris is complex 
and is represented in Figure 1.4. 
 
 
Figure 1.4 Methanol metabolism in P. pastoris. Diagrammatic representation of the Pichia 
pastoris peroxisome outlining the methanol metabolism pathway. Red boxes indidcate name 
of enzyme involved in reaction. DHA is dihydroxyacetone and GAP is glyceraldehyde-3-
phosphate.  
 
 P. pastoris first oxidises methanol to formaldehyde by the action of a flavoprotein, AOX, whose 
expression is strongly suppressed by carbon sources such as glucose, glycerol and ethanol but is 
induced in the presence of methanol. The reaction occurs within specialised compartments 
called peroxisomes and generates hydrogen peroxide. This metabolic by-product is toxic to the 
cell and it is subsequently catalysed by hydrogen peroxidase, into water and oxygen (Gellissen, 
2000).  
The formaldehyde generated from the breakdown of methanol enters a cytosolic dissimilatory 
pathway where it is catalysed to generate energy for the cells, as well as simultaneously 
activating an assimilatory pathway which results in an increase in cellular biomass. During this 
assimilatory pathway, residual formaldehyde reacts with xylulose-5-monophosphate and is 
catalysed to dihydroxyacetone and glyceraldehyde-3-phosphate by dihydroxyacetone synthase 
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(DAS). These products leave the peroxisome and are used to regenerate xylulose 5-
monophosphate and glyceraldehyde-3-phosphate (Gellissen, 2000, Cereghino and Cregg, 2000).  
1.2.2.2. Growth characteristics of S. cerevisiae and P. pastoris 
A typical growth curve for S.cerevisiae and P. pastoris consists of a lag, log or exponential and 
a stationary phase. The lag phase is where the cells adapt to grow on the carbon source. The 
exponential phase is the where the cells grow in a doubling manner. The stationary phase is 
when the cells stop increasing in number due to limiting nutrient availability and build-up of 
toxins and waste products (Werner‐Washburne et al., 1996). From the exponential phase, the 
specific growth rate can be calculated. This is defined as the increase in cell mass per unit time 
(h
-1
) and can be described by the equation:  
  
where  = cell biomass, t = time and µ = specific growth rate (h
-1
) 
Upon integration, the equation becomes: 
xt = x0e
µt 
where x0 is the original cell biomass, xt is the cell biomass after time (t) and e is the base of the 
natural logarithm. If the natural logarithm is taken for all the cell biomass values, a straight line 
plot should be achieved and hence the specific growth rate, µ, can be resolved with the 
following equation: 
y = mx + c 
where c = the y intercept when x is 0 and m is the slope or gradient of the line. In this instance, 
m = µ or the specific growth rate (Stanbury, 1988). 
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Figure 1.5 Theoretical growth curve of microbial cells. The curve shows the lag, acceleration, 
log, decline, stationary and death phases. For each phase the specific growth rate (µ) is 
predicted to be either equal or approximate to 0 or less than or approximate to the maximum 
growth rate (µmax).(Adapted from Doran, 1995). 
Figure 1.5 shows a theoretical representation of a yeast growth curve. The cells are initially in 
the lag phase and this is where they are adapting to the new medium environment and so there is 
little or no growth, giving rise to a specific growth rate which is approximately zero (µ ≈ 0). 
Next is the acceleration phase and this is where the cells start growing and therefore the specific 
growth rate is less than the maximum growth rate (µ < µmax). The third phase is the log or the 
exponential phase where the cells achieve their maximum growth rate and so the specific 
growth rate is approximately equal to the maximum growth rate (µ ≈ µmax). This phase is 
important as it forms the linear part of the curve and hence specific growth rate data can be 
derived from this section. The decline phase shows that the cells start to slow down in growth 
due to nutrient limitation and build-up of toxins and therefore the specific growth rate is less 
than the maximum specific growth rate (µ < µmax). In the stationary phase, growth ceases and 
therefore the specific growth rate is equal to zero (µ = 0). The final phase is the death phase 
where the cells start to lyse and die and so the specific growth rate is in theory less than zero (µ 
< 0) (Doran, 1995).  
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1.2.2.3. Genomic characterisation and strain selection of S. cerevisiae and P. pastoris 
S. cerevisiae was the first eukaryotic organism to be sequenced in 1996 (Goffeau et al., 1996). 
The genome‘s annotations are regularly updated and can be viewed on the World Wide Web 
(www.yeastgenome.org). The sequence includes ~12000 kb and from those, ~5900 protein 
encoding genes. It was found that approximately, 140 genes were ribosomal RNA; 40 genes 
were small nuclear RNA molecules and 275 genes were transfer RNA genes. The sequencing 
project also organised the 16 chromosomes (Goffeau et al., 1996). 
The P. pastoris genome has been fully sequenced more recently and it has been estimated that it 
is 9.7 Mbp in total and organised into four chromosomes and one mitochondrial genome (De 
Schutter et al., 2009, Mattanovich et al., 2009).  Some of the main findings which came from 
this project were that although all the genes coding for enzymes and their promoters involved in 
methanol metabolism were identified, there were no common sequence motifs or promoter 
organisation. Many of the endogenous signal sequences for the secretory pathways of P. 
pastoris were revealed and many sequences of vacuolar and secreted proteases were reported, 
thereby aiding the development of protease deficient strains (De Schutter et al., 2009, 
Mattanovich et al., 2009). 
Both S. cerevisiae and P. pastoris genomes have sequences for 2 homologs of low affinity sugar 
transporters genes but P. pastoris has 4 H
+
/glycerol transporters present and S. cerevisiae do not 
(De Schutter et al., 2009). It was also found that where the 5S rRNA gene was localised to the 
rDNA locus in the S. cerevisiae genome, 21 copies of the same gene were located across the 
entire length of all the chromosomes for P. pastoris (De Schutter et al., 2009). The genomic 
sequencing of P. pastoris revealed a multitude of endogenous signal sequences. This mitigates 
the use of the alpha-mating factor signal sequence from S. cerevisiae which is frequently 
employed to induce Sec61p-mediated translocation of protein in the endoplasmic reticulum of 
P. pastoris during recombinant protein production (Prabha et al., 2009). The sequencing also 
confirmed that many highly immunogenic terminal α-1 3-mannosyl glycotypes were present for 
S. cerevisiae but were not detected at all in the P. pastoris genome (Bretthauer and Castellino, 
1999, De Schutter et al., 2009).  
Consideration should be given to the S. cerevisiae and P. pastoris strains selected for 
recombinant protein production. P. pastoris has three major strain backgrounds based on their 
methanol metabolising phenotypes and subsequent strain types with additional phenotypes are 
based on these three. They are the wild-type methanol utilisation plus phenotype (Mut
+ 
); a 
strain with deleted a AOX1 gene, so only the AOX2 gene is active, which is termed a methanol 
utilisation slow phenotype (Mut
S
); and a third strain with a deletion of both the AOX1 and AOX2 
genes resulting in a methanol utilisation minus phenotype (Mut
-
) (Daly and Hearn, 2005).  Table 
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1.1 lists the common P. pastoris strains used in recombinant protein production and their 
phenotypes. 
Table 1.1 P. pastoris strains commonly used in recombinant protein production and their 
phenotypes. In this thesis, the X33 and SMD1163 strain were used. Adapted from (Bora, 2012). 
Strain Phenotype 
X-33 Mut
+ 
His
+
 
GS115 Mut
+ 
His
-
 
KM71 Mut
s
 His
-
 Arg
+
 
SMD1163 
Mut
+
 His
-
 , proteinases A, B and 
carboxypeptidase Y deficient 
SMD1165 Mut
+
 His
-
 , proteinase B deficient 
SMD1168 
Mut
+
 His
-
 , proteinase A and carboxypeptidase 
Y deficient; partial reduction in proteinase B 
activity 
MC100-3 Mut
-
 His
-
 
 
For S. cerevisiae a plethora of strains are available for use in recombinant protein production. A 
set of single, non-essential gene deletion strains are available from EUROSCARF as well as a 
collection of tetracycline-regulated essential genes (Open Biosystems).  S. cerevisiae 
yTHCBMS1 is a strain from the tetracycline-regulated gene strain and is used in Chapter 3 since 
it is therefore considered a high-yielding strain. Bonander and colleagues (Bonander et al., 
2005) showed that 39 host cell genes‘ expression levels were significantly altered when Fps1, a 
glycerol facilitator, was produced under high yielding conditions compared to standard growth 
conditions. This included elevated levels of BMS1 (involved in ribosome biogenesis). Further 
studies showed that tuning the amount of BMS1 transcript levels by varying doxycycline 
amounts had an effect on the yields of other functional proteins such as hA2AR and also soluble 
GFP (Bonander et al., 2009). Another strain that was considered high-yielding and is used in 
Chapter 3 is the S. cerevisiae TM6* strain developed by Otterstedt and colleagues (Otterstedt et 
al., 2004). This strain was produced by integrating a gene encoding for a chimeric hexose 
transporter which mediates decreased sugar uptake into the genome of hexose transporter null 
yeast strain and is called TM6* (Otterstedt et al., 2004). It is fully respiratory and does not 
switch to fermentative metabolism even at high glucose concentrations. This leads to a higher 
biomass yield thereby increasing production of recombinant proteins. Commercially, this strain 
is available as AlcoFree™ (Cereduce, Sweden) and is used in heterologous protein production, 
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fine chemical productions and alcohol-free production of beers and wines (Henricsson et al., 
2005).  
1.2.2.4. S. cerevisiae and P. pastoris as cell factories for recombinant protein production 
Both S. cerevisiae and P. pastoris are excellent host systems for recombinant protein production 
as they are cheap to cultivate, can grow to high biomass yields and can perform post-
translational modifications (Darby et al., 2012).  Such modifications include disulphide bond 
formation, glycosylation (both O-linked and N-linked), phosphorylation, acetylation and 
acylation of the recombinant protein and would not be possible in prokaryotic systems such as 
E. coli (Bonander and Bill, 2012). However, it is important to consider that the type of 
glycosylation carried out by S. cerevisiae differs from that in mammals. For example, O-linked 
oligosaccharides carry only mannose moieties rather than sialylated O-linked chains (Bretthauer 
and Castellino, 1999). S.cerevisiae is known to hyperglycosylate N-linked sites which 
potentially modify binding sites leading to altered immunogenic responses in therapeutic 
applications (Gerngross, 2004). However there is an added advantage when glycosylation is 
carried out the in the P. pastoris host, where the oligosaccharides are shorter in length 
(Bretthauer and Castellino, 1999). Furthermore, a strain has been developed that can produce 
terminally sialylated humanised proteins (Li et al., 2006).   
Table 1.2 summarises the differences between S. cerevisiae and P. pastoris as host systems for 
recombinant protein production and Table 1.3 shows some examples of recombinant protein 
production for clinically relevant proteins that target specific diseases in both S. cerevisiae and 
P. pastoris. 
Table 1.2 Comparison of some main characteristics of S. cerevisiae and P. pastoris. 
Characteristic S. cerevisiae P. pastoris 
Industrial application Yes Yes 
Recombinant protein products Yes Yes 
Food grade (GRAS) Yes No 
Annotated genome Yes Yes 
Metabolism Respiro-fermentative Aerobic 
Secretion efficiency Low High 
Hyperglycosylation Yes No 
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Table 1.3 Examples of clinically relevant recombinant proteins produced from S. cerevisiae or P. 
pastoris host cells. Table section highlighted in grey colour show recombinant proteins produced as 
biopharamceuticals in either S. cerevisiae or P. pastoris. Table section in white show recombinant 
proteins as drug targets produced in etiher S. cerevisiae or P. pastoris. 
S. cerevisiae Disease targeted P. pastoris Disease 
targeted 
 
Insulin (Lindholm et 
al., 2002) 
Diabetes 
Angiostatin 
(Chen et al., 2010) 
Cancer 
treatments 
B
io
p
h
a
rm
a
ce
u
tica
ls 
Interferon-α-2a, 
hepatitis B surface 
antigen (Ryff, 1993) 
Hepatitis B 
Anti-HBs Fab fragment 
(Ning et al., 2003) Liver diseases 
Human papilloma 
virus vaccine 
(Siddiqui and Perry, 
2006) 
Papilloma virus 
Granulocyte-
macrophage colony-
stimulating factor 
(hGM-CSF) (Pal et al., 
2006) 
Non-Hodgkin‘s 
lymphoma, HIV, 
Crohn‘s disease 
Human α(2)-
adrenergic receptor 
subtype 2C (Blaxall 
et al., 1991) 
Hypertension, 
vasoconstriction 
Tetanus toxin fragment 
C (Clare et al., 1991) Tetanus 
M5 muscarinic 
acetylcholine 
receptor (Huang et 
al., 1993) 
Central and 
peripheral nervous 
system diseases e.g. 
Parkinson‘s 
Human µ-opioid 
receptor (Sarramegna 
et al., 2002) 
Receptor for 
analgesia 
D
ru
g
 ta
rg
ets 
Rat adenosine 2A 
receptor (Price et al., 
1996) 
Heart disease, 
inflammation, 
cancer, epilepsy 
Human dopamine D2S 
receptor (de Jong et al., 
2004) 
Depression, 
psychosis, 
Parkinson‘s 
Human adenosine 2A 
receptor (hA2AR) 
(Ferndahl et al., 
2010) 
Heart disease, 
inflammation, 
cancer, epilepsy 
Human muscarinic 
acetylcholine receptor 
M2 sub-type (CHRM2) 
(Asada et al., 2011) 
Heart disease 
SERCA1a (Jidenko 
et al., 2005) 
Malaria 
Human histamine H1 
receptor complex with 
doxepin (Shimamura et 
al., 2011) 
Inflammation, 
allergies 
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1.2.3. Molecular biological considerations  
When a target protein is chosen for recombinant production, its DNA sequence is usually 
amplified via PCR from genomic DNA or cDNA or the gene can be synthesised. It is then 
cloned into a suitable expression vector within an expression cassette which contains a yeast 
promoter and a termination sequence (Darby, 2010). The vector is a vehicle by which the target 
DNA can be introduced into the yeast strain of choice by transformation (Mattanovich, 2012). 
Transformation can be carried out by spheroplast preparation (Burgers and Percival, 1987); 
lithium acetate preparation (Gietz and Woods, 2002) or electroporation (Sanchez et al., 1993).  
The target DNA sequence is usually designed with sequences to encode for purification tags and 
signal sequences and the complete sequence is termed as a DNA construct. When designing 
constructs for target proteins, it is valuable to design sequences for several tags which aid in the 
purification and detection of the protein. The most common tags used for these types of proteins 
are poly-histidine, FLAG, haem-agglutinin, Biotin and c-myc tags (Terpe, 2003). Larger fusion 
proteins are increasingly used for recombinant membrane protein production, and these include 
green fluorescent protein (GFP) (Drew et al., 2005), maltose binding protein (MBP)(Duplay et 
al., 1984, di Guana et al., 1988), thioredoxin (TRX)(LaVallie et al., 1993) or glutathione-S-
transferase (GST)(Taylor et al., 1994, Smith and Johnson, 1988). They are used to improve 
stability as certain proteases such as the E.coli FtsH complex can degrade proteins from their 
free amino (N-) or carboxy (C-) ends (Wagner et al., 2006, Mancia et al., 2004). Tucker and 
Grisshammer tested various combinations of fusion proteins and tags in an attempt to improve 
recombinant MBP-neurotensin (NTR) receptor production and they found that a fusion with 
TRX significantly improved the yields of the receptor (Tucker and Grisshammer, 1996). Other 
studies found that a combination of an N- terminal MBP and a poly-histidine tagged C- terminal 
TRX fusion protein was successfully used to produce the cannabinoid 2 receptor and the 
adenosine receptor in E. coli (Yeliseev et al., 2005, Weiß and Grisshammer, 2002).  
GFP is 24kD, naturally occurring secreted protein that was first isolated from Pacific jellyfish 
where it interacts with another protein called aequorin to produce green light.  Since its 
discovery, it has been extensively used for recombinant protein studies to assist in localisation 
of target proteins. There are many variations of the recombinant version of GFP, but the wild 
type version has a major excitation peak at 395 nm and an emission peak at 509 nm (Prasher, 
1995).  
1.2.3.1. Vector choices and promoters for S. cerevisiae  
There are a number of expression vectors available and for S. cerevisiae that may be episomal 
or integrative (Darby, 2010). Promoter sequences and selection markers are usually included in 
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the vector. The promoters can be categorised as inducible or constitutive. Inducible promoters 
prompt target protein expression when an inducer is added to the culture medium, thereby 
controlling the recombinant protein production.  Constitutive promoters allow continuous 
expression of the target protein and therefore offer less control. There are three inducible 
promoters for S. cerevisiae; GAL1, ADH2 and CUP1(Schneider and Guarente, 1991). The main 
constitutive promoter available for S. cerevisiae is the triose-phosphate isomerase (TPI) 
promoter (Zhang et al., 1996). 
 
1.2.3.2. Vector choices and promoters for P. pastoris 
P. pastoris vectors tend to be integrative. Integrative vectors allow the target DNA to 
homologously recombine into the host genome and can be quite stable. However, most 
transformants often exhibit heterogeneous expression levels and therefore extensive colony 
screening is required (Darby et al., 2012). The types of promoters available for P. pastoris 
vectors like S. cerevisiae vectors can be either inducible or constitutive. AOX1 is a tightly 
regulated, inducible promoter used in P. pastoris host systems and is induced in the presence of 
methanol. Although this is the most common promoter to be exploited, it does come with 
disadvantages, such as the need to use toxic and flammable methanol. Therefore alternative 
promoters have been investigated (Cos et al., 2006a). These include constitutive expression via 
the glyceraldehyde 3-phosphate dehydrogenase (GAP) promoter (Waterham et al., 1997, Kim, 
2009) whilst strong induction via the formaldehyde dehydrogenase (FLD1) promoter has also 
been reported in the presence of methylamine as well as methanol (Resina et al., 2005) Figure 
1.6 shows a typical P. pastoris expression vector system from Life Technologies Corporation. It 
shows an example of the pPICZ series of vectors for P. pastoris systems.  
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Figure 1.6 pPICZα expression vector series map from Life Technologies Corporation. 
Showing AOX1 promoter, terminator and a choice of multiple cloning sites.  
This vector includes an α-factor signal sequence. It is thought that the presence of this sequence 
may improve the chances of a membrane protein being inserted into the yeast membrane via the 
yeast secretory pathway. This signal peptide is derived from the S. cerevisiae mating factor α1 
(MFα1) (Weiss et al., 1998). This peptide contains a ‗pre‘ and ‗pro‘ protein signal which are 22 
and 61 residues, respectively. In the endoplasmic reticulum, the pre-protein signal is cleaved by 
peptidases and then the pro-protein signal is cleaved by the cells‘ Kex proteases in the Golgi 
apparatus. It is important to note that if these signal sequences are not cleaved, the activity of 
the membrane protein may be compromised (Zhang et al., 2007). 
1.3. Recombinant protein production in yeast: from clone to culture 
Once the molecular biology of the target protein and successful transformation has occurred into 
the yeast cell, a change in discipline is required where microbiology and bioengineering are 
given thought in order to produce the highest yield and quality of the target protein from yeast 
cultures.  
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1.3.1. Screening for high yielding clones 
Traditionally, colony screening and screening for the best culture environmental conditions for 
recombinant protein production are carried out in shake flasks or deep well plates. This is a 
cheap and quick method to ascertain optimal growth and production conditions for the target 
protein in question. However, when it is time to scale-up the growth to larger bioreactors, the 
conditions do not necessarily translate. This is due to the lack of control and monitoring of 
environmental conditions available when grown in shake flasks (Schapper et al., 2009). 
Therefore the development of culture vessels with the capability of control and monitoring at a 
small scale and high throughput level is an attractive option. The Micro-24 microreactor (Pall 
Corporation) is a technology which encompasses this by enabling temperature, pH and 
dissolved oxygen (DO) control and monitoring for 24 5-10 mL bioreactors in a plate well 
format. Figure 1.7 shows the Micro-24 microreactor set-up at Aston University. 
 
 
Figure 1.7 Micro-24 microreactor at Aston University. Photograph on the left shows the 24 
well plate of individually controlled mini bioreactors. Photograph on the right shows the plate 
sitting inside the instrument. 
The Micro-24 wells can be controlled individually for temperature, pH and DO and also be run 
in parallel. In the bottom of each well, DO, pH optical sensors, a sparging port and thermal 
conduction pads are present to provide control and monitoring. The pH and DO of the culture 
are controlled by a set point by sparging gas through the medium, in this instance, O2 for DO 
and CO2 or ammonium hydroxide gas for pH. Figure 1.8 shows the online monitoring capability 
of all the individual wells for temperature, pH and DO. 
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Figure 1.8 Micro-24 microreactor software screen shot. Screen-shots show the real-time 
collection of the data for DO in this instance (left side of screen). On the right side, real-time 
plots are constructed for a specific well for temperature, pH and DO. 
With access to such technology, it is feasible to more systematically establish optimal 
recombinant protein production conditions or parameters such as temperature, pH and DO for a 
host cell. Chapter 3 uses this technology to improve hA2AR yields in S. cerevisiae strains. 
 
1.3.2. Culture vessels 
Once a high-yielding clone has been identified, recombinant proteins produced in yeast can be 
generated in shake flasks or bioreactors (sometimes referred to as fermenters). Shake flasks are 
a laboratory standard consumable and small scale screening of recombinant protein production 
tends to begin using these vessels. However, they do not allow control and monitoring of culture 
parameters such a temperature, pH, and DO of the culture medium but bioreactors do. 
Bioreactors are culture vessels of varying size and allow control of these parameters via control 
of input gases and air supplies, acid, base and temperature which are monitored via probes and 
sensors. Set-points of a desired input condition are entered and the bioreactor software and 
controllers maintain the set-points. The difference between bench-top and pilot-scale bioreactors 
is minimal and the main difference is the vessel capacity (Baumann et al., 2010, Schmidt, 2005, 
Abad et al., 2010). Bench-top bioreactors typically have a culture capacity between 1-10 L and 
pilot-scale bioreactors have a culture capacity between 10-100 L. An example of a bench-top 
bioreactor set-up at Aston University is shown in Figure 1.9 and an example of a pilot-scale 
bioreactor at AstraZeneca Ltd, is shown in Figure 1.10. 
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Figure 1.9 Bench-top 2 L bioreactor set-up at Aston University. Photograph shows 2 L vessel 
with growing P. pastoris culture and acid, base and methanol feed pumps. 
 
Figure 1.10 Pilot-scale 35 L bioreactor set-up at AstraZeneca Ltd. Photograph shows 35 L 
vessel with growing P. pastoris culture. Several pumps are employed for acid, base, feed and 
anti-foam addition via the use of controller software. 
1.3.3. Bioprocessing parameters 
The use of bioreactors is vital when developing the production of a recombinant protein. They 
allow the precise control of temperature, pH, aeration and addition of carbon source. This is 
important to achieve in order to maximise recombinant protein yields but also to maintain the 
Stirrer motor
Sample port line
Feed pump
Jacketed vessel
Feed bottle
DO probe
pH probe
Acid/base pumps
P. pastoris culture
Base
Acid
Temperature probe
pH probe
DO probe
Sampling port
Entry lines for feed, acid, 
base and antifoam
Peristaltic pumps
concentrated H2SO4
25% NH4OH
Carbon source feed (glycerol
Or methanol)
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integrity of the protein. Such requirements are essential in industrial, pharmaceutical and 
commercial settings (Macauley-Patrick et al., 2005).  
1.3.3.1. Temperature 
It is important to maintain optimal temperature for growth of any micro-organism. For yeast, 
this is 30°C. However, the optimal temperature for growth is not necessarily the same as that for 
recombinant protein production (Cos et al., 2006a). For example for the recombinant production 
of hA2AR, the temperature is usually lowered to 22°C at the induction phase of P. pastoris 
cultivation (Singh et al., 2008, Singh et al., 2010). Constrastingly, the optimal recombinant 
production of the human tetraspanin, CD81 in P. pastoris was found to be at growth 
temperature of 30°C (Bonander et al., 2013). 
1.3.3.2. pH 
pH is an important factor that must be considered when growing yeast as an optimal pH will aid 
in high biomass and recombinant protein production (Routledge, 2012). A desired set-point is 
often stated, so that the pH is maintained. Often the pH will change as the yeast grows (usually 
metabolites are released creating an acidic environment during yeast growth); therefore it is 
important for a system to maintain it. Optimal pH will give high yields for growth and 
recombinant protein expression (Çalık et al., 2010). For secreted proteins, the pH will also have 
an effect on their stability via their iso-electric point (pI) (Schmidt, 2005). 
1.3.3.3. Dissolved oxygen concentration (DO) 
Yeast require oxygen as they grow and this requirement can be met in bioreactors by supplying 
external air and oxygen directly into the culture medium. The amount of dissolved oxygen (DO) 
is a measure of the oxygen available to the growing culture (Visser et al., 1990). The air flow 
rate is regulated via a mass flow controller and air bubbles enter the vessel through a sparger at 
the vessel base. Impellers then disperse the bubbles and the oxygen dissolves in the medium as 
the bubbles travel up the surface of the culture medium. DO in the medium can be increased in 
three ways; by increasing the stirrer speed, by increasing the airflow and by increasing the 
oxygen-enriched airflow. A ‗cascade‘ mechanism can be employed where each method can be 
activated in turn until the DO set-point is reached and maintained (Visser et al., 1990, Schmidt, 
2005).   
1.3.3.4. Additives 
Chemical additives can be added to a defined culture medium to further assist in maximising 
recombinant protein yields. Murata and colleagues (Murata et al., 2003) showed that dimethyl 
sulphoxide (DMSO) can change cell membranes physically and therefore have a downstream 
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effect on intracellular biochemical pathways. This was further investigated to see if the presence 
of DMSO in yeast culture medium had an effect on GPCR yields. It was reported that the 
binding activity of more than half of the GPCRs in an expression screen were increased in the 
presence of DMSO (Andre et al., 2006, Lundstrom et al., 2006). 
1.3.3.5. Antifoams 
Antifoams are almost always required when using bioreactors since continuous stirring will 
cause the formation of bubbles and foam in the culture and this can have a detrimental effect on 
recombinant protein production. Routledge and colleagues carried out an extensive study on the 
effects of antifoams for bioreactor and shake flask cultures and showed that specific antifoam 
agents could increase GFP yields in P. pastoris cultures (Routledge and Bill, 2012, Routledge et 
al., 2011). 
1.3.4. P. pastoris bioreactor cultivations 
P. pastoris is often cultured in media with non-limiting amounts of a repressing carbon source 
such as glycerol to generate biomass, followed by an induction period with limiting amounts of 
methanol. The distinct feeding phases of P. pastoris tend to follow the specific growth rate 
trends for the typical growth described. During the first or batch phase, cells grow at their 
maximum growth rate (µmax) (section 1.2.2.2) until the initial carbon source, typically glycerol, 
has been depleted. In a subsequent fed-batch phase, the same carbon source is fed continuously 
with the objective of yielding high pre-induction biomass; during this phase, growth is nutrient 
limited and a constant specific growth rate, lower than µmax, is achieved. A transition phase, 
when the glycerol feed is stopped and the cells are monitored for glycerol depletion, allows the 
cells to adapt to low concentrations of inducer (typically methanol); in some cases temperature 
changes are also applied to facilitate induction at a temperature optimised for a given target 
protein. Finally, in the induction phase, methanol is added in a controlled manner to induce 
AOX1-driven recombinant protein production (Cereghino and Cregg, 2000) (Minning et al., 
2001). Figure 1.11 illustrates this cultivation process for P. pastoris. 
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Figure 1.11 Typical P. pastoris bioreactor cultivation for recombinant protein production. 
Theoretical growth curve shows the batch phase where the cells adapt to the glycerol carbon 
source (lag phase). In the fed-batch phase, glycerol is continuously fed in order to increase the 
cell biomass. The induction phase is carried out with controlled addition of methanol (once all 
the glycerol has been consumed) to induce target protein production. 
Although the simple addition of methanol to a P. pastoris culture induces protein production, 
careful consideration must be given to its addition rate and duration as methanol can be toxic to 
the cells if accumulation occurs within the culture (Guarna et al., 1997). Conversely insufficient 
methanol will result in sub-optimal protein yields; therefore it is imperative to strike the optimal 
balance (Thorpe et al., 1999). The general ―rule-of-thumb‖ is that the concentration of methanol 
within the culture should be maintained below 5 g L
-1
 to avoid cyto-toxicity (Guarna et al, 
1997). Although it is common practice to induce expression in P. pastoris cultures solely using 
methanol, some reports have demonstrated increased protein yields by inducing with a mixed 
feed of glycerol and methanol (d'Anjou and Daugulis, 2000, Jungo et al., 2007) and sorbitol and 
methanol (Cos et al., 2006b) (Holmes et al., 2009). It is possible that both these strategies 
decrease the potential toxicity to the yeast cells caused by methanol overload as well as 
permitting enhanced biomass generation in the induction phase compared with a solely 
methanol fed system. 
Since the specific growth rate of P. pastoris during the induction phase can influence both 
recombinant protein and cell biomass yields, a theoretical constant specific growth rate (µset) 
can be applied to a P. pastoris cultivation, in a ―feed forward strategy‖, to control methanol 
uptake (Potvin et al., 2012).  
 
x 
B
io
m
a
ss
Batch 
(glycerol)
Fed-batch cell accumulation
(glycerol) 
Induction of protein 
production 
(methanol)
B
io
m
a
ss
50 
 
The equation upon which these calculations can be made is: 
 
where F(t) is the feed rate (g h
-1
) at time, t (h); Fo is the initial feed rate and µset is the desired 
theoretical constant specific growth rate (h
-1
). 
For example, (Celik et al., 2009) reported that when producing recombinant human 
erythropoietin (hEPO) in P. pastoris, higher protein yields were achieved at µset = 0.03 h
-1
 than 
µset = 0.02 h
-1
, while the cell biomass yield was lower. This strategy, which employed a mixed 
feed of methanol and sorbitol, gave similar results to another study by the same team on the 
recombinant production of human growth hormone (Celik et al., 2010). Notably, hEPO appears 
to have been produced prior to the onset of the methanol feed in these studies (Celik et al., 
2009). Three other studies also demonstrated the effect of specific induction phase growth rates 
on recombinant soluble protein yields (Kobayashi et al., 2000, Zhang et al., 2000). While this 
suggests that the yield of a given soluble target protein may increase as a function of µset, the 
reasons for this are not fully understood. It could be, as previously reported by Holmes and 
colleagues, that there is a requirement to match the methanol feeding strategy with the 
metabolic capacity of the cells, as exemplified by the recombinant production of soluble green 
fluorescent protein (GFP); (Holmes et al., 2009).  
Few, if any, detailed studies have been published on the influence of the methanol feed profile 
during the induction phase for membrane proteins. This contrasts with the numerous studies on 
the influence of parameters such as the temperature and pH of the culture, the amount of 
dissolved oxygen (DO) in the culture medium and, specifically, the addition of chemical 
additives and ligands for optimal GPCR production in the pre-induction and induction phases of 
P. pastoris cultivations (Andre et al., 2006, Cos et al., 2006b, Schmidt, 2005, Lundstrom et al., 
2006, Singh et al., 2010). Notably, Singh and colleagues observed active hA2AR in bioreactor 
cultures prior to the methanol feed (Singh et al., 2008), while this was not apparent in shake 
flasks (Singh et al., 2012). These findings are especially noteworthy as glycerol is a known 
repressor of the AOX1 promoter: glycerol, glucose, ethanol and acetate have all been shown to 
support growth of P. pastoris cells without inducing the AOX1 promoter (Inan and Meagher, 
2001). An example of this, is work by Hellwig and colleagues in 2001 who demonstrated that 
glycerol in the culture medium inhibited production of a recombinant single-chain antibody in 
mixed feed bioreactor cultures.  They also noted that ethanol and acetate  accumulated (Hellwig 
et al., 2001). 
In Chapter 4, the impact of set growth rates (µset) on hA2AR production in P. pastoris 
cultivations are investigated during the induction phase. 
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1.3.5. The application of Design of Experiments (DoE) for recombinant protein production  
Statistical Design of Experiments (DoE) is a concept that is frequently applied in process 
optimisation in the biotechnology and other industries.  It provides an effective way of 
investigating the impact of multiple conditions whilst reducing the overall number of 
experiments and not compromising the quality of the data (Mandenius and Brundin, 2008). DoE 
was first proposed by Sir Ronald A. Fisher in 1935 as an alternative to the changing of ‗one 
factor at a time‘ (OFAT) approach, which is time consuming and costly. He based his approach 
on the statistical method ‗analysis of variance‘ (ANOVA). This concept was further developed 
in the 1950s by Genichi Taguchi to improve the quality of manufactured goods and now the 
Taguchi DoE method is used (along with other developed DoE methods) in biotechnology. In 
particular, DoEs are viewed as integral components of industrial bioprocess development and 
are recognised as valid methods by the US Food and Drug Administration (Bora et al., 2012). 
Information on the relationship between the parameter temperature and the response e.g. 
specific binding activity of a receptor, is derived in the form of an equation. This means that it is 
not necessary to carry out all the possible experimental combinations of the parameters since the 
equation will predict outcomes of a response if the statistics of the DoE model are robust. For 
example, Holmes and colleagues investigated increasing GFP yields in P. pastoris by exploring 
temperature, pH and DO as input parameters and found that with the use of a DoE only 13 
experimental combinations were required out of a possible 27 and furthermore since the model 
was statistically robust, the equation generated was able to predict accurate responses (Holmes 
et al., 2009).  
1.3.5.1. Factors, levels and responses for a DoE set-up 
A typical DoE set-up includes the input factors (also referred to as conditions or parameters 
interchangeably) to be tested usually at a number of levels with a number of replicates specified 
in a design matrix. Factors are usually variables that have defined set-points, e.g. temperature, 
pH, DO or the components of a growth medium. Input factors may also be an ‗attribute‘ e.g. the 
presence or absence of a medium component at a specific level. Other factors referred to as 
‗noise factors‘ should be considered in the DoE as they distort the data. Their effects can be 
minimised by applying ‗blocking‘ or ‗randomisation‘ in a DoE (Bora et al., 2012, Isar et al., 
2007).   
The simplest DoE designs are ones where the factors are studied at 2 levels only, a high and low 
level. They are known as 2
k 
designs and the levels can be coded as +1 for the high level and -1 
for the low level in a design matrix. The levels can vary in number and in general more than 2 
levels will enable detection of non-linear relationships (Burdick et al., 2005). However, the 
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levels should be considered carefully as certain levels may not be biologically practical to be 
performed such as very low pH levels or very high temperatures.  
A response in a recombinant protein production experiment is typically protein yield, protein 
activity, culture density or biomass and tends to be a continuous variable. Once the response has 
been generated by running the specific experimental combinations of input factors as defined by 
the matrix, statistical analysis is used to fit this response to a model which is either linear or 
non-linear. The effect of each input factor on this response is determined quantitatively and the 
amount of error in the model is calculated to see if there is a significant lack of fit (Bora et al., 
2012).  
1.3.5.2. DoE process screening  
The DoE steps are usually screening, characterisation and optimisation for recombinant protein 
production (Bora et al., 2012). Screening designs are used to reduce the initial number of input 
factors that are to be tested, for example if there are between 4-12 or more. Alternatively, a 
screen could test 3-5 input factors for a more detailed study. Usually, full factorial designs are 
run at the screening stage (Montgomery, 2006). They take into account all the input factors in 
the experiments and all the possible combinations associated with them. Because of this they 
tend to require many experimental runs; however the results retrieved are valuable as they can 
give information regarding any main effects or interactions between factors (Bora et al., 2012, 
Mandenius and Brundin, 2008). Figure 1.12 illustrates the concept of a full factorial design 
when compared to an OFAT approach. More of the response surface is covered by carrying out 
a full factorial design compared to the OFAT approach. 
 
Figure 1.12 One Factor At a Time (OFAT) versus full factorial design. Graph on left shows 
X1 variable versus X2 variable. If either X1 or X2 are varied and the other is kept constant, 5 
separate experiments would need to be performed. This is called achieving the ‘quasi-optimum’ 
and the correct optimum is never reached. The graph on the right however, shows that if 
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simultaneous variations were carried out for both X1 and X2 the true optimum may be found by 
software analysis. Taken from Mandenius & Brundin, 2008. 
Fractional factorials take a ‗fraction‘ of the full factorial experiments in order to reduce the 
number of experiments to be run, however this impacts the design power of the model as certain 
experimental runs will be missing from the design matrix (Figure 1.13); (Mandenius and 
Brundin, 2008); (Chen et al., 1993).  
 
 
 
  
 
 
 
Figure 1.13 Fractional factorial design. 3 variables X1, X2 and X3 investigated at only 4 points 
in the design space, a high and low level for each variable. Taken from Mandenius & Brundin, 
2008. 
Other screening designs are available such as Plackett-Burman designs (Vindevogel and Sandra, 
1991) (Montgomery, 2006)  where only 2 levels are investigated for each factor (Plackett-
Burman) and the number of experimental runs are reduced via a computer based method (d-
optimal) (de Aguiar et al., 1995).  
1.3.5.3. DoE process characterisation and optimisation 
The process characterisation goal is to identify and quantify the influence of the key factors 
(established from the screening designs) in order to improve the bioprocess by predicting an 
optimal response under a range of operating conditions via an equation. Process optimisation 
involves zooming in on a particular portion of the design space or by exploring any non-linear 
behaviour (e.g. quadratic behaviour) that was observed in the previous stages. This is achieved 
by carrying out a response surface methodology (RSM) (Montgomery and Myers, 1995). Box-
Behnken, Composite Face Centred (CCF) or a Central Composite Circumscribed (CCC) are 
different examples of RSM designs (Mandenius and Brundin, 2008). Figure 1.14 illustrates a 
CCF and CCC design where a 3 factor experiment is shown.  
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Figure 1.14 CCF design (left) and CCC design (right). For 3 factors including triplicate points 
in the centre of the design space (red spheres), corner points on the cube are black spheres and 
the face points are green spheres. Taken from Mandenius & Brundin, 2008. 
The design points for the CCC design appear to spread beyond the confines of the design space. 
Because of this, CCC may be a better design than CCF, as it covers more volume. Additionally, 
the CCC design covers 5 levels for each factor and hence will enable the investigation of the 
cubic response behaviour even more that the CCF design. Once the CCF or CCC experiments 
are run, a contour plot or a response surface plot be may be generated where the optimum can 
be clearly visualised (Mandenius and Brundin, 2008). 
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RSM allow a close examination of each factor and its interactions and what relationship exists 
between them. Data from one round of results in a model can provide information for an 
improved design in subsequent rounds. Table 1.4 gives examples of DoE used in bioprocess 
applications including recombinant protein production experiments. 
Table 1.4 Examples of DoE in bioprocess development. 
Protein  DoE goal DoE design used 
Recombinant GFP from P. 
pastoris 
Maximise GFP yield as a 
function of temperature, pH 
and DO in the culture medium 
RSM (Box-Behnken) 
(Holmes et al., 2009) 
Polyglutamic acid from 
Bacillus subtilis 
Maximise polyglutamic acid 
yield as a function of the 
composition of the growth 
medium 
Fractional factorial and RSM 
(Shi et al., 2006) 
Recombinant Fab′ fragment 
from E. coli 
Maximise Fab′ fragment yield 
as a function of agitation rate 
and DO in the culture medium 
Full factorial (2
2
) (García-
Arrazola et al., 2005) 
Clavulanic acid from 
Streptomyces clavuligerus 
Maximise clavulanic acid 
yield by optimising the 
composition of the growth 
medium 
Fractional factorial and RSM 
(Wang et al., 2005) 
Recombinant cystatin C 
mutant from P. pastoris 
Maximising yield and protein 
glycosylation as a function of 
three nitrogen sources 
Full factorial (2
3
) (Pritchett 
and Baldwin, 2004) 
Neomycin from Streptomyces 
marinensis 
Maximising neomycin yield 
by optimising the composition 
of the growth medium 
Full factorial and RSM 
(Adinarayana et al., 2003)  
 
1.4. The challenges of recombinant membrane protein production in yeast 
Producing recombinant membrane proteins is more challenging than producing recombinant 
soluble proteins. This is because recombinant membrane proteins must be inserted into the cell 
membrane in vivo, and then removed from the cell membrane for further downstream 
processing such as X-ray crystallography for structural determination. This is a difficult process 
as removing the membrane protein from the lipid bilayer generally causes the protein to lose its 
integrity (Kalipatnapu and Chattopadhyay, 2005). For G Protein-Coupled receptors (GPCRs), 
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the largest family of membrane proteins, various strategies have been used to overcome this 
difficulty and other issues associated with X-ray structural determination (Moraes et al., 2014). 
These include: recombinant membrane protein overexpression (Wagner et al., 2008, Drew et al., 
2005, Bonander et al., 2013, Fraser, 2006, Tate, 2001); novel solubilisation approaches with 
new detergents or chemicals (Prive, 2007, Chae et al., 2010, Serebryany et al., 2012, Knowles et 
al., 2009); improvement of protein stability via mutations, engineering of fusion partners and 
monoclonal antibodies (Tate and Schertler, 2009, Serrano-Vega et al., 2008, Serrano-Vega and 
Tate, 2009, Chun et al., 2012); automation and high-throughput screening of initial 
crystallisation conditions (Stevens et al., 2001) and synchrotron radiation and beamline 
developments (Duke and Johnson, 2010).  
1.4.1. The target protein: the GPCR, human adenosine A2A receptor (hA2AR) 
GPCRs moderate many physiological processes and are therefore targeted by many clinical 
drugs (Foord et al., 2005). The signalling pathways for these physiological processes are 
controlled by heterotrimeric guanine-nucleotide-binding proteins or G proteins constituting α, β 
and γ subunits. These proteins act as molecular switches by coupling the activation of GPCRs at 
the cell surface to intracellular signalling pathways. In the resting state, G proteins are inactive 
and Gα binds guanine diphosphate (GDP) and Gβγ. When extracellular stimuli such as 
hormones, neurotransmitters, chemokines, light or odourants activate the GPCR, a 
conformational change occurs in the receptor which allows G protein binding and GDP is 
released from the Gα sub-unit. This results in a more stable, high affinity complex between the 
activated receptor and the G protein. Guanine triphosphate (GTP) then binds to Gα and makes 
the complex unstable which leads to a dissociation of the α and βγ sub-units from the receptor. 
The Gα (GTP) and Gβγ sub-units interact with downstream effector proteins such as enzymes or 
channels that promote intracellular changes leading to a biological response. The Gα subunit 
then hydrolyses GTP to GDP and re-associates with Gβγ which completes the G protein cycle 
and ends the cellular response (Oldham and Hamm, 2006).  Figure 1.15 summarises G protein 
cycling. 
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Figure 1.15. Summary of G protein cycle. G proteins are heterotrimers of GDP-bound alpha 
(blue) beta (green) and gamma (yellow) subunits in the resting state. As an agonist (black) 
binds to the receptor (red) in the cell membrane, a conformational change results leading to G 
protein binding and subsequent GDP release. This is stable until GTP binding causes 
dissociation of R*, Gα (GTP) and Gβγ. The subunits then activate a variety of effector proteins 
(E, purple). The signal ends when GTP is hydrolysed to GDP by Gα and then maybe catalysed 
by RGS proteins (grey). 
 
Structurally, GPCRs possess seven transmembrane α-helices. These α-helices are connected by 
three intracellular loops (ICL) and three extracelluar loops (ECL); an intracellular carboxy or C-
terminus and an extracellular amino or N- terminus are also present (Ahuja and Smith, 2009, 
Congreve and Marshall, 2010). Within different GPCR families, there are many amino acid 
sequence similarities and conserved residues which has led to the identification of  motifs such 
as the DRY motif at the cytoplasmic end of the third transmembrane domain (Foord et al., 
2005). The extracellular portions of a GPCR may be subjected to biochemical modifications 
such as glycosylation and disulphide bond formation (Karchin et al., 2002, Jacoby et al., 2006). 
GPCRs can also interact with other proteins such as GPCR kinases (GRKs), arrestin molecules 
and receptor-activity modifiying proteins (RAMPs) which lead to specific actions such as 
trafficking (Brady and Limbird, 2002).  The first mammalian GPCR structure to be resolved via 
GTP
GDP
R*
α β γ
E
E
RGS
Pi
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crystallisation was bovine rhodopsin by Palczewski and colleagues (Palczewski, 2000). The 
next milestone for GPCR structure resolution was the human β2 adrenergic receptor 
(Rasmussen et al., 2007, Cherezov et al., 2007).  
Figure 1.16 shows a representation of a Family A GPCR with the transmembrane portion (the 7 
α-helices) embedded in the lipid bilayer of the plasma membrane and also ICLs and ECLs. 
Appendix A1 describes in more detail the other GPCR families and their characteristics 
(Bockaert and Philippe Pin, 1999). 
 
 
Figure 1.16 Diagrammatic representation of Family A GPCR. 7 cylindrical shapes in red 
outline represent 7 α-helices embedded in lipid bilayer (blue). Black lines represent ICLs (in the 
cell cytosol) or ECLs (outside the cell membrane). The ECL has the N-terminus and the ECL 
has the C-terminus (adapted from http://structbio.vanderbilt.edu/) 
 
The human adenosine A2A receptor (hA2AR) is a Family A or rhodopsin-like GPCR 
(Palczewski, 2000) and is 47 kDa in size. The hA2AR structure was first determined at a 2.6 Å 
resolution with the high-affinity antagonist ZM241385 bound. The receptor was recombinantly 
produced from S. frugiperda insect cells (Figure 1.17) (Jaakola et al., 2008). This was an 
example of a GPCR fusion protein where T4 lysozyme replaced the conformationally dynamic 
ICL3 between the TM helices V and VI. Table 1.5 summarises the hA2AR crystal structures that 
have been resolved since 2008. It can be seen that all the hA2AR receptors were recombinantly 
produced as fusion proteins and/or contained mutations and were additionally co-crystallised 
with ligands. This was necessary as the receptor is highly dynamic and therefore these 
modifications increased its stability. Xu and colleagues (Xu et al., 2011) resolved the first 
hA2AR structure with an agonist bound. Previously it had been shown that agonist-bound 
receptors formed poorly diffracting crystals due to highly increased dynamics of the receptor. 
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However, Xu and colleagues (Xu et al., 2011) showed that careful selection of the agonist, UK-
432097, which is a conformationally selective ligand, provided a less dynamic receptor for 
crystallisation trials.  Furthermore, they showed that agonist binding at the extracellular domain 
triggers only small changes at the binding pocket but generally led to large scale seven 
transmembrane rearrangement that is required for G protein binding. Lebon and colleagues 
(Lebon et al., 2011) crystallised two versions of the hA2AR with the bound agonists, adenosine 
and NECA.  These agonist bound forms were able to be crystallised due to a thermostabilised 
construct (A2AR-GL3) which contained 4 point mutations. In general, the structures revealed 
that when these agonists are bound to the receptor, the ligand binding pocket is narrowed or 
contracted due to the helices III, V and VII moving inwards. Dore et al., 2011 also used a 
different thermostable hA2AR construct (A2A-StaR2) for crystallising three structures with bound 
ZM241385 or the xanthines, XAC or caffeine. These structures showed inactive conformational 
states which were characterised by an ionic lock (a salt bridge) and the visibility of the third 
intracellular loop which is responsible for G protein coupling. Hino and colleagues (Hino et al., 
2011) reported the first crystal structure of hA2AR that was recominantly produced in P. 
pastoris, whereas all other structures were recombinantly produced in insect cell lines. The 
receptor was in complex with an antibody Fab fragment (Fab2838) which gave a stable, inactive 
conformation when bound to the antagonist, ZM241385 demonstrating that ICL3 did not need 
to be replaced with the T4 lysozyme fusion protein. The general features of the structure were 
that the Fab2838 recognised the intracellular surface of the hA2AR and that one of the 
complimentarity determining regions (CDR) of the Fab2838 locks the hA2AR in an inactive 
conformation. The most recent structure of hA2AR to be resolved was by Liu and colleagues 
(Liu et al, 2012) to an increased resolution of 1.80 Å, which was not previously achieved. Due 
to this higher resolution, more information regarding the water and lipid molecules was 
revealed. It was found that 57 ordered water molecules were present inside the receptor and 
formed three clusters. The middle cluster contained a sodium ion which was bound to the highly 
conserved aspartate residue. Furthermore it was found that two cholesterol molecules stabilised 
the helix VI conformation. One lipid from the 23 ordered lipids was present inside the binding 
pocket. Functional studies revealed that sodium ion binding and antagonist binding in hA2AR 
was non-competitive whereas agonist binding and sodium ion binding require different 
conformational states of the receptor for binding to occur. This suggests that the concentration 
of sodium ions affect functionally-relevant conformational states and therefore new ligands 
could be designed to exploit the sodium ion binding pocket (Gutiérrez-de-Terán et al., 2013).  
So far these structures have revealed novel information about the differences between active and 
inactive conformations as well as some atomic detail of water and lipid positions in the receptor. 
However, the need for higher resolution structures is increasingly desired as these can provide 
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more atomic level information which is highly valuable as demonstrated by Liu et al., 2011 and 
Gutiérrez-de-Terán et al., 2013. Furthermore, developing methods for stable forms of the 
receptor for crystallisation without native loops or sections being replaced with fusion proteins s 
sought after to investigate the receptor in as native-like form as possible. 
Table 1.5 Human adenosine A2A crystal structures resolved. The table summarises the 
resolution of the structure, the recombinant host from which the receptor was produced for 
crystallisation studies and the main features and findings of the structures.  
Reference Resolution (Å) Recombinant host Features 
(Xu et al., 2011) 2.71 S. frugiperda 
Agonist, UK-432097; 
T4 lysozyme inserted 
between helices V 
and VI; structural 
changes in helices III, 
V and VI compared 
to (Jaakola et al., 
2008) structure 
(Lebon et al., 2011) 3.00 Trichoplusia ni 
Agonist NECA and 
adenosine; 
thermostable receptor 
(Dore et al., 2011) 
3.60 S. frugiperda 
Caffeine bound; 
thermostable receptor 
3.30 S. frugiperda 
ZM241385 bound; 
thermostable versions 
of receptor 
3.31 S. frugiperda 
XAC bound; 
thermostable receptor 
(Hino et al., 2012) 2.70 P. pastoris 
ZM241385 bound; in 
complex with 
inverse-agonist 
antibody  (mouse 
Fab2838) 
(Liu et al., 2012) 1.80 S. frugiperda 
ZM241385 bound;  
apocytochrome b562 
replaces ICL3; 23 
lipids and 57 water 
molecules 
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Figure 1.17 Crystal structure of hA2AR with ZM241385 antagonist bound.  A. The 
transmembrane domain is coloured brown, ZM241385 is coloured light blue and the four lipid 
molecules bound to the receptor are coloured red. The four disulphide bonds are yellow. The 
extracellular loops (ECL1-3) are coloured green and the intracellular loops are coloured blue. 
The T4L is coloured as cyan. B. The molecule rotated 180° around the x-axis (image taken from 
Jaakola et al, 2008) 
The hA2AR has been implicated in diseases such as Parkinson‘s disease (Bara-Jimenez et al., 
2003), Huntington‘s disease (Cha, 2000), asthma (Luijk et al., 2008), epilepsy (Boison, 2005) 
and numerous other neurological disorders (Boison, 2008). In mammalian cells, its natural 
agonist is adenosine. There are  three other adenosine receptors including : the adenosine A1, 
A2b and A3 receptors (Fredholm et al., 2001). Adenosine is known to have role in reducing 
inflammation (Sitkovsky et al., 2004) and therefore the hA2AR is a target for therapeutic drugs 
treating diseases such as heart disease (Yang et al., 2006) and cancer (Stagg and Smyth, 2010). 
The main antagonists include caffeine, theophylline (a caffeine derivative) (Kulisevsky et al., 
2002), ZM241385 (Poucher et al., 1995), 5'-N-Ethylcarboxamidoadenosine (NECA) (Arslan et 
al., 1999) and xanthine amine congener (XAC) (Jacobson et al., 1992). 
1.4.1.1. Ligand-binding assay for hA2AR 
The hA2AR can be assayed accurately by ligand binding analysis (Singh et al., 2012). This is 
where known agonists or antagonists of the receptor can be radio-labelled and the amount of 
bound radioactivity can be measured (Hulme and Trevethick, 2010). 
Agonists are synthetic or naturally occurring compounds that bind to receptors and activate 
them, therefore triggering a response. Antagonists are compounds that bind to the same 
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receptors without causing activation and can therefore block the action of an agonist (Leach, 
2010). 
Most radio-ligand binding experiments are based on the law of mass action: 
 
where the ligand binds to the receptor to form a receptor - ligand complex. The rate at which the 
ligand binds to the receptor is defined by the association rate constant, kon. As this equation is 
reversible, one can also define the dissociation rate constant, koff. Equilibrium between 
association and dissociation is reached when the rate of formation of new receptor - ligand 
complexes equals the rate at which the receptor - ligand complexes dissociate (Motulsky, 1995). 
At equilibrium,the ratio of  kon and koff values can provide information regarding the strength of 
the ligand-receptor interaction and this is termed the equilibrium dissociation constant, Kd: 
 
Kd is equivalent to the concentration of ligand which binds 50% of the receptors. From this 
information, the Hill-Langmuir Binding Isotherm equation is derived: 
 
 
Where [ReceptorT] = [Receptor] + [Receptor ∙ Ligand] and Kd = koff / kon 
 
 
 
 
 
 
 
[Receptor ∙ Ligand] = 
[ReceptorT] x [Ligand]  
[Ligand] + Kd
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From the above fundamentals, three types of radio-ligand binding experiments are possible. In 
saturation binding experiments, the binding of an increasing concentration of radio-ligand, L, is 
measured at equilibrium to determine its binding constant (Kd) and the total number of the 
specific binding sites for the radio-ligand (Bmax). In competition binding experiments, a fixed 
concentration of radio-ligand is measured at equilibrium in the presence of increasing 
concentrations of non-labelled ligand. The data derived from this can determine the binding 
constant (Ki) of a compound for the un-liganded receptor using the Cheng – Prusoff equation: 
 
 
where Ki = dissociation constant; IC50 = the concentration of competing ligand that displaces 
50% of the specific binding of the radioligand and [Radio-ligand] = concentration of the radio-
ligand. Finally, kinetic binding experiments are where the binding of one or more 
concentrations of radio-ligand is measured at increasing time points to determine the association 
(kon) and dissociation (koff) rate constants (Hulme and Trevethick, 2010). For the purposes of 
this research both saturation and competition binding experiments were employed (Motulsky, 
1995). 
1.4.2. The yeast plasma membrane 
In order to understand the complexities of recombinant membrane protein production, it is 
important to understand the physical structure of the yeast plasma membrane as this is where the 
recombinant human membrane protein is inserted.  It is also important to distinguish the 
differences between yeast and mammalian plasma membranes (Spira et al., 2012). 
The yeast plasma membrane is about 7 nm thick with some cytosolic invaginations. It is a 
phospholipid bilayer with hydrophobic or non-polar (tails) and hydrophilic or polar (head) 
layers (Zinser and Daum, 1995, Spira et al., 2012). Figure 1.18 shows the chemical structure for 
the phospholipid in general (Figure 1.18A) where the hydrophobic tails are hydrocarbons of 
varying length that are attached to the hydrophilic head where a phosphate group is present. 
Figure 1.18B shows a simplified diagram of the phospholipid and Figure 1.18C shows how the 
phospholipid forms a bilayer in the plasma membrane.  
Ki = 
IC50
1 + [Radioligand] / Kd
64 
 
 
Figure 1.18 General structure of phospholipid. A) shows the chemical structure of the 
phospholipid with the hydrophobic (non-polar) tails which are hydrocarbon chains and 
hydrophilic (polar) heads with a phosphate group. B) shows a representation of the 
phospholipid, with one polar head and 2 non-polar tails. C) shows the phospholipids organised 
within a plasma membrane to form a lipid bilayer. Adapted from 
http://homepage.smc.edu/wissman_paul/anatomy2textbook/phospholipids.html. 
The main phospholipids found in yeast plasma membranes are phosphatidylcholine such as 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC); 1,2-dilauroyl-sn-glycero-3-phosphocholine 
(DLPC); 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and phosphatidylethanolamine 
such as 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE) and 1,2-dipalmitoyl-sn-
glycero-3-phosphoethanolamine (DPPE). Other phospholipids and lipids found in the plasma 
membrane but in small amounts include phosphatidylinositol, phosphatidylserine, 
phosphatidylglycerol, unsatuarated fatty acids and sterols such as ergosterol, zymosterol, 
fecosterol and episterol (Zinser and Daum, 1995).  
Native yeast membrane proteins are categorised into cytoskeleton anchors, cell wall synthesis 
enzymes, signal transduction proteins, solute transport proteins (permeases, transport channels 
and ATPases) and transport facilitators. It can be noted that the sterol, cholesterol is absent from 
A)
B)
C)
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yeast plasma membrane but this is a major sterol in mammalian cells. Cholesterol and ergosterol 
are not biologically equivalent as ergosterol possesses two additional double bonds at positions 
C7 and C22 and a methyl group at C24 of the side chain (Figure 1.19) (Tierney et al., 2005).  
 
Figure 1.19 Chemical structure of cholesterol and ergosterol. Ergosterol has two additional 
double bonds at positions C7 and C22 and a methyl group at C24 of the side chain when 
compared to cholesterol (Image from Tierney et al., 2005).  
Furthermore, some human GPCRs are only active in the presence of cholesterol. Efforts are 
therefore being made in engineering yeast strains that make cholesterol-like sterols (Kitson et 
al., 2011). More commonly, cholesterol derivatives e.g. cholesteryl hemi-succinate are added 
when the extraction of the membrane protein is being performed (Section 1.4.3). Figure 1.20 
shows a simple representation of a yeast plasma membrane. 
 
 
 
Figure 1.20 Yeast plasma membrane. Picture shows a representation of the phospholipid 
bilayer with the hydrophobic and hydrophilic regions. Membrane protein along with sterols are 
also shown. Image adapted from www.distillique.co.za 
The way in which lipids are organised in the plasma membrane are also important when 
considering membrane proteins and their interactions with the lipids. This helps with efficient 
Hydrophilic 
heads
Hydrophilic 
heads
Hydrophobic  
tails
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co-ordination of functions if the membrane proteins are segregated into distinct domains in the 
lipid bilayer (Spira et al., 2012). There are several models for this theory and these include the 
lipid-raft theory where liquid-ordered domains (cholesterol and sphingolipids, the ‗rafts‘) are 
separated from liquid-disordered domains (phospholipids) (Lingwood and Simons, 2010); 
protein-protein interactions (Douglass and Vale, 2005); cortical actin (Kusumi et al., 1993) and 
the extracellular matrix (Sackmann, 1996). These theories should be given some thought when 
producing recombinant membrane proteins, although separate and detailed research would need 
to be performed in order to fully characterise the target membrane protein in the yeast lipid 
bilayer.  
1.4.3. Extraction of recombinant membrane proteins from the yeast plasma membranes 
Helenius and Simons in 1975 first developed a method to extract membrane proteins from cell 
membranes referred to as surfactant solubilisation (Helenius and Simons, 1975). The term 
surfactant (an abbreviation of surface active agents) is used less commonly than detergent even 
though a detergent is defined as a formulation of a surfactant or cleaning product (Jamshad et 
al., 2011). However, for the purpose of this thesis, the term detergent will be used. Detergent 
use in membrane protein extraction involves maintaining the membrane protein of interest in a 
functional, correctly folded state without its native membrane present. This process is required 
for any purification methods of the membrane protein and for any further biophysical studies 
such as X-ray crystallography (Prive, 2007).  
1.4.3.1. Detergent use in membrane protein solubilisation 
Detergents are typically used to extract membrane proteins from their native lipid bilayer. This 
process, which is often referred to as membrane protein solubilisation, involves the replacement 
of lipids with detergent molecules as shown in Figure 1.21. Detergents possess a hydrophilic or 
polar head group and a hydrophobic tail group similar to the phospholipids in the membrane 
bilayer (Kalipatnapu and Chattopadhyay, 2005, Duquesne and Sturgis, 2010). Following a 
solubilisation experiment, the resulting aqueous solution contains membrane protein in complex 
either with detergent or with detergent and lipid (Figure 1.21) which are then suitable for 
purification and further analysis. The most common issues with detergent solubilisations are 
protein aggregation and protein denaturation which lead to loss of protein function and will 
prevent any further structural studies (Prive, 2007). Detergents are amphipathic in nature due to 
their hydrophilic head groups and hydrophobic alkyl tail groups. Detergent molecules exist as 
monomers in aqueous solutions when at low concentrations. When the concentration of the 
detergent increases to a certain level they start to self-assemble into small spherical and 
thermostable structures called micelles. At this minimum concentration when the micelles are 
formed it is termed the Critical Micelle Concentration (CMC) (le Maire et al., 2000). In order 
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for a detergent to solubilise a membrane protein, the detergent concentration must reach above 
its CMC (Prive, 2007).  Moreover, the critical solubilisation concentration (CSC) is the 
minimum detergent concentration required to disperse the lipid bilayer into micelles (Prive, 
2007) 
The head group of the detergent typically influences the interaction with proteins and the alkyl 
chain affects the CMC and the aggregation number. The aggregation number is the number of 
molecules in a micellar particle (Prive, 2007). Therefore in general, shorter chain detergents 
(C8) tend to be harsher and cause denaturation of a protein when compared to more gentle 
longer chained detergents (C12). When considering the head group, the smaller, highly charged 
head group will be a more harsh detergent than one with a larger more neutral head group. 
These properties must be considered when solubilising the lipid bilayer as the more harsh 
detergents may denature the protein and render them non-functional or conversely a more mild 
detergent may be poorly soluble (Prive, 2007). 
Figure 1.21 Scheme to show stages of lipid bilayer solubilisation by detergent. (A) shows the 
lipid bilayer of a membrane (B) shows low concentrations of detergent (grey with single tails) 
and lipid bilayer (C) shows higher concentrations of detergent and the lipid bilayer disrupts (D) 
shows the mixed populations retrieved as result of high concentrations of detergents (taken from 
(Kalipatnapu and Chattopadhyay, 2005)). 
There are many detergents available that can be classified into four groups (ionic, bile salts, 
non-ionic and zitterionic detergents) according to their chemical structure. Table 1.6 
summarises the structures and properties of given examples and their effectiveness.  
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Table 1.6 Four main groups of detergents used for solubilisation of membrane proteins. 
 Ionic Bile-acid Non-ionic Zwitterionic 
Chemical structure 
 
 
 
 
 
Properties 
Polar head group (anionic or 
cationic); hydrophobic tail 
(hydrocarbon chain or 
steroidal backbone) 
Same as ionic detergents 
with rigid steroidal group 
backbone, results in polar 
and apolar face instead of 
well-defined group 
Uncharged hydrophilic head 
groups of either 
polyoxyethylene or 
glycosidic groups 
Combination of ionic and 
non-ionic detergents and 
more denaturing than non-
ionic detergents  
Examples 
Sodium dodecyl sulphate 
(SDS) 
Sodium deoxycholate, 
sodium cholate 
Alkylglucosides: n-octyl-β-
D-glucopyranoside, decyl-
β-D-maltoside and 
dodcecyl-β-D-maltoside, all 
(DDM 
3-[(3-
cholamidopropyl)dimethylammoni
o]-1-propanesulfonate 
(CHAPS), 3-[(3-
cholamidopropyl)dimethylammoni
o]-2-hydroxy-1-propanesulfonate 
(CHAPSO) 
Effectiveness 
Extremely effective but 
almost always denatures 
membrane proteins (Seddon 
et al, 2004) 
Quite mild and therefore 
less denaturing (De Foresta 
et al., 1989) 
Very mild detergents and so 
do not denature proteins 
readily. Very popular.  
(Kragh-Hansen et al., 1993) 
More denaturing than non-
ionic detergents. (Sardet et 
al., 1976) 
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1.4.3.2. Alternative solubilising agents  
Although, detergents have been used to solubilise membrane proteins for more than 50 years, 
protein-detergent micelles are unstable and tend to aggregate leading to loss of membrane 
protein function.  Furthermore, detergent molecules tend to be disordered and therefore the 
formation of crystal lattices maybe compromised (Alguel et al., 2010). Biophysical studies have 
shown that detergent micelles can only give an approximation of the native environment 
provided by the lipid bilayer. Neutron-scattering studies have shown that the membrane bilayer 
is made up of many layers running perpendicular to the membrane normal (Lin and Guidotti, 
2009) (Wiener and White, 1992). This is something that a detergent micelle will struggle to 
replicate along with alterations that can occur in the composition of the lipid bilayer such as 
changes to the phospholipid head or acyl chain, which can lead to varied interactions with the 
membrane protein (Charalambous et al., 2008). Also the presence of lipid rafts and other lipid 
organisational theories, as discussed in section 1.4.3., contribute to the challenges of using 
detergents for solubilisation. Furthermore, a study on two membrane protein transporters; the  
E. coli transporter, EmrE and the Mycobacterium tuberculosis transporter, TBsmr (both multi-
drug resistance family members) showed that the phospholipid, phosphatidylethanolamine can 
alter the lateral pressure profile of the lipid bilayer. These lipid bilayer lateral pressures can 
affect membrane protein insertion, folding and activity and hence contribute to further  
difficulties in using detergents for solubilisation (Charalambous et al., 2008).  
Research in this area has focused on identifying a more robust system to solubilise membrane 
proteins in a more stable manner using the tools of nanoscience and nano-self-assembly 
(Jamshad et al., 2011). Several types of novel systems some still in development, have been 
proposed for solubilising membrane proteins as outlined in Table 1.7. 
1.4.3.2.1. Bicelles 
Bicelles are composed of a central planar bilayer of long-chain phospholipids, such as DMPC, 
surrounded by a rim of short-chain phospholipids, such as DHPC, which shield the long-chain 
lipid tails from water (Sanders and Prestegard, 1990). As the long-chain phospholipid molecules 
in the bicelles are positioned in the planar core region, this region is thought to mimic natural 
membranes much better than micelles that are formed by detergents (Glover et al., 2002). 
1.4.3.2.2. Amphipols 
Amphipols are milder forms of detergents that allow a membrane protein to be surrounded by 
annular lipids (Picard et al., 2006), which are a shell of lipid molecules that surround the 
membrane penetrating surface of the membrane protein (Lee, 2011b).  Amphipols are 
amphipathic polymers consisting of hydrophilic backbones and hydrophobic side chains. They 
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have the ability to hypercoil around the membrane protein region and therefore helps them to 
stay folded correctly (Popot, 2010). 
1.4.3.2.3. Nanodiscs 
Nanodiscs and nanodisc technology are also referred to as nanoscale apolipoprotein bound 
bilayers (NABB) or high-density lipoprotein (HDL) particles. The technology was developed by 
Bayburt and colleagues in 2002 (Bayburt and Sligar, 2003). Nanodiscs contain a central lipid 
bilayer (with the membrane protein within) and two molecules of membrane scaffold protein 
(MSP) which is a helical repeat protein with a hydrophobic and hydrophilic face. The MSP 
wraps itself around the hydrophobic perimeter of the lipid disc and stabilises it (Bayburt and 
Sligar, 2010). 
1.4.3.2.4. Maltose-neopentyl glycol (MNG) amphiphiles 
Maltose-neopentyl glycol (MNG) amphiphiles comprise a tetra-substituted carbon replaced with 
one hydrophilic and three hydrophobic substituents (Chae et al., 2010). Furthermore this 
quaternary carbon causes a subtle restraint on the conformational flexibility of the amphiphile. 
The quaternary carbon is derived from neopentyl glycol and the hydrophilic groups are derived 
from maltose, hence the name MNG amphiphiles (Chae et al., 2010). 
1.4.3.2.5. Responsive hydrophobically associating polymers 
Responsive hydrophobically associating polymers contain both hydrophilic and hydrophobic 
groups rendering them amphipathic. The polymers used in this thesis are poly (maleic acid-
styrene) or PMAS. The maleic acid is a weakly negatively charged (hydrophilic) carboxylic 
acid and the styrene is an aromatic compound and highly hydrophobic. When the pH is high 
(above 7.0), the polymer is in chain form due to repulsive interactions between negatively 
charged hydroxyl groups and is soluble in water but as the pH decreases (lower than 6.0), the 
maleic acid becomes protonated and the hydrophobicity of the molecule increases. This causes 
the formation of a compact and insoluble molecule i.e. the polymer chain collapses and hyper-
coiling occurs. It is thought that as the hyper-coiling takes place it encapsulates some of the 
lipid bilayer and also the membrane protein embedded within it (Tonge and Tighe, 2001). 
Variations of these polymers are achieved by altering the molecular weight and also the ratio of 
styrene to maleic acid. Modified side chains may also be attached.  
Previously, Knowles and colleagues had worked with one version of the PMAS which they 
named SMA (styrene-co-maleic acid) and when mixed with the plasma membrane, the resulting 
structure was termed SMALP (poly(styrene-co-maleic acid) lipid particle (Knowles et al., 2009) 
(Jamshad et al., 2011). They were able to solubilise membrane proteins such as PagP and 
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bacteriorhodopsin with success leading to positive biophysical experiments (Knowles et al., 
2009; Jamshad et al., 2011). It should be noted for this thesis, that the polymer named PMAS 
2000P, has the same molecular structure as SMA (Chapter 5). 
There are several advantages known when considering the use of PMAS for solubilisation of 
membrane proteins. These include the production of homogenous particles with a diameter of 9-
11 nm and that these particles can be studied using a wide range of biophysical techniques such 
as CD, AUC, DSC (differential scanning calorimetry) and fluorescence. Furthermore, CD 
studies have shown that the PMAS solubilised material can be carried out at lower wavelengths 
(Jamshad et al., 2011). The polymer itself is very cheap to purchase and easy to prepare when 
compared to the detergents. The main disadvantage of these polymers is that there is limited 
published data for solubilisation of membrane proteins.  
Table 1.7 summarises the chemical structure, the main properties of the solubilising agent, main 
advantages and disadvantages and an example of any membrane proteins that were solubilised 
with solubilising agent. Figure 1.22 shows a schematic diagram of what the specific solubilising 
agent, the membrane bilayer and the membrane protein may look like. 
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Table 1.7 Alternative solubilising agents  
 Chemical structure Properties Advantage Disadvantage Example of membrane 
protein solubilisation 
      
Maltose 
neopentyl glycol 
(MNG) 
amphiphiles  
Tetra-substituted 
carbon with one 
hydrophilic and three 
hydrophobic 
substituents 
Successful in 
crystallisation trials 
Little information on 
size of micelles 
Human β2 adrenergic 
receptor –T4L, 
muscarinic M3 
acetylcholine receptor 
(Chae et al, 2011) 
Bicelles 
 
Long chain and short 
chain phospholipids 
mimic natural 
membrane 
Successful in NMR, 
where the presence of 
some surfactant not an 
issue 
Intermediate 
detergent step 
required  
Opsin protein to form 
the GPCR, rhodopsin 
(Reeves et al, 1999) 
Amphipols 
 
Form tight 
interactions with 
membrane protein, 
increased stability 
Successful 
solubilisation, no 
interfering with 
membrane protein 
function 
Certain pH lead to 
aggregated amphipol  
Bacteriorhodopsin 
(Tribet et al, 1996) 
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Table 1.7 Alternative solubilising agents (continued) 
 Chemical structure Properties Advantage Disadvantage Example of membrane 
protein solubilisation 
      
Nanodiscs 
 
Membrane scaffold 
protein (MSP) wraps 
itself around the 
hydrophobic perimeter 
of the lipid disc and 
stabilises it 
Similar constituents as 
lipid bilayer, more 
efficient integration 
Scaffold protein 
remains a contaminant  
Human β2 adrenergic 
receptor (Leitz et al, 
2006) 
Responsive 
hydrophobically 
associating 
polymers 
(styrene maleic 
acid) 
 
 
Responsive 
hypercoiling 
amphiphiles 
Produces homogenous 
particles, able to 
solubilise GPCR 
(unpublished); little 
evidence for interfering 
with CD or AUC 
techniques 
No published studies 
on  GPCRs 
 
 
Bacteriorhodopsin and 
PagP (Knowles et al, 
2009); Human 
adenosine A2A receptor 
(unpublished, Chapter 5 
of this thesis) 
74 
 
 
 
 
Figure 1.22 Images of proposed structures formed with alternative solubilising agent, lipid and membrane protein A) Bicelle – membrane protein (blue) is 
embedded inside the bicelle made from long-chain lipids (red) and a mixture of short-chain lipids and detergent molecules (grey) (reproduced from 
Serebryany et al, 2012). B) Amphipol - the amphipol (red) is hypercoiled around the lipid bilayer (blue) (reproduced from Jamshad et al, 2011). C) Nanodisc 
– membrane protein (blue) embedded in a nanodisc composed of a lipid bilayer (red) and a membrane scaffold protein (MSP) (reproduced from Serebryany 
et al, 2012). D) Poly(maleic-anhydride styrene) or PMAS hyper-coiled (green) and wrapped around the lipid bilayer and (Image supplied by Dr. Paul 
Topham, Aston University). 
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1.5. Project aims 
This project aimed to improve recombinant membrane protein production yields in yeast and 
study novel polymers for extracting a specific membrane protein from the plasma membrane.  
The studies primarily utilised the methylotrophic yeast species, Pichia pastoris but also 
Saccharomyces cerevisiae. The membrane protein that was chiefly studied in this thesis was the 
GPCR, human adenosine 2A receptor, hA2AR. This was selected as it is a well-characterised 
GPCR and therefore served as an appropriate model protein to study the novel extraction 
process and also the yield improvement processes which were the focus of the study. 
More specifically, the optimisation strategies that were the primary focus of this research were 
the application of statistical Design of Experiments in a small scale, high –throughput system 
for hA2AR production in Saccharomyces cerevisiae were investigated as a method of bioprocess 
optimisation prior to scale-up (Chapter 3).An investigation into the methanol feeding regimes, 
the pre-induction and cytotoxic culture environments for hA2AR production in Pichia pastoris 
(Chapter 4). An in-depth study into the extraction of the hA2AR from Pichia pastoris 
membranes using novel polymers (Chapter 5).   
In summary this project sought to address three major challenges in recombinant protein 
production in yeast: 
 Achieving optimised production with minimal trial and error through a DoE approach 
 Maximising production through controlled feeding regimes 
 Using novel polymers to improve the process of extracting proteins from cell 
membranes 
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Chapter 2: Material and methods 
2.1. Materials 
2.1.1. Reagents and buffers  
2.1.1.1. Stock solutions and buffers 
2.1.1.1.1. 10× YNB (13.4% yeast nitrogen base with ammonium sulphate without amino 
acids) 
134.0 g yeast nitrogen base was dissolved in distilled water to a total volume of 1 L and filter 
sterilised. The medium was stored at 4°C. 
2.1.1.1.2. 500× biotin (0.02%) 
20 mg biotin was dissolved in distilled water to a total volume of 100 mL and filter sterilised.  It 
was stored at 4°C. 
2.1.1.1.3. 10× glycerol (10%) 
100 mL glycerol was mixed with 900 mL distilled water.  It was filter sterilised and stored at 
room temperature. 
2.1.1.1.4. 10× methanol (5%) 
5 mL methanol was mixed with 95 mL distilled water and filter sterilised.  The medium was 
stored at 4°C. 
2.1.1.1.5. 40× glucose (40%) 
400 g glucose was dissolved in distilled water to a total volume of 1 L and filter sterilised. The 
solution was stored at 4°C. 
2.1.1.1.6. 1 M potassium phosphate buffer, pH 6.0 
1 M solution of K2HPO4 was made by dissolving 174.2 g in distilled water to a total volume of 1 
L.  1 M solution of KH2PO4 was made by dissolving 136.1 g in distilled water to a total volume 
of 1 L. 132 mL 1 M K2HPO4 was mixed with 868 mL KH2PO4 and the pH adjusted to 6.0.  The 
solution was autoclaved and stored at room temperature. 
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2.1.1.1.7. 1× T.A.E. buffer 
40 mM Tris acetate and 1 mM EDTA were mixed to a final volume of 1 L and the pH adjusted 
to 8.2-8.4. 
2.1.1.1.8. 1 M DTT (Dithiothreitol) 
1.54 g DTT powder was dissolved in double distilled water to a final volume of 10 mL. The 
solution was filter sterilised and stored at 4°C. 
2.1.1.1.9. 1 M HEPES (2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid)  buffer pH 
8.0 
238.3 g HEPES powder was dissolved in double distilled water to a final volume of 1 L. The 
solution was adjusted to pH 8.0, filter sterilised and stored at 4°C. 
2.1.1.2. E. coli culture medium 
2.1.1.2.1. LB (Luria-Bertani) 
20 g LB powder was dissolved in distilled water to a total volume of 1 L. For culture plates, 20 
g agar was added and the solution autoclaved at 121°C for 20 min then cooled to room 
temperature and stored at 4°C. 
2.1.1.3. S. cerevisiae culture media 
2.1.1.3.1. Yeast peptone dextrose (YPD) 
20 g peptone and 10 g yeast extract were dissolved in distilled water to a total volume of 900 
mL.  For the agar plates, 20 g agar was added.  The solution was autoclaved and then cooled to 
room temperature before adding 100 mL 10× glucose and stored at 4°C. 
2.1.1.3.2. 2× CBS (Centralbureau voor Schimmelcultures) medium 
10 g ammonium sulphate, 6 g potassium dihydrogen phosphate and 1 g magnesium sulphate 
heptahydrate were dissolved in 646 mL distilled water. This was autoclaved and then 50 mL 
40× glucose, 100 mL MES, pH 6.0, 200 mL 10× DO solution (-uracil for S.cerevisiae wild type 
and S. cerevisiae TM6* strains, and -histidine for S.cerevisiae BMS1 strains), 2 mL vitamin 
solution and 2 mL trace elements were added. 
2.1.1.3.3. CSM (complete synthetic medium) 
1.7 g yeast nitrogen broth without amino acids, 5 g ammonium sulphate, 20 g agar and 750 mL 
were dissolved and then autoclaved. 100 mL 10× DO solution (-uracil for S.cerevisiae wild type 
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and S. cerevisiae TM6* strains, and -histidine for S.cerevisiae BMS1 strains). 100 mL MES pH 
6.0 and 50 mL 40× glucose added to the solution and plates were then poured, cooled and stored 
at 4°C. 
2.1.1.3.4 10× Drop out solution (DO solution) (minus uracil) 
200 mg L-adenine hemi-sulphate salt, 200 mg L-arginine HCl, 200 mg L-histidine HCl 
monohydrate, 300 mg L-isoleucine, 1000 mg L-leucine, 300 mg L-lysine HCl, 200 mg L-
methionine, 500 mg L-phenylalanine, 2000 mg L-threonine, 200 mg L-tryptophan, 300 mg L-
tyrosine and 1500 mg L-valine were added to 1 L distilled water then autoclaved and stored at 
4°C. 
2.1.1.3.5 10× Drop out solution (DO solution) (minus histidine) 
200 mg L-adenine hemi-sulphate salt, 200 mg L-arginine HCl, 300 mg L-isoleucine, 1000 mg 
L-leucine, 300 mg L-lysine HCl, 200 mg L-methionine, 500 mg L-phenylalanine, 2000 mg L-
threonine, 200 mg L-tryptophan, 300 mg L-tyrosine, 200 mg L-uracil and 1500 mg L-valine 
were added to 1 L distilled water then autoclaved and stored at 4°C. 
2.1.1.3.6 Trace elements solution 
3.75 g EDTA and 1.125 g zinc sulphate heptahydrate in 190 mL water were dissolved and the 
pH was adjusted to 6.0 with 1 M NaOH. Whilst maintaining the pH, the following were added: 
0.25 g magnesium chloride tetra-hydrate, 0.075 g cobalt (II) chloride hexahydrate, 0.075 g 
copper (II) sulphate pentahydrate, 0.1 g sodium molybdenum dehydrate, 1.125 g calcium 
chloride dehydrate, 0.75 g iron sulphate heptahydrate, 0.25 g boric acid, 0.025 g potassium 
iodide. The pH was adjusted to 4.0 with 1 M HCl and topped up to 250 mL with water. The 
bottle was covered in foil to exclude light, autoclaved and stored at 4°C.  
2.1.1.3.7. Vitamin solution 
0.0125 g biotin was dissolved in 2.5 mL 0.1 M NaOH. 190 mL water was added and the pH 
adjusted to 6.5 with 1 M HCL. Whilst maintaining the pH, the following were added: 0.25 g 
calcium D-pantothenate, 0.25 g nicotinic acid, 6.25 g myo-inositol, 0.25 g thiamine HCl, 0.25 g 
pyridoxol HCl and 0.05 g d-amino benzoic acid. This was topped up to 250 mL, filter sterilised 
and stored at 4°C in the dark. 
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2.1.1.4. P. pastoris culture media 
2.1.1.4.1. Buffered complex glycerol medium (BMGY) 
10 g yeast extract and 20 g peptone were dissolved in distilled water to a total volume of 700 
mL. The solution was autoclaved then cooled to room temperature. The following was then 
added: 100 mL 1 M potassium phosphate buffer pH 6.0, 100 mL 10× YNB, 2 mL 500× biotin 
and 100 mL 10× glycerol. The medium was stored at 4°C. 
2.1.1.4.2. Buffered complex methanol medium (BMMY) 
10 g yeast extract and 20 g peptone were dissolved in distilled water to a total volume of 700 
mL. The solution was autoclaved then cooled to room temperature. The following was then 
added: 100 mL 1 M potassium phosphate buffer pH 6.0, 100 mL 10× YNB, 2 mL 500× biotin 
and 100 mL 10 × methanol. The medium was stored at 4°C. 
2.1.1.4.3. Basal salts medium (BSM) 
0.93 g calcium sulphate, 18.2 g potassium sulphate, 14.9 g magnesium sulfate heptahydrate, 
4.13 g potassium hydroxide, 40 g glycerol and 26.7 ml 85% phosphoric acid were dissolved in 
distilled water to make 1 L. The medium was autoclaved and used immediately or stored at 4°C. 
2.1.1.4.4. PTM1 trace salts 
6 g cupric sulphate pentahydrate,  0.08 g sodium iodide, 3 g manganese sulfate monohydrate, 
0.2 g sodium molybdate dihydrate, 0.02 g boric acid, 0.5 g cobalt chloride, 20 g zinc chloride, 
65 g ferrous sulfate heptahydrate, 0.2 g biotin, 5.0 mL sulphuric acid were dissolved in a final 
volume of 1 L distilled water. The solution was filter sterilised and stored at 4°C in the dark. 
2.1.1.4.5. Fermentation medium 22 (FM22) 
42.9 g potassium dihydrogen phosphate, 5 g ammonium sulphate, 1 g calcium sulphate 
dihydrate, 14.3 g potassium sulphate, 11.7 g magnesium sulphate heptahydrate and 10 g  
glycerol were dissolved in 1 L of distilled water. The medium was autoclaved and used 
immediately or stored at 4°C. 
2.1.1.4.6. PTM4 trace salts 
2 g cupric sulphate pentahydrate,  0.08 g  sodium iodide, 3 g  manganese sulfate monohydrate, 
0.2 g  sodium molybdate dihydrate, 0.02 g boric acid, 0.5 g cobalt chloride, 7 g  zinc chloride, 
22 g  ferrous sulfate heptahydrate, 0.2 g  biotin  and 1.0 mL  sulphuric acid were dissolved in a 
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final volume of 1 L distilled water. The solution was filter sterilised and stored at 4°C in the 
dark. 
2.1.1.4.7. 1 M Sorbitol 
182.2 g sorbitol was dissolved in double distilled water to a final volume of 1 L. The solution 
was filter sterilised and stored at 4°C. 
2.1.1.4.8. YPDS (yeast extract, peptone, dextrose, sorbitol) plus 100 µg mL
-1
 zeocin culture 
plates 
1% yeast extract (5 g), 2% peptone (10 g), 1 M sorbitol (91.1 g) and 10 g agar were added to 
distilled water to 487 mL and autoclaved. After cooling, 12.5 mL 40× glucose was added with 
0.5 mL 100 mg mL
-1
 zeocin. The plates were poured aseptically, stored at 4°C in the dark and 
had a shelf-life of 2 weeks. 
2.1.1.4.9. YPDS (yeast extract, peptone, dextrose, sorbitol) plus 250 µg mL
-1
 zeocin culture 
plates 
1% yeast extract (5 g), 2% peptone (10 g), 1 M sorbitol (91.1 g) and 10 g agar were added to 
distilled water to 486.25 mL and autoclaved. After cooling, 12.5 mL 40× glucose was added 
with 1.25 mL 100 mg mL
-1
 zeocin. The plates were poured aseptically, stored at 4°C in the dark 
and had a shelf-life of 2 weeks. 
2.1.1.4.10. YPDS (yeast extract, peptone, dextrose, sorbitol) plus 500 µg mL
-1
 zeocin 
culture plates 
1% yeast extract (5 g), 2% peptone (10 g), 1 M sorbitol (91.1 g) and 10 g agar were added to 
distilled water to 485 mL and autoclaved. After cooling, 12.5 mL 40× glucose was added with 
2.5 mL 100 mg mL
-1
 zeocin. The plates were poured aseptically, stored at 4°C in the dark and 
had a shelf-life of 2 weeks. 
2.1.1.4.11. YPDS (yeast extract, peptone, dextrose, sorbitol) plus 1000 µg mL
-1
 zeocin 
culture plates 
1% yeast extract (5 g), 2% peptone (10 g), 1 M sorbitol (91.1 g) and 10 g agar were added to 
distilled water to 482.5 mL and autoclaved. After cooling, 12.5 mL 40× glucose was added with 
5 mL 100 mg mL
-1
 zeocin. The plates were poured aseptically, stored at 4°C in the dark and had 
a shelf-life of 2 weeks. 
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2.1.1.4.12. Antifoams 
Two antifoams were used in this research: Mazu DF 204 (Sigma) and P2000 polyethylene 
glycol (Fluka). 
2.1.1.4.13. Glycerol analysis 
A glycerol quantitation kit was used to evaluate residual glycerol concentration in culture media 
(r-biopharm, Roche) and was carried out according to manufacturer‘s instructions. 
2.1.1.4.14. Methanol analysis 
Methanol standards were prepared for gas chromatography analysis and were made with 100% 
methanol and double distilled water. Dilutions included: 0, 0.013, 0.065, 0.13, 0.25, 0.38, 0.5, 1, 
2, 5 and 10%. 
2.1.1.5. Antibiotics 
2.1.1.5.1. Zeocin 
250 mg zeocin was dissolved in 10 mL sterile water to give a working concentration of 25 mg 
mL
-1
. It was stored at -20°C in the dark. 
2.1.1.5.2. Ampicillin 
500 mg ampicillin was dissolved in 10 mL sterile water to give 50 mg mL
-1
. It was stored at -
20°C.  
2.1.1.5.3. Doxycycline 
5 mg mL
-1 
stock was made with sterile water and stored at -20°C. 
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2.1.1.6. Molecular biology reagents 
2.1.1.6.1. pPICZB vector 
The pPICZB vector was used as the backbone for the novel hA2AR construct (Chapter 5). The 
key features are shown in Figure 2.1.  
 
 
Figure 2.1 pPICZB expression vector developed by Life Technologies Corporation. Vector 
contains a multiple cloning site with a choice of restriction enzymes and includes the AOX1 
promoter region (reproduced from www.lifetechnologies.com). 
2.1.1.6.2. Restriction enzyme PmeI  
The source is an E.coli strain that carries the PmeI gene from Pseudomonas mendocina. The 
reaction was carried out at 37°C (New England Biolabs) 
2.1.1.6.3. Mini-preparation kit 
The GeneJET plasmid DNA mini-prep kit (Fermentas) was used according to the 
manufacturer‘s protocol. 
2.1.1.6.4. Purification of PmeI digestion 
The QIAquick PCR purification kit (Qiagen) was used according to the manufacturer‘s 
protocol. 
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2.1.1.6.5. XL-10 Gold E.coli cells 
E.coli competent cells were purchased from Agilent Technologies Inc. and were used to amplify 
the plasmid DNA for transformation into P. pastoris cells. XL-10 Gold yield high efficiency 
transformations of large plasmids. They are tetracycline and chloramphenicol resistant. The 
strain is endonuclease (endA) and recombination deficient (recA). The genotype is: 
Tet
rΔ(mcrA)183Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte 
[F′ proAB lacIUPSIDEDOWNbZΔM15 Tn10 (Tetr)Amy Camr] 
2.1.1.7. Yeast strains  
2.1.1.7.1. P. pastoris X33 
The X33 strain is a wild-type strain with a His
+
, Mut
+ 
phenotype. This strain was obtained from 
laboratory stocks at Aston University but is also available from Life Technologies Inc. A de-
glycosylated version of a hA2AR construct (Fraser, 2006) (Chapters 4 and 5) developed by Dr. 
Niall Fraser, Glasgow University was transformed into the X33 strain by Dr. Richard A.J. 
Darby, Aston University. This strain was also the background to a green fluorescent protein 
(GFPuv) construct cloned into the pPICZα vector created by Dr. William J. Holmes, Aston 
University (Holmes et al., 2009). This X33-GFP strain was used in Chapter 4. 
2.1.1.7.2. P. pastoris SMD1163 
The genotype of this protease deficient strain is: his4 pep4 prb1. PEP4 encodes for proteinase 
A, which is a vacuolar aspartyl protease required for the activation of other vacuolar proteases 
such as carboxypeptidase Y and proteinase B. The PRB1 gene encodes for proteinase B (Cregg, 
1985). This strain was used as the background for the novel hA2AR construct (Chapter 5) and 
was a kind gift from Dr. Shweta Singh, Evotec (UK) Ltd., Abingdon, United Kingdom.  
2.1.1.7.3. S. cerevisiae BY4741 
Wild type strain BY4741has the genotype : MATα, ura3Δ0, leu2Δ0, met15Δ0, his3Δ1. The 
vector pYX212 cloned with the hA2AR construct was obtained from Dr. Renaud Wagner, 
Université de Strasbourg, France and was transformed into the BY4741 strain. Uracil selection 
was used to identify expressing colonies. 
BY4741 is also used as the parental strain of an over-expression mutant developed by Dr. 
Nicklas Bonander, Chalmers University, Goteborg, Sweden (Bonander et al., 2005, Bonander et 
al., 2009). The endogenous promoter of the essential gene, BMS1was replaced by a tetracycline 
titratable promoter and hence levels of the BMS1 gene could be regulated by the addition of 
doxycycline (a tetracycline derivative) (yTHCBMS1) (Bonander et al., 2009). The vector 
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pYX222 containing the hA2AR construct was transformed into the strain. Histidine selection was 
used to identify expressing colonies. 
2.1.1.7.4. S. cerevisiae KOY-TM6* 
The strain used was KOY-TM6* as the parental strain which is a respiratory strain containing 
the gene that encodes a chimeric hexose transporter, TM6* (Otterstedt et al., 2004, Ferndahl et 
al., 2010).  The pYX212 vector containing the hA2AR construct was transformed into the strain 
and uracil selection was used to identify expressing colonies. 
2.1.1.8. Membrane preparation reagents and materials 
2.1.1.8.1. Breaking buffer pH 7.4 
50 mM Na2HPO4 , 50 mM NaH2PO4, 2 mM EDTA, pH 7.4, 100 mM NaCl and 5% glycerol were 
added to a final volume of 1 L with double distilled water, the pH adjusted and autoclaved.  
2.1.1.8.2. Buffer A pH 7.0 
20 mM HEPES, 50 mM NaCl and 10% glycerol were added to a final volume of 1 L with 
double distilled water, the pH adjusted to 7.0 and autoclaved.  
2.1.1.8.3. Glass beads 
Acid-washed glass beads 212 - 300 μm in size (Sigma-Aldrich) were used for small scale 
membrane preparations. 
2.1.1.9. Protein quantification reagents 
2.1.1.9.1. Bovine serum albumin (BSA) standard 
BSA (Sigma) was diluted to a final amount in each well of 0-10 µg from a 1mg mL
-1
 stock for 
all protein determinations. 
2.1.1.9.2. Copper (II) sulphate solution 
1:50 4% (w/v) copper (II) sulphate (Sigma) solution was used for the BCA assay in conjunction 
with BSA (Sigma).  
2.1.1.9.3. Bicinchoninic acid (BCA) 
BCA solution (Sigma) was used in the BCA assays. 
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2.1.1.10. Immunoblot reagents 
2.1.1.10.1. 5 × Laemmli sample buffer 
1.25 mL 0.5 M Tris-HCl pH 6.8, 1 mL 100% glycerol, 2 mL 10% SDS, 0.5 mL β-
mercaptoethanol, 10 µL bromophenol blue were mixed with double distilled water to a final 
volume of 8 mL. 
2.1.1.10.2. SDS Tris buffer 
100 mL 10× SDS Tris buffer (GeneFlow) was added to 900 mL double distilled water. 
2.1.1.10.3. Immunoblot Tris buffer  
100 mL 10× Tris buffer (GeneFlow) and 200 mL methanol was added to 700 mL double 
distilled water. 
2.1.1.10.4. Phosphate buffered saline (PBS) 
5 PBS tablets (Sigma) were dissolved in 1 L of double distilled water.  
2.1.1.10.5. PBS-Tween buffer  
2 mL Tween-20 (0.2%) was added to 1 L PBS. 
2.1.1.10.6. PBS-5% milk 
5 g powdered milk (generic brand) was dissolved in 100 mL PBS which is sufficient for 2 
nitrocellulose membranes 
2.1.1.11. Solubilisation reagents 
2.1.1.11.1. n-dodecyl-β-d-maltopyranoside (DDM) 
DDM (Anatrace) was diluted to 5% (w/v) with double distilled water and stored at 4°C. 
2.1.1.11.2. Cholesteryl hemi-succinate (CHS) 
0.5% CHS (w/v) (Sigma) solution was made with 50 mM Tri-HCl pH 8.0 and sonicated for 10 
s, cooled in ice and repeated 3 times. The solution was stored at 4°C. 
2.1.1.11.3. 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) 
10% DMPC (w/v) (Avanti Polar Lipids) solution was made with 50 mM Tri-HCl pH 8.0 and 
sonicated for 10 s cooled in ice and repeated 3 times. The solution was stored at 4°C. 
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2.1.1.11.4. Poly (maleic anhydride-styrene) (PMAS) 
To a powder form of PMAS (Sigma), 1 M NaOH was added drop-wise, continuously stirred and 
heated at 80°C to dissolve the powder and also to achieve a pH of 11.0. The reaction was 
refluxed if the anhydride rings were difficult to open. The dissolved PMAS solutions were 
checked that the pH were at 11.0 prior to use and also a batch of the same PMAS were prepared 
at pH 7.0 by adding concentrated HCl drop-wise. The final concentration of the PMAS was 3% 
and was supplied by Dr. Anisa Mahomed, Aston University. Variations in molecular weight in 
the PMAS were supplied by the manufacturer. 
2.1.1.11.5. Esterification of poly (maleic anhydride-styrene) (PMAS) 
3 g of PMAS was dissolved in 6 mL methyl ethyl ketone (MEK) and heated to 60 - 70°C whilst 
stirring. 1.5 mL methanol was added and the solution was refluxed at 70 - 80°C with stirring for 
14 h. An additional 3 mL MEK was added followed by a further 2.25 mL aliquot of methanol 
15 min later. The solution was allowed to reflux for a further 6 h before being separated out 
using petroleum ether (60 - 80°C). The PMAS was precipitated out, filtered and dried in a 
vacuum oven. This was prepared and supplied by Dr. Anisa Mahomed, Aston University.  
2.1.1.11.6. Styrene maleic acid (SMA) 
10% SMA solution was dissolved in 1 M NaOH and stirred overnight at room temperature. The 
solution was refluxed for 2 h and incubated at 4°C for 48 h. The SMA was then dialysed 
overnight against 50 mM Tris-HCl, pH 8.0 using dialysis membranes (3500 MWCO, Thermo 
Scientific) to remove the NaOH. The final concentration was 2.5% at pH 8.0 and was prepared 
by Dr. Mohammed Jamshad, University of Birmingham. One molecular weight version of SMA 
was used in experiments. 
2.1.1.12. Radio-ligand binding reagents 
2.1.1.12.1. Binding buffer 
This solution was prepared by mixing 11.3 mL 1M NaH2PO4, 38.7 mL 1M Na2HPO4 and 1 mL 
0.5 M EDTA, adjusting to a final volume of 1 L (final concentration 50 mM sodium phosphate, 
0.5 mM EDTA) with deionised water and adjusting to pH 7.4. 
2.1.1.12.2. Gel filtration columns 
P30 mini-spin gel filtration columns (Bio-Rad Laboratories Inc.) and Illustra G50 gel filtration 
columns (GE Healthcare) were used. 
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2.1.1.12.3. Tritiated ZM241385 ([
3
H]ZM241385) 
Tritiated ZM241385 was purchased from American Radio Chemicals (ARC Inc). Dilutions 
were carried out using binding buffers and daughter products were stored at 4°C in a 
radiochemical laboratory.  
2.1.1.12.4. Unlabelled ZM241385 (cold ZM241385) 
Stock dilutions of cold ZM241385 (Tocris) were made with 100% DMSO and included: 0.1 
mM, 10 µM, 1 µM, 0.1 µM, 100 nM, 10 nM and 0.1 nM where the final concentration of the 
cold ZM241385 was a 1:100 dilution of these stock solutions. 
2.1.1.12.5. Unlabelled theophylline (cold theophylline) 
Stock dilutions of cold theophylline (Sigma) were made with 100% DMSO and included: 1 M, 
500 mM, 100 mM, 50 mM, 10 mM, 5 mM and 1 mM where the final concentration of the cold 
theophylline was a 1:100 dilution of these stock solutions. 
2.1.1.12.6. Unlabelled NECA (cold NECA) 
Stock dilutions of cold NECA (Tocris) were made with 100% DMSO and included: 1 mM, 500 
µM, 100 µM, 50 µM, 10 µM, 5 µM and 1 µM where the final concentration of the cold NECA 
was a 1:100 dilution of these stock solutions. 
2.1.1.12.7. Unlabelled XAC (cold XAC) 
Stock dilutions of cold XAC (Sigma) were made with 100% DMSO and included: 10 mM, 5 
mM, 1 mM, 500 µM, 100 µM, 10 µM, 5 µM and 1 µM where the final concentration of the cold 
XAC was a 1:100 dilution of these stock solutions. 
2.1.1.12.8. Scintillant 
ScintiSafe (Fisher Scientific) scintillant was used for the radio-labelled counting procedure.  
2.1.1.12.9. Soluene 
Soluene®-350 (Perkin-Elmer) was used as a tissue solvent to solubilise membrane fraction 
pellets. 
2.1.1.13. Protein purification reagents 
2.1.1.13.1. Purification columns 
Ni-NTA agarsoe resin columns (Qiagen) were used according to the manufacturer‘s 
instructions. 
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2.1.1.13.2. Lysis buffer 
This solution was prepared by mixing 11.3 mL 1M NaH2PO4, 38.7 mL 1M Na2HPO4, 1 mL 3 M 
NaCl and 10mL 1M imidazole (final concentration 50 mM NaH2PO4, 300 mM NaCl and 10 
mM imidazole) adjusting to a final volume of 1 L with deionised water and adjusting to pH 8.0. 
2.1.1.13.3. Wash buffer 
This solution was prepared by mixing 11.3 mL 1M NaH2PO4, 38.7 mL 1M Na2HPO4, 1 mL 3 M 
NaCl and 20mL 1M imidazole (final concentration 50 mM NaH2PO4, 300 mM NaCl and 20 
mM imidazole) adjusting to a final volume of 1 L with deionised water and adjusting to pH 8.0. 
2.1.1.13.4. Elution buffer 
This solution was prepared by mixing 11.3 mL 1M NaH2PO4, 38.7 mL 1M Na2HPO4, 1 mL 3 M 
NaCl and 300mL 1M imidazole (final concentration 50 mM NaH2PO4, 300 mM NaCl and 300 
mM imidazole) adjusting to a final volume of 1 L with deionised water and adjusting to pH 8.0. 
2.1.1.14. Green fluorescent protein (GFP) assay 
2.1.1.14.1. Recombinant GFP 
Recombinant GFP (Vector Labs) standards were made: 0, 1, 2 and 4 mg mL
-1
. 
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2.1.2. Equipment 
Equipment and instruments used in this research are listed. 
2.1.2.1. Pilot-scale 35 L bioreactors AstraZeneca Ltd. Alderley Park, United Kingdom 
35 L pilot-scale bioreactors, Biostat C (Sartorius) (Figure 2.2 and 2.3) were controlled by 
Supervisory Control And Data Acquisition software (SCADA) software.  They were located in 
a dedicated fermentation facility and the parts include: 
1.  35 L jacketed stainless steel culture vessel with impellers and baffles, Biostat C (Sartorius). 
2. MatLab software for input of feeding rate conditions. 
3. Mass spectrometer for off-gas analysis (Sartorius). 
4. SCADA controller software and hardware (Sartorius). 
5. Oxygen and sterile air gas supply (BOC). 
6. 100 mL Schott-Duran sterile bottles for sampling. 
7. Peristaltic pumps for acid, base, feed and antifoam addition (EasyLoad Masterflex). 
8. Sterile filters (Sartorius, midistart 2000 0.2 µm PTFE) for tubing. 
9. Dissolved oxygen (DO) probe (Broadley-James). 
10. pH probe (Broadley-James). 
11. pH 4.0 and 7.0 standard buffers (Sigma). 
12. Clamps (Fisher). 
13. Tubing for peristaltic pumps (PharMed). 
14. 25% ammonium hydroxide (Sigma) 
15. Concentrated sulphuric acid (Sigma) 
16. P2000 antifoam (Fluka) 
17. 50% methanol (Sigma) 
18. 50% glycerol (Sigma) 
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Figure 2.2 Pilot-scale fermentation facility set-up. Image shows the Sartorius bioreactor 
system with several others in the fermentation dedicated facility. Main features from this image 
include a 35 L culture vessel, the SCADA control software and the off-gas lines that lead 
directly to a mass spectrometer for analysis. The pilot plant was located at AstraZeneca Ltd., 
Alderley Park, United Kingdom. 
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Figure 2.3 Sartorius 35 L pilot-scale bioreactor. Image shows the Sartorius 35 L bioreactor 
including: foam detection probes for different heights of foam production, tubing lines for feeds, 
acid, base and antifoam addition, temperature, pH and DO probes, a sampling port with a 
steam sterilising line, separate peristaltic pumps for the feed, acid, base and antifoam tubing 
lines. P2000 antifoam (Fluka), concentrated sulphuric acid and 25% ammonium hydroxide 
(acid and base) are also required. The carbon source, in this instance, the glycerol and 
methanol are pre-weighed before the cultivation begins and the decrease in mass as the feed is 
pumped into the culture is monitored and recorded by the mass balances that are connected to 
the output software. 
 
 
 
 
 
 
 
 
Temperature probe
pH probe
DO probe
Sampling port
Steam sterilising line for sample port
Foam detection probes 
(high, medium and
low foam)
Emergency switch-off
Entry lines for feed, acid, 
base and antifoam
Peristaltic pumps
P2000 (Fluka) anti-foam
concentrated H2SO4
25% NH4OH
Carbon source feed (glycerol
Or methanol)
Mass balance for feed bottle
92 
 
2.1.2.2. Bench-top 2 L bioreactors 
2 L bench-top bioreactors (Applikon) (Figure 2.4) controlled by BioXpert version 2 software 
and their parts include:  
1.  2 L jacketed glass culture vessel (Applikon). 
2. Heads plate for 2 L bioreactor with ports and impellers (Applikon). 
3. BioXpert version 2 software (Applikon). 
4. Thermo circulator AD 1018 (Applikon). 
5. TanDem off gas analyser (Applikon). 
6. Gas supply unit ADI 1026 (Applikon). 
7. 60%:40% oxygen : nitrogen supply (BOC). 
8. Recirculating chiller (Grant, LTL1). 
9. Air compressor 75/150 (Bambi). 
10. Peristaltic pumps for acid and base addition (EasyLoad Masterflex). 
11. Peristaltic pumps for feed addition (Masterflex C/L). 
12. Dissolved oxygen (DO) probe (Broadley-James). 
13. pH probe (Applikon). 
14. Temperature probe (Applikon). 
15. Silicon tubing (Fisher). 
16. Sterile filters (Sartorius, midistart 2000 0.2 µm PTFE) for tubing. 
17. Tubing for acid/base addition (PharMed). 
18. pH 4.0 and 7.0 standard buffers (Sigma). 
19. Clamps (Fisher). 
20. 25% ammonium hydroxide (Sigma) 
21. Concentrated phosphoric acid (Sigma) 
16. P2000 antifoam (Fluka) 
17. 50% methanol (Sigma) 
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18. 50% glycerol (Sigma) 
19. Optek controller (Applikon). 
20. Optek probe (Applikon). 
21. Tubing connectors and Y connectors (Fisher). 
22. Clamps (Fisher). 
23. Needles (Fisher). 
24. Plastic syringes (Fisher). 
25. Sample collection tubes (20 mL). 
26. Tin foil (Fisher). 
 
 
 
Figure 2.4 2 L Bench-top bioreactor set-up at Aston University. Photograph shows P. pastoris 
culture with methanol feeding in progress. Main pieces of associated equipment are labelled. 
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2.1.2.3. Micro-24 microreactor (small-scale bioreactors) 
The parts required for the Micro-24 microreactor (Figure 2.5) small-scale bioreactor included: 
1. Micro-24 microreactor (Pall Corporation). 
2. 24 well culture plate or cassette with 10 mL culture capacity (Pall Corporation). 
3. Gas supplies of oxygen, nitrogen and carbon dioxide (BOC). 
4. Light duty nylon tubing for gas connections (RS components). 
5. Pressure valve controlled ammonia bubbler vessel (Pall Corporation). 
6. Air compressor (Jun Air). 
 
 
Figure 2.5 Micro-24 microreactor (Pall Corporation) bioreactor at Aston University. A) 
Micro-24 microreactor with a 24 well culture plate. B) The general set-up at Aston University 
including the controller software on the laptop, air compressor, ammonia bubbler and the gas 
input lines at the back of the instrument.  
2.1.2.4. Centrifuges 
The centrifuges used for this research were an Optima TLX bench-top ultra-centrifuge, Allegra 
25R centrifuge, Avanti J-20 XP floor centrifuge and Optima XE floor ultra-centrifuge (all 
Beckman Coulter, Inc.) 
2.1.2.5. Gas chromatograph (GC) 
The GC used in this work was Thermo Scientific FOCUS Gas Chromatograph and utilised 
QuanLab® software for identification of peaks. 
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2.1.2.6. Cell lyser for small scale membrane preparations 
The Tissue Lyser LT (Qiagen) was used for small scale membrane preparations. 
2.1.2.7. Cell lyser for large scale membrane preparations 
The Emulisflex-C3 pressure homogeniser (Avestin) was used for large scale membrane 
preparations. 
2.1.2.8. Scintillation counter for measurement of radioactivity 
A liquid scintillation counter (Packard 1600TR Liquid Scintillation Analyser) for counting 
tritium was used. 
2.1.3. Software 
Software used in this research is outlined below. 
2.1.3.1. Graphpad Prism software 
GraphPad Prism
®
 4 software was used primarily for radio-ligand binding analysis. 
2.1.3.2. Minitab statistical software 
Minitab
®
 15.1.30.0 was used primarily for Design of Experiments work. 
2.1.3.3. Clone Manager 
Clone Manager
® 
v5.02 was used primarily for construct design work. 
2.1.3.4. Origin software 
OriginPro 8.5
®
 software was used primarily for construction of multi-axes graphs. 
2.1.3.5. Microsoft Excel 
Microsoft Excel
®
 2010 was used primarily for general data analysis, table and graph 
construction. 
2.2. Methods 
2.2.1. Molecular biology techniques 
2.2.1.1. Construct design and virtual cloning 
The design of a novel hA2AR construct was carried out with the aid of specific software 
programmes such as ExPASy Proteomics Server (http://www.expasy.ch) and a vector design 
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tool, Clone Manager v5.02. Once the design was confirmed to work virtually in the pPICZB 
vector (Life Technologies), the vector was sent to Life Technologies and the DNA sequence of 
the hA2AR construct was synthesised by them and cloned into the vector. The vector with the 
cloned sequence of the construct was returned to Aston University where the molecular biology 
work continued. As a control, the pPICZB vector only was transformed into the SMD1163 P. 
pastoris cells using the same transformation protocol described in 2.2.1.5. to 2.2.1.8. 
2.2.1.2. Mini-preparations (Minipreps) of vector DNA 
Minipreps were carried out using Fermentas GeneJET plasmid miniprep kit. 5 mL over-night E. 
coli (LB zeocin (25 µg mL
-1
) culture at 37°C were centrifuged at 3000 rpm for 5 min. The 
supernatant was discarded and the cells were re-suspended in 250 µL resuspension solution. 250 
µL lysis solution was mixed by inverting the tube 6-8 times or until the solution became slightly 
viscous. 350 µL neutralisation solution was added and left for a few seconds. The solution was 
pipetted and a precipitation was seen. The solution was transferred to a clean tube and 
centrifuged at 13000 rpm for 5 min to pellet the cell debris. The supernatant was transferred to a 
GeneJET spin column whilst not disturbing the precipitation. The column was spun for 1 min at 
13000 rpm and the flow through was discarded. 500 µL wash (containing ethanol) solution was 
added to the column and spun again at 13000 rpm for 1 min. A second spin was carried out to 
remove any traces of ethanol. 50 µL deionised water were added directly onto the column 
membrane and incubated at 37°C for 4 min. The column was then spun at 13000 rpm for 2 min 
and the eluted DNA was stored at -20°C. 
2.2.1.3. DNA quantification 
DNA quantification was carried out using a Nanodrop 1000 spectrophotometer (Thermo 
Scientific) with ND2000 software. 2 µL deionised water was loaded onto the Nanodrop 
platform and was measured as a calibration blank. 2 µL water was added again to the Nanodrop 
platform and was measured as a sample blank. Next 2 µL of the sample DNA was added to the 
platform and measured with the DNA-50 function (double-stranded DNA) at 260 nm.  
2.2.1.4. Agarose gel electrophoresis 
For one gel, 1 g high resolution agarose was dissolved in 100 mL 1× T.A.E. buffer and melted 
in a microwave. Once cooled, but not set, 5 µL ethidium bromide was added to the solution and 
mixed carefully. The gel was poured and an appropriate comb was added to form the wells. The 
DNA ladder was typically the 1 kb GeneRuler (Fermentas) ladder. 
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2.2.1.5. Linearisation of pPICZB vector-hA2AR construct DNA 
5 µg of vector DNA was linearised with 1.5 µL PmeI (25U, New England Biolabs), 20 uL 10× 
NEB buffer 4, 2 µL BSA (100 µg mL
-1
) and deionised water to a final volume of 200 µL. The 
reaction mixture was heated to 37°C for 1 h and then the enzyme heat inactivated by incubating 
for a further 20 min at 65°C.  
2.2.1.6. Purification of linearised pPICZB vector-hA2AR construct DNA 
A QIAquick purification kit was used to purify the linearised DNA. 1 mL Buffer PB (a 
proprietary buffer that contains a high concentration of guanidine hydrochloride and 
isopropanol) was added to the completed linearisation reaction and applied to a QIAquick 
column. The tube was centrifuged for 30-60 s at 17900 ×g in a table-top centrifuge. The flow-
through was discarded and 0.75 mL Buffer PE (a proprietary buffer containing 96-100 % 
ethanol) was added to the same column and centrifuged for 1 min at the same centrifugal force. 
The column was transferred to a clean collection tube and 50 µL deionized water was added to 
the centre of the column and allowed to equilibrate for 1 min. The column and tube were 
centrifuged for a further 1 min to elute the purified linear vector-construct DNA. 
2.2.1.7. Preparation of P. pastoris electrocompetent cells 
A fresh SMD1163 P. pastoris colony was used to inoculate 100 mL YPD medium which was 
incubated overnight in a shaker incubator at 30°C. The optical density was measured at 600 nm 
and the culture was diluted to an OD600 of 0.25 in a total of 400 mL YPD medium and was 
incubated at 30°C. The OD600 was monitored and when it reached 1 after about 4 h incubation at 
30°C, the cells were harvested by centrifugation in sterile tubes at 2000 × g for 5 min at 4°C. 
The cells were re-suspended in 100 mL YPD, 20 mL 1 M HEPES, pH 8.0 and 2.5 mL 1 M DTT 
with gentle mixing. These cells were incubated for a further 15 min at 30°C. The cells were then 
transferred onto ice and sterile, cold water was added to a final volume of 500 mL. The cells 
were harvested by centrifugation at 2000 × g for 5 min at 4°C. The cell pellet was washed with 
250 mL of sterile, cold water and then centrifuged again at 2000 × g for 5 min at 4°C. The pellet 
was re-suspended in 20 mL cold 1 M sorbitol by gentle mixing and then the cells were 
harvested by centrifuging at 2000 × g for 5 min at 4°C. The pellet was re-suspended in 500 µL 
of cold 1 M sorbitol by gentle mixing and 40 µL aliquots were made and stored at -80°C for use 
within 6 months.  
2.2.1.8. Electroporation and recombinant clone selection 
An electroporation cuvette (Fisher) was placed on ice for at least 15 min prior to performing the 
transformation. 40 µL electrocompetent cells (section 2.2.1.7.) were mixed with 7.5 µL 
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linearised pPICZB-hA2AR DNA (section 2.2.1.6.) in the electroporation cuvette by gently 
pipetting and then incubating on ice for 5 min. The electorporator (Eppendorf multiporator
TM
) 
was set at 1800 V 15 ms pulse length, the cuvette was placed into the electroporator chamber 
and the electric pulse was applied once. The electroporated mixture was immediately re-
suspended in 1 mL cold sorbitol and the cells were transferred to a sterile tube. The cells were 
allowed to recover for about 1 h at 30°C then they were harvested at 2000 × g for 10 min at 4°C. 
The supernatant was discarded and the pellet was re-suspended in 500 µL 1 M sorbitol and 0.5 
mL YPD. The cells were transferred to 1.5 mL tubes and placed in a 30°C incubator at the 
lowest shaking speed for 1.5 h. The culture was plated onto YPDS plates with increasing 
concentrations of zeocin (100, 250, 500 and 1000 µg mL
-1
). These plates were incubated at 
30°C for up to 8 days. 
2.2.1.9. Transfection of hA2AR vector into human embryonic kidney cells (HEK) 
HEK 293 cells were cultured in Dulbecco‘s Modified Eagle‘s Medium (DMEM) supplemented 
with 10% v/v fetal calf serum and 1% penicillin/streptomycin in a tissue culture treated 75 cm
2
 
cell culture flask and incubated at 37°C with 5% carbon dioxide. Once 70-90% confluency was 
reached, the cells were seeded at 30000 cells in 200 µL per well in a 48 well plate. 24 h after the 
seeding, cells were transiently transfected with 1 µg vector DNA (pcDNA3.1 with MT-hA2AR, 
Chapter 5) per well. Figure 2.6 shows the annotated pcDNA3.1 vector used. The transfection 
mix consisted of 4.5 µL 20 mM poly(ethylenimine) (PEI) per 1 µg vector DNA, 40 µL 5% 
glucose and DMEM to a total volume of 200 µL per well. DNA was first added to the 
appropriate volume of 5% glucose, mixed and incubated for 10 min at room temperature. The 
appropriate volume of PEI was added to 5% glucose, mixed and incubated for 10 min at room 
temperature. The PEI mixture was added to the DNA, mixed and incubated at room temperature 
for 20 – 30 min. DMEM was added to the required volume. The growth medium was removed 
and replaced with the transfection mixture. The plates were agitated and returned to the 
incubator. Binding assays were performed 48 h after transfection.  (This protocol was performed 
by Dr. Sarah Routledge, Aston University). 
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Figure 2.6 pcDNA3.1 expression vector developed by Life Technologies Corporation. Vector 
contains a multiple cloning site with a choice of restriction enzymes and includes the T7 
promoter region (reproduced from www.lifetechnologies.com). 
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2.2.2. Yeast cultivations 
2.2.2.1. Shake flask cultures 
Yeast cells from frozen glycerol stocks were streaked onto YPD plus zeocin (100 µg mL
-1
) 
plates and incubated for 2 days at 30°C. 5 mL appropriate medium (YPD or BMGY) was then 
inoculated with a single yeast colony, grown to logarithmic phase and used to inoculate baffled 
250 mL shake flasks containing 50 mL growth medium (YPD, BMGY or FM22) at a culture to 
flask volume ratio of no more than 1 in 5. Cultures were incubated at 30 °C, 220 rpm until the 
required OD600 was obtained. Growth rates of yeast were determined using the equation 
defining a logarithmic curve:  
y=ce
μt
 
Where c is a constant, e is the exponential, μ is the specific growth rate (h-1) and t is the time (h) 
The doubling time of the yeast was then calculated from the specific growth rate:  
Doubling time= ln(2)/μ 
If methanol induction was carried out in shake flasks, the required volume of log phase cells 
taken from a BMGY culture in order to achieve an OD600 of 1 was calculated and the cells were 
centrifuged at 5000 × g for 10 min and the pellet re-suspended in the required volume of 
BMMY.  
2.2.2.2. Pilot-scale 35 L bioreactor cultivations 
2.2.2.2.1. Preparation of 35 L bioreactor 
Before the experimental runs began, several preparative steps were taken in accordance with the 
laboratory operating procedure from AstraZeneca Ltd. and also from the Biostat C operating 
manual.  
2.2.2.2.1.1. Vessel pressure hold testing 
To ensure the system could withstand high pressure levels safely, any pierced septa from the 
head-plate were replaced, the head-plate bolts were tightened with a torque wrench set to 50 
Nm, the vessel side ports were tightened and all probes (DO, pH) were fitted and tightened. The 
test applied 1000 mBar pressure for 30 min via the controller software. The actual pressure 
values were noted after 5 min and the system was monitored for any leaks. At the end of the 
test, the actual pressure was compared to the pressure set-point after 30 min.  Any deviation 
above 10 mBar was a system fail. 
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2.2.2.2.1.2. pH and DO probe calibration 
The pH probe was calibrated with pH standards, 4.0 and 7.0. The DO probe was calibrated by 
unplugging the DO cable from the controller unit and then setting it to 0. The bioreactor was 
then aerated with 1 vvm of sterile air and the slope was calibrated when the DO signal was 
stable. 
2.2.2.2.1.3. Bioreactor sterilisation 
The valves on the bioreactor were positioned as shown in Figure 2.7 (closed if horizontal, open 
if vertical). High pressure steam was applied to the bioreactor at a temperature of 121° for 30 
min. Care was taken during this process, adequate warning signs were in place and no lone 
working was permitted. Once the sterilisation was completed and the temperature of the system 
had cooled to 37°C or less, the over pressure of 200 mBar on the pressure controller was 
switched off and the cooling water valve condenser was opened. A final check before the 
bioreactor was inoculated with the P. pastoris culture was priming the pH control lines by 
inspecting the interior of the pump head for obstructions. 
 
Figure 2.7 Biostat C valve settings. Valves numbered according to Biostat C manufacturing 
show horizontal (closed) or vertical (open) positions. 
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2.2.2.2.2. Performing a 35 L bioreactor cultivation for P. pastoris producing hA2AR 
10 L FM22 medium supplemented with 1 mL P2000 antifoam (Fluka), 40 mL PTM4 salts and 8 
mL 10 g L
-1 
biotin were transferred into each of two 35 L (total volume) jacketed steel 
bioreactors (Biostat C, Sartorius Ltd.). Culture temperature was maintained at 30°C and pH at 5. 
The maximum agitation rate was 1500 rpm. X33 P. pastoris producing hA2AR (dG-hA2AR, 
Chapter 4) was inoculated in each bioreactor to a starting OD600 of 1. For both cultivations, the 
end of the glycerol batch phase (phase I) was indicated by a spike in DO to 100%. A glycerol 
fed-batch phase (phase II) was then maintained for 40 h by employing an exponential feed rate 
of 50% aqueous glycerol (v/v) 4 g L
-1
 h
-1
 increasing exponentially first at a rate of 0.15 h
-1
 for 
10 h and subsequently at a rate of 0.03 h
-1
 via the use of MatLab
®
 analysis software. The first 
section of the transition phase (phase IIIA; starvation), during which no further carbon source 
was fed into the bioreactor, was maintained for 1 h. The second section of the transition phase 
(phase IIIB) comprised a further 1 h, where a constant methanol feedstock (50% (v/v) aqueous 
methanol) was applied at 8 g L
-1 
h 
-1
. The culture temperature was lowered to 22°C and an 
exponential methanol (50% (v/v) aqueous methanol) feed profile was applied by exponentially 
increasing the feed rate at 0.01 h
-1 
(µlow) or 0.03 h
-1 
(µhigh). The induction phase continued for 40 
h. Table 2.1 summarises these cultivation events for both µlow and µhigh set-ups. 
Table 2.1 Summary of bioprocess events during two simultaneous P. pastoris cultivations 
producing recombinant dG - hA2AR with different exponential methanol feed rates (µset). I 
denotes batch phase; IIA and B denotes fed-batch phase; IIIA and B denotes transition phase 
and IV denotes the induction phase. The µhigh cultivation has another induction phase, V where 
the µset is adjusted to 0.05 h
-1
. 
 
Samples (1 mL) were taken for optical density measurements at 600 nm. For dry cell weight 
measurements, 1.5 mL culture was sampled in triplicate, placed in pre-weighed tubes and 
Age of Cultivation (h) Temperature (°C)
0.0
14.4
16.4
18.4
19.1
20.4
22.4
23.6
28.8
38.4
40.6
42.2
42.9
44.4
µlow µhigh µlow µhigh
45.4
46.4
47.4
62.4
64.4
66.4
68.4
70.4
86.4
86.4
87.4
88.9
90.4
91.2
Phase
Glycerol Batch (10 g)
Transition (Methanol pre-induction constant feed at 46 g L 
-1 
h
 -1
 )
IIIA
IIIB
I
Transition (No feed)
Feed Event
IIA
IIB
Glycerol Fed-batch (Exponential feed at µset = 0.15 h 
-1
Glycerol Fed-batch (Exponential feed at µset = 0.03 h 
-1
22
Induction (Methanol exponential feed at µset = 0.05 h 
-1
)
Induction (Methanol exponential feed at µset = 0.03 h 
-1
)
Induction (Methanol exponential feed at µset = 0.01 h 
-1
) IV
IV
V
30
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centrifuged at 5000 × g for 5 min. The supernatant was removed and stored at -20°C for residual 
glycerol and/or residual methanol analysis and the tubes were placed in a 100°C oven with the 
lids open and dried overnight. The dried tubes were then moved to a desiccator for 2-3 days and 
then the tubes weighed on a microbalance. The dry cell weights were calculated for g DCW per 
L of culture and were reported as g L 
-1
). Wet cells were stored at -80°C for membrane 
preparations and specific binding activity of the hA2AR. Specific growth rates (µ) were 
calculated as described in section 2.2.2.1. Yield co-efficients were calculated according to the 
equation: 
 
 
where Y = yield co-efficient, x = biomass (g) and s = substrate (g). 
2.2.2.2.3. Finishing the 35 L bioreactor run 
Once the runs were completed, the bioreactor was inactivated (via steam, 30 min at 121°C) and 
cleaned once cooled and the pressure had been released. This was done by harvesting or 
draining the vessel of the culture. All the contaminated spears from the vessel head-plate and 
side ports were removed and prepared for autoclaving. The acid and base were reverse pumped 
until the lines were clear. The lines were then detached from the head-plate. All other tubing 
fixtures were removed. The spray ball water attachment was connected to the head-plate. 20 g 
of haemosol
®
 was added into the vessel and 60°C water was applied. Once the vessel was ¾ full 
with water, the stirrer was set at 400 rpm for 1 h at 60°C. The water was drained and the vessel 
was checked for any residual debris.  
2.2.2.3. Bench-top 2 L bioreactor cultivations 
2.2.2.3.1. Preparation of the 2 L bioreactor 
1 L BSM or FM22 medium was prepared and poured into the glass vessel. The head plate was 
attached and secured with bolts. Silicon tubes were attached to each of the ports on top of the 
head plate, clamped and the ends wrapped in foil. The pH probe was added after calibrating 
using pH 4.0 and pH 7.0 buffers. The DO and Optek (optical density measurement) probes were 
also connected. A 0.2 μm PTFE (polytetrafluoroethylene) gas filter was added to the inlet gas 
sparger and left unclamped to allow pressure equalisation and avoid vessel damage during 
autoclaving. A 250 mL glass sample bottle was attached to the sample port and a length of 
silicon tubing with a filter attached to the fork. The bioreactor was then autoclaved and 
sterilized at 121°C for 20 min with a slow cool cycle. A 0.5 L glass liquid addition bottle 
ss
xx
ds
dx
Y
o
o
s
x
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containing 50% (v/v) phosphoric acid and a 0.5 L glass liquid addition bottle of 28 % 
ammonium hydroxide were prepared for pH control. PharMed
®
 tubing was used and filters 
attached to the caps. Figure 2.4 shows the set-up at Aston University. 
 
2.2.2.3.2. Connecting the bioreactor to the control unit 
 
The bioreactor was removed from the autoclave and placed next to the control unit. The DO 
probe was connected to the ADI 1010 controller and allowed to polarize for a minimum of 6 h. 
The pH probe was also connected to the ADI 1010 controller and the Optek probe connected to 
the Optek controller. 5 mL 50% (w/v) glycerol was added to the port for the temperature probe 
(the thermo-well tube) and the temperature probe inserted. The chiller was turned on and 
connected by silicone tubing to the condenser. The silicone tubing attached to the condenser 
was connected to the off-gas analyser. The compressor and the 60%: 40% oxygen: nitrogen 
cylinder were connected to the gas supply ADI 1026 unit. The gas supply was attached to the 
sparger line on the bioreactor with a length of silicon tubing from the ADI 1026 unit with a 
filter also added. The stirrer motor was attached to the head plate. Acid and base bottles were 
connected to the controller via pumps. The foil was removed from the acid and base lines on the 
bioreactor and sprayed with 70% ethanol before connecting to the lines on the acid and base 
bottles. The water jacket lines were connected to the thermo circulator ADI 1018 unit. The feed 
bottles were also connected to the bioreactor by inserting the tubing from the bottles into a 
peristaltic pump and connecting the tubing to the feed line tubing on the bioreactor, spraying the 
line ends with 70% ethanol. 
 
2.2.2.3.3. Performing a 2 L bioreactor cultivation for P. pastoris producing hA2AR 
Recombinant hA2AR production in P. pastoris was carried out in 2 L bioreactors at 30 °C, pH 
5.0, 30% DO and stirrer speed of 700 rpm.  The temperature was reduced from 30°C to 22°C 
during the induction phase. The DO was initially maintained at 30% as the stirrer speed was in 
cascade mode of 700-1250 rpm. When the stirrer was no longer able to maintain the set-point, 
the mass flow controller (MFC) increased the proportion of air drawn from the 40%: 60% 
nitrogen: oxygen cylinder. The air flow into the bioreactor was set to 2 L min
-1
 and the cylinder 
pressure was set to 2.5 Bar. The flow rate of exit gas to the off-gas analyser was set to 
approximately 0.4 L min
-1
 by adjusting the clamp on the open end of the forked tubing. 5 mL 
PTM1 or PTM4 trace salts were added using a syringe and needle in a sterile manner through the 
septum and into the vessel. The pH was then adjusted to pH 5.0 by entering this set-point into 
the ADI1010 controller, causing the pumps to add the required volume of acid or base. The 
bioreactor was left running at these settings for approximately 1 h before inoculating. 
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To start the experiment, a pre-culture was prepared as described in section 2.2.2.1. and the 
required volume was inoculated into the 1 L medium in the vessel via the septum via aseptic 
technique to achieve and OD600 of 1. The BioXpert software was activated immediately prior to 
the inoculation.  
 
2.2.2.3.4. Glycerol batch and fed batch phase in 2 L bench-top bioreactor 
The cultures initially grew on the 40 g L
-1
 glycerol present in the BSM or FM22 media. Once 
consumed, usually ~20 h and indicated by a DO spike, a fed batch phase was started. 50% w/v 
glycerol with 12 mL PTM1 trace salts L
-1
 was fed into the vessel at a flow rate of 12 mL h
-1 
for 4 
h for the BSM run and 14 mL h
-1 
for 40 h for the FM22 run. The transition phase was 1-2 h after 
the feed was stopped and before methanol induction began.  
 
2.2.2.3.5. Induction phase in 2 L bench-top bioreactor 
Induction was begun (after starvation) using 20% v/v methanol with 12 mL PTM1 trace salts L
-
1
. The pump was set at 2.04 mL h
-1
 for 40 h and remained at that speed until the run ended at 
~100 h. Optical density, dry cell weight and wet cell weights were monitored as in section 
2.2.2.2.2. 
 
2.2.2.4. Micro-24 microreactor cultures 
2.2.2.4.1. Preparation of Micro-24 microreactor cultivations 
The Micro-24 bioreactor from Pall Corporation comprises a control unit, a lap top and a 24 well 
plate. Figure 2.8 and 2.9 shows the set-up of the Micro-24 microreactor at Aston University and 
also a close up of the 24 well plate. The control unit both monitored and controlled the culture 
conditions of each well independently via the laptop. The 24 well plates held a working volume 
of 3-7 mL and in these experiments 5 mL was used. The 0.22 µm filter caps or closures for the 
wells used were Type D and were required for experiments that used more than 40% DO.  Type 
A 0.22 µm filter caps or closures with airlock valves were required for experiments that used 
less that 40% DO. In the 24 well plates, two optical sensor spots and a sparging port were 
present in the bottom of each well. Culture pH and DO was monitored by the sensor spots and 
controlled by the sparging port with allowed oxygen, carbon dioxide and ammonium hydroxide 
gas (produced via a pressure vessel containing 15% ammonium hydroxide) all at constant gas 
cylinder pressures of 2 Bar. The culture temperature was controlled and monitored via the use 
of a thermo-cycler type heating element and coolant fans. It was important to have a 
temperature difference of no more than 2°C between adjacent wells. The vacuum was generated 
via the use of sterile clean dry air (CDA) compressor which was set at 6 Bar. The 24 well plate 
was set at 500 rpm agitation with a circular orbit of 5 mm. The Micro-24 microreactor 
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instrument was controlled using the Micro cellerator software installed on the laptop. These 
were both connected via an uninterruptable power supply (UPS).  
 
Figure 2.8 Micro-24 microreactor set-up at Aston University. Photograph shows the 
components required for the Micro-24 to operate, including a laptop with controlling 
software, gas supplies, air compressor and a gas bubbler to generate ammonium 
hydroxide gas. 
 
 
Figure 2.9 Micro-24 microreactor 24 well plate. The plate is clamped onto the shaking, 
vacuum platform of the instrument. The caps shown here are Type D, for use with high 
aeration rates (>40% DO). 
 
 
 
Oxygen, carbon dioxide 
and nitrogen gas supply
Laptop with controller 
software
UPS Micro-24 microreactor
Ammonium hydroxide
pressure vessel
CDA compressor for 
constant 6 Bar supply
CDA filter
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2.2.2.4.2. Antifoam and medium assessment in Micro-24 well plates 
Prior to carrying out experiments, the medium and antifoam were tested in the well plates to 
ensure that no gas delivery membranes present in the bottom of each well would ‗wet‘ out or 
that any blockages would occur because of the medium composition. Antifoam is required as a 
crucial component in fermentation processes. Foam or bubbles are often introduced during 
fermentation due to mixing in a system and therefore aeration. Severe foaming may introduce 
contamination and also reduce yields of a product. Mazu DF 204 (Sigma) was used as an 
antifoam agent. It is a proprietary organic agent that is widely used in the manufacturing, 
chemical and petroleum industries and is not harmful to micro-organisms.  Figure 2.10 shows a 
medium and antifoam test incubation cassette set up. The test was run with 2× CBS defined 
medium, Mazu DF 204 antifoam and 2.5% DMSO. The Micro-24 Bioreactor was configured to 
provide the wells with a continuous flow of sterile CDA at 20 cm
2
 per min and at 500 rpm 
orbital speed. Temperature, pH and DO control were switched off. This test was run for 10 min 
and observations were made for sufficient bubbling in the wells and also the bottom of the 
incubation cassette was checked for any wetness.  
Figure 2.10 Antifoam and media test set up of the Micro-24 microreactor 24 well plate. 
The test showed that there was no detrimental effect of the medium and antifoam. It was 
decided that 600 ppm of Mazu DF 204 would be used for all proceeding experiments.  
2.2.2.4.3. Performing the Micro-24 microreactor cultivations 
The run conditions were programmed into the Micro-24 control software according the DoE 
input factors required (temperature, pH and DO). A fourth input factor was also investigated, 
the presence and absence of 2.5% DMSO. The medium composition for wells that required 
DMSO was 111.78 mL 2× CBS, 0.125 mL 100% DMSO, 7.5 mL 40× glucose, 30 mL 10× drop 
out solution (for S.cerevisiae wild type and TM6* strains 10× drop out solution without uracil 
was used and for the S.cerevisiae BMS1 strain, 10× drop out solution without histidine was 
used), 0.3 mL trace elements solution and 0.3 mL vitamin solution. 5 mL of this medium was 
aliquotted into wells where DMSO was to be added. The medium composition for wells where 
that did not require DMSO was 111.90 mL 2× CBS, 7.5 mL 40× glucose, 30 mL 10× drop out 
solution (composition as above), 0.3 mL trace elements solutions and 0.3 mL vitamins solution. 
5 mL of this medium was aliquotted into wells where DMSO was not present. The PI settings 
were altered to minimise oscillations after 2 h of culture growth. The PI settings that were used 
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for all yeast strains were pH (P = 8, I = 2) and DO (P = 2, I = 20). Cultures were grown and 
glucose levels were monitored via the use of Accu-Chek Active glucose analyser (Roche 
Diagnostics). The run was stopped when the glucose levels were between 10–30 mM for each 
well. The 5 mL cultures were centrifuged at 5000 × g, 4°C for 5 min. The cell pellets were 
frozen in liquid nitrogen and stored at -80°C for subsequent membrane fraction preparations.  
2.2.3. Glycerol assay 
Residual glycerol in the culture supernatants was analysed using a glycerol quantitation kit (r-
biopharm, Roche).  The basis of the kit is that glycerol is phosphorylated by adenosine-5′-
triphosphate (ATP) to L-glycerol-3-phosphate by glycerokinase (GK): 
 
The adenosine-5′-diphosphate (ADP) formed in the above reaction is then re-converted into 
ATP by phosphoenolpyruvate (PEP) with the aid of pyruvate kinase (PK) and the formation of 
pyruvate: 
 
In the presence of L-lactate dehydrogenase (L-LDH), pyruvate is reduced to L-lactate by 
reduced nicotinamide-adenine dinucleotide (NADH) and the oxidation of NADH to NAD
+
: 
 
The amount of NADH oxidised to NAD
+
 is stoichiometric with respect to the glycerol 
phosphorylated by GK and is measured by light absorption at 334, 340 or 365 nm. The kit 
includes 4 bottles: bottle 1; glycylglycine buffer (pH 7.4), 7 mg NADH, 22 mg ATP, 11 mg 
PEP-CHA, magnesium sulphate, bottle 2; 240 U of pyruvate kinase and 220U of L-lactate 
dehydrogenase, bottle 3; 34 U glycerokinase solution and bottle 4; glycerol assay positive 
control solution (known amount of glycerol). All samples to be tested were placed at 80°C for 
15 min to de-activate any naturally-occurring enzymes in the sample. Bottle 1 contents were 
dissolved into 11 mL distilled water. The bottle was left to stand for 10 min at 25°C. For the 
blank sample, in a plastic disposable cuvette, 333.3 µL of bottle 1, 666.6 µL of water and 3.3 
µL of bottle 2 were added, covered with parafilm, mixed by inverting and left to stand for 7 
min. The absorbance at 340 nm was recorded and constituted the Absorbance 1 (A1) reading. 
Glycerol + ATP 
GK
L-glycerol-3-phosphate + ADP 
ADP + PEP 
PK
ATP + Pyruvate 
Pyruvate + NADH + H+
L-LDH
L-lactate + NAD+
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Then 3.3 µL bottle 3 was added to the same cuvette, mixed and left to stand for 10 min. The 
absorbance was recorded at 340 nm, which constituted Absorbance 2 (A2) reading. For the 
control or sample measurement, 33.3 µL bottle 4 was included in the first part of the reaction. 
The following equation was used to calculate the concentration of glycerol: 
 
2.2.4. Methanol assay 
Residual methanol in culture supernatants was analysed using a Thermo Scientific FOCUS Gas 
Chromatograph. Appropriately-diluted culture supernatants (typical dilutions were 1:100) were 
filter sterilised with syringe filter to remove any debris. 1μL of each sample was injected onto 
the column and the methanol peak was integrated using QuanLab
® 
software. The sample was 
repeated to achieve a duplicate reading and was followed by a blank sample (filter-sterilised 
water) injection before the next sample was loaded. The mean value of the integrated peak area 
was used to estimate the residual methanol within the sample by comparison with methanol 
standards (0, 0.013, 0.065, 0.13, 0.25, 0.38, 0.5, 1, 2, 5 and 10%) and a standard curve (Figure 
2.11). 
 
c = (V × MW / ε × d × v 1000) × ΔA 
Where:
c = concentration of glycerol (g/L)
V = final volume (mL)
MW = molecular weight of glycerol (g/mol)
ε = extinction coefficient of NADH at 340 nm (6.3 L x per mmol x per cm)
d = light path (cm)
v = sample volume (mL)
ΔA = (A1 - A2)sample - (A1 - A2) blank
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Figure 2.11 A representative calibration curve for determining the concentration of 
methanol. Inset is a representative gas chromatograph for one of the methanol standards from 
which the integrated peak areas are calculated (Bawa et al, 2012). 
2.2.5. Green Fluorescent Protein (GFP) assay 
100 μL supernatant was added to black 96 well plates followed by 50 μL 1M potassium 
phosphate buffer, pH 8.0. A recombinant GFP standard was used (Vector Laboratories); the 
standard curve ranged from 5 mg mL
-1
 to 20 mg mL
-1
. The relative fluorescence units (RFU) 
were determined using a Spectramax Gemini plate reader with λexe of 397 nm and λem of 506 nm 
all measured at 25°C.   
2.2.6. Small scale membrane preparations 
Since yeast cell pellets retrieved from Micro-24 microreactor wells were relatively small 
(between 50-300 mg) it was appropriate to use the glass bead agitation method. Each pellet was 
mixed with 500 µL ice cold breaking buffer and 500 µL acid washed glass beads (Sigma) in a 2 
mL breaking tube. A 1:2000 dilution of a protease inhibitor cocktail IV set (Calbiochem) was 
added to each tube. The caps of the tubes were secured and placed on ice. The tubes were 
agitated in a chilled Tissue Lyser LT (Qiagen) at 50 Hz for 10 min. The supernatant was 
removed from the tube by carefully creating a small hole at the bottom of the breaking tube with 
a sterile needle. The tubes were placed in larger 15 mL Falcon tubes with an adapted lid to hold 
the breaking tube in place. The tubes were centrifuged at 5000 × g for 3 min. The recovered 
material was transferred to a new 1.5 mL Eppendorf tube and centrifuged at 15000 × g for 15 
min. The resultant supernatant was transferred to 1 mL ultra-centrifuge tubes and centrifuged at 
100000 × g for 1 h at 4°C. The supernatant was discarded and the pellet was re-suspended with 
100 µL ice cold buffer A. The samples were stored at -20°C.  
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2.2.7. Large scale membrane preparations 
For large scale membrane preparations, when at least 20 g of culture pellet was available for 
processing (typically from 35 L and 2 L bioreactors), homogenising pressure was applied 
instead of agitation to break the yeast cell walls. The cells were re-suspended in ice cold 
breaking buffer at a ratio of 2:1 buffer to cells. A 1:2000 dilution of a protease inhibitor cocktail 
IV set was added to cells and buffer. The cells were passed through an Emulsiflex-C3 cell 
disrupter (Avestin) fitted with a chilled heat exchanger for 20 min at a homogenising pressure of 
30000 psi. Figure 2.12 shows the Emulsiflex-C3 set-up at Aston University. The cells were 
observed under a light microscope to check the extent of the cell breakage. Typically, more than 
90% of the cells were disrupted. The sample was centrifuged at 10000 × g for 30 min to remove 
the unbroken cells and cellular debris. The supernatant was transferred to ultra-centrifuge tubes 
and centrifuged at 100000 × g for 1 h. The pellet was re-suspended in ice cold buffer A using a 
glass homogeniser at a ratio of 10 mL per gram of pellet. The samples were stored at -80°C. 
 
Figure 2.12 Emulisflex-C3 (Avestin) pressure homogeniser. Photograph shows the set-up at 
Aston University and the associated parts including an ice box with ice-water mix for the chiller 
and external pump to pump chilled water for the sample chiller. 
2.2.8. Protein quantification 
Total protein quantification was determined by using a bicinchoninic acid (BCA) assay. A 1:50 
mixture of BCA : copper (II) sulphate solution (4.9 mL : 0.1 mL) and bovine serum albumin 
standards were prepared (0-10 µg). The membrane fraction sample to be analysed was diluted 
appropriately (typically a dilution of 1:100 was made) and added to the BCA : copper (II) 
Sample chamber
Pressure regulator
Disruption chamber
Chiller
Sample outlet tubing
Pressure gauge of disruption 
chamber
Tubing to flow ice cold water for
chiller
Ice box with ice cold water
Pump for tubing
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sulphate solution. The final volume of either the standard or sample was 200 µL. This was 
pipetted into a clear, flat-bottomed 96 well plate. After thorough mixing of the wells, the plate 
was incubated in the dark at 37°C for 15 min. The absorbance was read with a plate reader 
(BioTek Instruments) at 570 nm and the protein concentration was determined by plotting a 
standard curve of the BSA standards and extrapolating the membrane fraction value from the 
straight line equation (y = mx +c). Figure 2.13 shows an example standard curve generated from 
a BCA assay.  
 
Figure 2.13 BCA standard curve. BCA reactions measured at 570 nm generated with BSA 
standards at 0, 2, 4, 6, 8 and 10 µg. Data plotted and a straight line equation (y =mx + c) 
generated to derive unknown samples. 
2.2.9. Immunoblot analysis 
2.2.9.1. Sodium dodecyl sulphate polyacrylamide electrophoresis (SDS PAGE) gels 
Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE) gels contained 
10% polyacrylamide in the separating gel and 4% polyacrylamide in stacking gel. Table 2.2 and 
2.3 show the components of these gels.  
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Table 2.2 10% separating gel. The APS was made fresh each time and the TEMED was always 
added last. Water saturated butanol was added on top of the gel to level it.  It was washed off 
with distilled water and the space between the two glass plates were dried with filter paper. 
10% separating gel Per gel 
30% polyacrylamide 1.9 mL 
Water 2.2 mL 
Tris-HCl 1.5M, pH 8.8 1.5 mL 
10% SDS 60 µL 
20% ammonium persulphate (APS) 20 µL 
TEMED 4.5 µL 
 
 
Table 2.3 4% stacking gel. The APS was made fresh each time and the TEMED was always 
added last. A gel comb was added and the gel was left to set. 
4% stacking gel Per gel 
30% polyacrylamide 0.3 mL 
Water 1.5 mL 
Tris-HCl 0.5M, pH 6.8 0.6 mL 
10% SDS 25 µL 
20% ammonium persulphate (APS) 10 µL 
TEMED 2.5 µL 
 
 Up to 15 µL of sample was mixed with 5 µL SDS Sample Buffer with β-mercaptoethanol. This 
was heated to 50°C for 5 min prior to loading onto the gel. 5 µL of a protein marker (PageRuler 
pre-stained protein ladder, Fermentas) was also loaded in one well. The marker ranged from 10 
kDa to 250 kDa. The gels were run in 1× SDS/tris/glycine running buffer (GeneFlow) at 100 V 
until the dye front reached the bottom of the gel.  
2.2.9.2. Immunoblots 
Once the SDS gel had run, the stacking gel was removed and discarded from the separating gel. 
The separating gel was placed into 1× tris/glycine/methanol transfer buffer (Geneflow). 
Nitrocellulose transfer membrane (Whatman PROTRAN) and 6 sheets of filter paper (Whatman 
3 mm chromatography paper) were cut to the same size as the separating gel. A fibre pad (pre-
soaked in transfer buffer) and three filter papers were placed on the black side of a Bio-Rad 
Easy Lock Cassette. The separating gel was carefully placed on top of the filter papers followed 
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by the nitrocellulose membrane and the remaining three filter papers. Air bubbles were removed 
by rolling a plastic serological pipette over the nitrocellulose sandwich. A final fibre pad was 
added and the cassette was locked. The cassette was inserted into an electrophoretic blotting 
cell. An ice cooling unit was also added to the cell and filled with the transfer buffer. It was 
important to have the nitrocellulose membrane facing the anode of the electrophoretic cell. The 
transfer ran at 100 V for 1 h. 
Once the transfer was complete, the nitrocellulose membrane was blocked with an aqueous 
solution of 5% dried milk in PBS for 1 h at room temperature on a rocker set at 20 rpm. A 
primary antibody, 6x His Monoclonal antibody (Serotec) at a dilution of 1:5000 was added to 
the 5% blocking solution and nitrocellulose membrane. This was placed at 4°C overnight. The 
membrane was washed twice in PBS 0.2% Tween-20 for 5 min. A secondary antibody, Anti-
mouse IgG (Sigma) was added to a 5% blocking solution for 1 h at room temperature on a 
rocker set at 20 rpm. The membrane was washed twice with PBS 0.2% Tween-20 for 5 min. 
EZ-ECL Chemiluminescence (Geneflow) solution was used following the manufacturer‘s 
instructions. The membranes were air dried and exposed using a CCD camera (Uvitec) for 25 
min and the image files saved. 
2.2.10. Yeast membrane solubilisation with DDM 
 
Solubilisation with n-dodecyl-ß-D-maltoside (DDM) was performed with the following 
solubilisation buffer: 20 mM HEPES, pH 7.4, 50% glycerol, 250 mM NaCl, 1 µL protease 
inhibitors, 5% (w/v) DDM and 0.5% (w/v) cholesteryl hemi-succinate (CHS). The membrane 
fraction added to the solubilisation buffer was 1:1 where the starting concentration was ~ 20mg 
mL
-1
 and therefore the final concentration in the solubilisation was ~ 10 mg mL
-1
. After 
incubation with slow rotation at 4°C for 4 h, the sample was centrifuged at 100000 × g for 1 h. 
The supernatant contained DDM solubilised hA2AR and was stored at 4°C for further studies for 
a maximum of 3 days.   
 
2.2.11. Yeast membrane solubilisation with styrene maleic acid (SMA) co-polymer 
 
Solubilisation with SMA polymer (supplied by Dr. Yu-pin Lin and Dr. Mohammed Jamshad, 
University of Birmingham) was carried out in the following solubilisation buffer: 10% glycerol, 
500 mM NaCl, 2.5% (w/v) SMA (prepared as in section 2.1.1.11.6.), 1% (w/v) DMPC and 50 
mM Tris-HCl, pH 8 with a final protein concentration between 20 - 40 mg mL
-1
. The slurry was 
stirred for 2 h at room temperature and then centrifuged at 100000 x g for 1 h. 
The supernatant contained the styrene maleic acid lipid particle (SMALP) solubilised hA2AR 
and was stored for no more than 3 days for further studies.  
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2.2.12. Yeast membrane solubilisation with poly (maleic anhydride-styrene) (PMAS) 
 
Solubilisation with PMAS polymers (supplied by Dr. Anisa Mahomed, Aston University) was 
prepared as in section 2.1.1.11.4. and 2.1.1.11.5. The initial solubilisations were carried out as 
in a solubilisation buffer similar to that in 2.2.11. This was termed a ‗standard‘ protocol and was 
compared to a protocol which only had the membrane fraction, the PMAS and the DMPC; this 
was termed the ‗simple‘ protocol. Both versions were tested for the highest specific binding 
activity (Chapter 5) of hA2AR.The effect of temperature (room temperature or 4°C) and the time 
of incubation (4 h or over-night) were also considered for the solubilisation protocol. It was 
found that the optimal protocol was adding a final concentration of 10-15 mg mL
-1
 total protein 
to 1 % DMPC (final concentration) and 2.3 % PMAS (final concentration). The solubilisation 
mixture was placed on a rocker at 20 rpm at room temperature and rocked for at 16 h or over-
night. This was then centrifuged at 100000 x g for 1 h and the supernatant contained the PMAS 
solubilised hA2AR and was stored at 4°C for no more than 3 days for further studies. 
 
2.2.13. Radio-ligand binding for hA2AR 
The radio-ligand binding assay is based on the use of a radioactively labelled compound which 
interacts with a receptor. Tritium [
3
H] is the most common isotope used to label these 
compounds due to its long half-life (12.3 years) (Lucas and Unterweger, 2000). All radio-ligand 
binding assays were performed using [
3
H]ZM241385 (ARC), a hA2AR antagonist (Palmer et al., 
1995). 
The binding buffer used was 50 mM sodium phosphate, 0.5 M EDTA, pH 7.4 for the all types 
of radio-ligand binding assays performed. For all reactions, the tubes were mixed by inversion 
and incubated in a water bath at 30°C for 2 h. For the membrane bound reactions, the tubes 
were centrifuged at 14000 rpm for 5 min. The supernatant was discarded and the tube washed 
with tap water twice. The tubes were left open and inverted on a rack to dry for 1-2 h. 100 µL 
soluene was then added to each tube and placed in a 50°C oven for 2 h to dissolve the pellet. 
This was transferred to a scintillant vial where 4 mL of scintillant solution was added, mixed 
thoroughly and placed on the scintillation counter (Packard 1600TR Liquid Scintillation 
Analyser) for counting.  
To analyse solubilised supernatants, 50 µL of binding reaction was applied to a Micro-BioSpin 
chromatography column (BioRad) and centrifuged at 3000 rpm for 2 min. These columns were 
previously equilibrated with 2 × washes of 500 µL binding buffer and centrifuged at 3000 rpm 
for 1 min. The eluate was transferred to a scintillant vial where 4 mL scintillant solution was 
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added, mixed thoroughly and placed on the scintillation counter (Packard 1600TR Liquid 
Scintillation Analyser) for counting.  
2.2.13.1. Single-point binding assays for hA2AR 
These assays were used as the initial test for correctly folded hA2AR to see if any binding was 
present. A single, high concentration, usually the concentration at the top end of the a saturation 
binding curve of [
3
H]ZM241385 (10 nM) was used to calculate specific binding activity (non-
specific binding – total binding = specific binding).  Table 2.4 shows the set-up for either 
membrane bound or solubilised hA2AR single-point binding reactions.  
Table 2.4 Single-point binding assay reaction set-up. Single-point assay for either membrane 
bound or solubilisation supernatant with the components of the total and non-specific reaction 
which include the tritiated ZM241385, adenosine deaminase, binding buffer, the amount of 
membrane or volume of solubilisation supernatant and unlabelled ZM241385 for the non-
specific reactions. 
 
2.2.13.2. Saturation binding assays for hA2AR 
A saturation binding assay was used to measure specific binding (by subtracting the total 
binding from the non-specific binding) at various concentrations of [
3
H]ZM241385. The assay 
results in a curve.  Non-linear regression is used to calculate the maximum number of binding 
sites that can be occupied (Bmax) and also the equilibrium dissociation constant (Kd and pKd (-
log(Kd)); (Hulme and Trevethick, 2010). Table 2.5 and 2.6 show the reaction set-up for either 
membrane bound or for the solubilised supernatant saturation binding curves. The experimental 
method was as described in section 2.2.13. 
 
 
 
 
 
 
Membrane (µg) 
or supernatant 
from 
solubilisation 
(µL)
Final 
[
3
H]ZM241385 
concentration 
(nM)
Adenosine 
deaminase 
(U)
Binding 
buffer 
(µL)
Final 
[
3
H]ZM241385 
concentration 
(nM)
Adenosine 
deaminase 
(U)
Unlabelled 
ZM241385 
concentration 
(µM)
Binding 
buffer 
(µL)
100 µg 10 0.1 up to 500 10 0.1 1 up to 500
50 µL 10 0.1 up to 200 10 0.1 1 up to 200
Total binding reaction Non-specific binding reaction
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Table 2.5 Saturation binding assay reaction set-up for membrane bound hA2AR. Saturation 
binding assay for membrane bound hA2AR with the components of the total and non-specific 
reaction which include the tritiated ZM241385 at different concentrations, adenosine 
deaminase, binding buffer, the amount of membrane or volume of solubilisation supernatant 
and unlabelled ZM241385 at one concentration for the non-specific reactions. 
 
Table 2.6 Saturation binding assay reaction set-up for solubilised hA2AR. Saturation binding 
assay for solubilised hA2AR with the components of the total and non-specific reaction which 
include the tritiated ZM241385 at different concentrations, adenosine deaminase, binding 
buffer, the amount of membrane or volume of solubilisation supernatant and unlabelled 
ZM241385 at one concentration for the non-specific reactions. 
 
2.2.13.3. Competition binding assays for hA2AR 
A competition binding assay is used to measure specific binding (by subtracting the total 
binding from the non-specific binding) at various concentrations of unlabelled ZM241385 or 
other antagonists or agonists whilst the [
3
H]ZM241385 remains constant at a low concentration, 
in this instance, 2 nM. When a homologous competitive binding curve was carried out, the 
Cheng-Prusoff equation was applied to a one site binding model on the curve generated. From 
this equation the Kd and hence the pKd could be calculated of the competitor: 
Kd = Ki = EC50 – [Radio-ligand] 
where Ki = dissociation constant and is equivalent to Kd for homologous curves; EC50 = half the 
effective concentration of the unlabelled ZM241385 and [Radio-ligand] = concentration of the 
[
3
H]ZM241385. 
Membrane (µg) 
Final 
[
3
H]ZM241385 
concentration 
(nM)
Adenosine 
deaminase 
(U)
Binding 
buffer 
(µL)
Final 
[
3
H]ZM241385 
concentration 
(nM)
Adenosine 
deaminase 
(U)
Unlabelled 
ZM241385 
concentration 
(µM)
Binding 
buffer 
(µL)
100 0.05 0.1 up to 500 0.05 0.1 1 up to 500
100 0.1 0.1 up to 500 0.1 0.1 1 up to 500
100 0.5 0.1 up to 500 0.5 0.1 1 up to 500
100 1 0.1 up to 500 1 0.1 1 up to 500
100 5 0.1 up to 500 5 0.1 1 up to 500
100 10 0.1 up to 500 10 0.1 1 up to 500
Total binding reaction Non-specific binding reaction
Supernatant 
from 
solubilisation 
(µL)
Final 
[
3
H]ZM241385 
concentration 
(nM)
Adenosine 
deaminase 
(U)
Binding 
buffer 
(µL)
Final 
[
3
H]ZM241385 
concentration 
(nM)
Adenosine 
deaminase 
(U)
Unlabelled 
ZM241385 
concentration 
(µM)
Binding 
buffer 
(µL)
50 0.05 0.1 up to 200 0.05 0.1 1 up to 200
50 0.1 0.1 up to 200 0.1 0.1 1 up to 200
50 0.5 0.1 up to 200 0.5 0.1 1 up to 200
50 1 0.1 up to 200 1 0.1 1 up to 200
50 5 0.1 up to 200 5 0.1 1 up to 200
50 10 0.1 up to 200 10 0.1 1 up to 200
Total binding reaction Non-specific binding reaction
118 
 
When a heterologous competitive binding curve was carried out, the Cheng-Prusoff equation 
was again applied to a one site binding model on the curve generated. From this equation the Ki 
and hence the pKi could be calculated of the competitor:  
 
where Ki = dissociation constant; EC50 = half the effective concentration of the unlabelled 
agonist or antagonist to hA2AR and [Radio-ligand] = concentration of the [
3
H]ZM241385 
(Motulsky, 1995). 
These assays allowed the pharmacological characterisation of hA2AR after solubilisation with 
various polymers (Chapter 5). The agonist, NECA and the antagonists, theophylline, XAC and 
ZM2413835 were assayed. Table 2.7, 2.8, 2.9 and 2.10 shows the competition binding reaction 
set-up for each drug (ZM241385, theophylline, NECA and XAC, respectively). The 
experimental methods are described in section 2.2.13. 
Table 2.7 Competition binding assay reaction set-up for membrane bound or solubilised 
hA2AR with ZM241385. Saturation binding assay for either membrane bound or solubilised 
hA2AR with the components of the total and non-specific reaction which include tritiated 
ZM241385 at one concentration of 2 nM, adenosine deaminase, binding buffer, the amount of 
membrane or volume of solubilisation supernatant and unlabelled ZM241385 at various 
concentration for the non-specific reactions. 
 
 
 
 
 
 
Membrane (µg) 
Solubilised 
(µL)
Final 
[
3
H]ZM241385 
concentration 
(nM)
Adenosine 
deaminase 
(U)
Unlabelled 
ZM241385 
concentration 
(nM)
Binding buffer  500 µL for 
membrane, 200 µL for 
solubilised
100 µg or 50 µL 2 0.1 1000 up to 500 or 200
100 µg or 50 µL 2 0.1 100 up to 500 or 200
100 µg or 50 µL 2 0.1 10 up to 500 or 200
100 µg or 50 µL 2 0.1 1 up to 500 or 200
100 µg or 50 µL 2 0.1 0.1 up to 500 or 200
100 µg or 50 µL 2 0.1 0.001 up to 500 or 200
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Table 2.8 Competition binding assay reaction set-up for membrane bound or solubilised 
hA2AR with theophylline. Saturation binding assay for either membrane bound or solubilised 
hA2AR with the components of the total and non-specific reaction which include tritiated 
ZM241385 at one concentration of 2 nM, adenosine deaminase, binding buffer, the amount of 
membrane or volume of solubilisation supernatant and unlabelled theophylline at various 
concentration for the non-specific reactions. 
 
Table 2.9 Competition binding assay reaction set-up for membrane bound or solubilised 
hA2AR with NECA. Saturation binding assay for either membrane bound or solubilised hA2AR 
with the components of the total and non-specific reaction which include tritiated ZM241385 at 
one concentration of 2 nM, adenosine deaminase, binding buffer, the amount of membrane or 
volume of solubilisation supernatant and unlabelled NECA at various concentration for the 
non-specific reactions. 
 
  
Membrane (µg) 
Solubilised 
(µL)
Final 
[
3
H]ZM241385 
concentration 
(nM)
Adenosine 
deaminase 
(U)
Unlabelled 
theophylline 
concentration 
(mM)
Binding buffer  500 µL for 
membrane, 200 µL for 
solubilised
100 µg or 50 µL 2 0.1 10 up to 500 or 200
100 µg or 50 µL 2 0.1 5 up to 500 or 200
100 µg or 50 µL 2 0.1 1 up to 500 or 200
100 µg or 50 µL 2 0.1 0.5 up to 500 or 200
100 µg or 50 µL 2 0.1 0.1 up to 500 or 200
100 µg or 50 µL 2 0.1 0.05 up to 500 or 200
100 µg or 50 µL 2 0.1 0.01 up to 500 or 200
Membrane (µg) 
Solubilised 
(µL)
Final 
[
3
H]ZM241385 
concentration 
(nM)
Adenosine 
deaminase 
(U)
Unlabelled 
NECA 
concentration 
(µM)
Binding buffer  500 µL for 
membrane, 200 µL for 
solubilised
100 µg or 50 µL 2 0.1 10 up to 500 or 200
100 µg or 50 µL 2 0.1 5 up to 500 or 200
100 µg or 50 µL 2 0.1 1 up to 500 or 200
100 µg or 50 µL 2 0.1 0.5 up to 500 or 200
100 µg or 50 µL 2 0.1 0.1 up to 500 or 200
100 µg or 50 µL 2 0.1 0.05 up to 500 or 200
100 µg or 50 µL 2 0.1 0.01 up to 500 or 200
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Table 2.10 Competition binding assay reaction set-up for membrane bound or solubilised 
hA2AR with XAC. Saturation binding assay for either membrane bound or solubilised hA2AR 
with the components of the total and non-specific reaction which include tritiated ZM241385 at 
one concentration of 2 nM, adenosine deaminase, binding buffer, the amount of membrane or 
volume of solubilisation supernatant and unlabelled XAC at various concentration for the non-
specific reactions. 
 
 
2.2.13.4. Competition binding curve on membrane bound hA2AR from HEK cells 
5 mL trypsin EDTA was added to a single T75 flask of HEK cells producing hA2AR and was 
placed on a shaker for 5 min until the cells came loose. The cells were scraped and transferred 
to a 50 mL tube. 10 mL binding buffer was added to the tube and was probe sonicated 
(Polytron) for 15 s. 50 µL cells were added to each competition binding curve reaction and 
followed the same set-up as described in section 2.2.13.3. The experimental conditions are 
described in section 2.2.13., following the steps for the membrane bound reactions.  
 
Membrane (µg) 
Solubilised 
(µL)
Final 
[
3
H]ZM241385 
concentration 
(nM)
Adenosine 
deaminase 
(U)
Unlabelled 
XAC 
concentration 
(µM)
Binding buffer  500 µL for 
membrane, 200 µL for 
solubilised
100 µg or 50 µL 2 0.1 100 up to 500 or 200
100 µg or 50 µL 2 0.1 50 up to 500 or 200
100 µg or 50 µL 2 0.1 10 up to 500 or 200
100 µg or 50 µL 2 0.1 5 up to 500 or 200
100 µg or 50 µL 2 0.1 1 up to 500 or 200
100 µg or 50 µL 2 0.1 0.1 up to 500 or 200
100 µg or 50 µL 2 0.1 0.05 up to 500 or 200
100 µg or 50 µL 2 0.1 0.01 up to 500 or 200
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Chapter 3: The application of ‘Design of Experiments’ (DoE) to 
membrane protein production 
Typically, maximising the yield of a functional membrane protein requires many ‗trial and 
error‘ attempts,  which may involve varying one factor at a time for a large number of variables, 
thereby amplifying the number of experiments and leading to high costs and increased times. 
Furthermore, there is no guarantee of establishing optimal conditions, even when all the factors 
have been tested because any interactions between these variables will not be tested; 
interactions between pH and temperature for example may be critical in any optimisation 
process (Isar et al., 2007, Shivam and Mishra, 2010). Statistical Design of Experiments (DoE) 
allows for a more rational approach that reduces the number of experiments required to 
determine what the key variables are and ultimately establishes a predictive model in the form 
of an equation for optimal protein yields. In this chapter, a DoE approach was used to 
investigate maximizing the yield of hA2AR. In order to keep the number of experimental factors 
to a minimum, the first experiments were designed using the yeast Saccharomyces cerevisiae as 
the production host because an induction step could be avoided by using constititive expression 
in this yeast species. The hA2AR construct used encodes a full length, glycosylated protein with 
a haem-agglutinin tag (HA3) and includes an alpha- factor signal sequence that was previously 
designed and cloned into pYX212 or pYX222 TPI vectors by Dr. Renaud Wagner, Université 
de Strasbourg, France. This was used because it was immediately available at Aston University. 
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The DoE process is normally sectioned into three parts: screening (where a large number of 
input factors are explored with the goal to reduce the number going forward for further 
investigation); process characterisation (identifies and quantifies key input factors by generating 
a predictive equation) and process optimisation (identifying previously unexplored responses 
that may require a different design) (Montgomery, 2006). 
Table 3.1 defines the key terminology used in this chapter. 
Table 3.1 Glossary of relevant DoE terminology. Adapted from (Antony, 2003). 
Main effect The effect of an independent variable on a dependent variable, 
averaging across the levels of any other independent variables 
Interaction A situation in which the simultaneous influence of two variables on 
a third is not additive 
Contour A function of two variables forming a curve along which the 
function has a constant value 
Residual The error in a result - the difference between an individual value and 
the mean value for a particular data set 
R² The coefficient of determination, which indicates how well data 
points fit a line or curve 
Adjusted R² (Radj
2
) A modified R² value that adjusts for the number of explanatory 
terms in a model relative to the number of data points, this prevents 
the R² value spuriously increasing when extra explanatory variables 
are added 
Analysis of Variance 
(ANOVA) 
A set of statistical models used to compare and analyse the 
differences between three or more mean values, looking for 
statistical significance 
Degrees of freedom 
(DF) 
The number of values or parameters in a system that are free to vary 
independently 
Sum of squares (SS) A measure of the total variability of a set of data around the mean, 
calculated by summing the squared deviations of the individual data 
points.   
Adjusted mean square An adjusted mean, corrected to compensate for data imbalances 
F statistic (Fisher‘s test) Derived from the difference between the mean responses at the level 
studied, it is analogous to a measure of signal to noise ratio for each 
factor. 
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Figure 3.1 outlines the steps for a DoE to be carried out. First, after the protein of interest is 
chosen, the input factors (also referred as parameters or variables) that the researcher wishes to 
interrogate need to be established. These are usually physical and environmental variables, such 
as temperature, pH, dissolved oxygen (DO) and medium composition that could have an effect 
on the yield of the protein at specific set-points levels. The simplest factor level design in a DoE 
is typically known as a , where  is the factor that is examined at 2 levels, usually a low and 
high level. In the design matrix, this is typically coded as -1 for the low level and +1 as the high 
level. This type of input factor is termed a ‗numeric‘ or quantitative input factor. The input 
factor could also just be treated as an ‗attribute‘ or qualitative factor where there are no levels 
associated with it. For instance, just testing the presence or absence of a reagent has an effect on 
protein yield (Montgomery, 2006, Antony, 2003). 
The output response or responses must also be defined in order to run a DoE. This is usually the 
recombinant protein yield but the total cell biomass is also an example of an output response. 
The input and output factors are considered in the DoE set-up which define the experiments to 
be run based on this information. There are now fully developed DoE specific software 
programmes that facilitate DoE design and statistical analysis and these include Minitab
®
, 
Modde
®
, ECHIP
®
 and Design - Expert
®
. The software programme returns several types of DoE. 
Each one has a specific ‗design matrix‘ appropriate for the input factors and number of levels to 
be interrogated. The design matrix will define the number of replicates, the layout of the 
experiments and the type of relationships that will be examined between the factors (linear, 
interaction or quadratic). Based on this information, the most suitable DoE is selected and the 
experiments are carried out as outlined by the DoE (Bora et al., 2012). 
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Figure 3.1 Carrying out a DoE- steps to follow in a bioprocess setting. The ‘road-map’ 
outlines a typical route to carrying out a DoE for recombinant protein production as described 
in detail in the text.  
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Following experimentation the output responses are collected and the values are entered back 
into the DoE. At this stage, statistical analysis is normally an ‗analysis of variance‘ (ANOVA). 
The ANOVA is used to fit the output response to either a linear or non-linear model and 
calculate the effect of each input factor on this output response (Montgomery, 2006, Mandenius 
and Brundin, 2008). 
 The DoE software provides useful plots or graphs to visualise this. These typically include 
main effects, interaction and in some cases, contour plots. The main effects plots will show if 
there is an effect with each input factor when considered alone. For example, did a certain pH 
value have a significant effect on the protein yield? An interaction graph plots input factors 
against each other to see if a combination of them has an effect on the protein yield. For 
example, does only a specific temperature and pH value combination have a significant effect 
on the protein yield, but on their own, they do not? A contour plot is generated after a ‗response 
surface method‘ DoE and will show how a response, visualised as contours of colour, changes 
in relation to two input factors plotted on the x and y axes (Montgomery, 2006). 
The DoE model can be validated by examining the residuals. This is done in two ways: by 
examining the R
2
 and the residual plots. The R
2 
value is interpreted as the proportion of the 
variability in the data explained by the ANOVA model, where a high R
2 
value indicates a better 
fit. A residual plot is a visual representation of the difference between individual values and the 
mean of the observable data set.  A low R
2
 may not represent a problem with the data itself, but 
rather could indicate that the model should be revised (Schmidt and Launsby, 1989). Figure 3.2 
shows how residual plots can be an important diagnostic tool. Figure 3.2A illustrates data that 
fit a linear model well while Figure 3.2B shows data that do not fit this model well and may be 
more suited to a quadratic model. 
 
126 
 
 
Figure 3.2. Illustration of residuals. A) in the upper graph, input variables are plotted against 
output variables and a line of fit is plotted; the lower graph shows the pattern of the residuals 
form and in this case the data fit the model B) in the upper graph, input variables are plotted 
against output variables and a line of fit is plotted showing; the lower graph shows the pattern 
of the residuals form and in this case data does not fit the model. Furthermore, the residuals 
can be referred to as unusual. 
A review by Mandenius and Brundin in 2008 suggested that good models that are published in 
the literature tend to give R
2
 values of >0.75 and poor models are usually <0.75 and should 
require re-evaluation (Mandenius and Brundin, 2008). 
Following examination of the R
2 
values and the residuals plots, the second phase of the DoE is 
process characterisation.  Here, the goal is to identify and quantify the influence of key input 
factors on the output response. This requires generation of a predictive equation or model that 
can be applied under a range of operating conditions. In other words, if certain input factors 
were entered into the equation, a predicted protein yield would be given. 
The third stage of the DoE method is process optimisation where previously unexplored 
responses are examined or ‗zoomed‘ in on and usually a different DoE design is applied. For 
example this can be the application of a response surface method (RSM) that can be used to 
interrogate the non-linear behaviour of the response (such as quadratic relationships). The DoE 
method is an iterative process where the results from this can feed-back until the design is 
improved and the ‗model building‘ is satisfactory. 
Previously, DoEs and the use of a micro bioreactor system (Micro-24 microreactor, Pall 
Corporation) were used to ascertain optimal recombinant soluble green fluorescent protein 
A) B)
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yields in P. pastoris (Holmes et al., 2009). In this chapter, hA2AR was used as a model GPCR to 
investigate the application of a DoE to find optimal growth conditions for the highest yield of 
active hA2AR produced in recombinantly in yeast.   
3.1. Defining of DoE model for optimising hA2AR yields in yeast 
When taking the DoE approach, various design models are available for use and the most 
appropriate design is selected based on the number of input factors, type of input factors 
(quantitative and qualitative) and the number of levels for the quantitative factors. The main 
types of DoE include but are not limited to: full factorial, fractional factorial, Plackett -Burman, 
Taguchi, d-optimal and response surface methodology (Schmidt and Launsby, 1989). The 
classical experimental approach of investigating one factor at a time (OFAT) is easy to 
understand and straight forward to perform, however it is not an efficient method to study a 
large sample size. Also, it is practically impossible to address interactions between input factors 
and usually unnecessary data points are collected leading to costly and time-consuming 
experiments. Table 3.2 summarise the different types of DoE. 
Table 3.2 Types of DoE design and their characteristics. 
Type of DoE Characteristics 
Full-factorial 
Take into account all possible combinations of input factors. Require 
many experimental runs but give main effects and interaction 
information. Linear response only (Fuller and Bisgaard, 1995). 
Fractional 
factorial 
Full factorial on selected factors, therefore fewer runs. Loses power 
when analysing interaction effects. Linear response only (Chen et al., 
1993). 
Plackett-Burman 
2-level screening designs. Do not consider any interaction effects. 
Linear response only (Vindevogel and Sandra, 1991). 
Taguchi 
Highly fractional, estimate main effects using few runs. Not limited 
to 2-level designs. Do not consider some interaction effects. Linear 
response only (Rao et al., 2008). 
d-optimal 
Full factorial where number of runs are reduced via a computer 
derived method. Loses power when analysing interaction effects. 
Linear response only (de Aguiar et al., 1995). 
Response surface 
methodology 
(RSM) 
Examination of quadratic responses. Not suitable for high number of 
input factors. Non-linear response (Holmes et al., 2009). 
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3.1.1. Experimental set-up 
The Micro-24 microreactor (Pall Corporation) used to conduct these experiments enabled the 
input conditions to be established as set-points. Figure 3.3 shows the set-up at Aston University.  
The instrument is controlled by software and the DO is controlled by gas cylinder oxygen and 
compressed sterile air. The pH is controlled by either addition of carbon dioxide or ammonia by 
bubbling nitrogen through an ammonium hydroxide bubbler. The instrument uses 24 modified 
deep wells or mini bioreactors as a plate format. These wells can be controlled individually for 
temperature, pH and DO and also be run in parallel. In the bottom of each well, DO tension, pH 
optical sensors, a sparging port and thermal conduction pads are present to provide control and 
monitoring. The pH and DO of the culture are controlled by a set point by sparging gas through 
the medium, in this instance, oxygen  for DO and carbon dioxide or ammonium hydroxide gas 
for pH.  
 
Figure 3.3 Micro-24 microreactor set-up at Aston University. Photograph shows the 
instrument and the components needed for its function including a lap-top with the software for 
control and monitoring, the gas supplies for DO and pH control, the ammonium hydroxide 
bubbler for ammonia production and a compressor to maintain a vacuum for the 24 well plates. 
3.1.2. Input parameters 
It is well known that the temperature, pH and the amount of DO in a culture will have an effect 
on yeast cell growth (Schubert et al., 1994). Other studies have also defined that these 
parameters will affect recombinant protein yields (Schmidt, 2005). Therefore these 3 factors 
were chosen as input factors for the DoE to test if optimal conditions could be achieved for 
hA2AR production. Moreover, for the temperature, DO and pH, 3 levels (low, medium and high) 
Oxygen, carbon dioxide 
and nitrogen gas supply
Laptop with controller 
software
UPS Micro-24 microreactor
Ammonium hydroxide
pressure vessel
CDA compressor for 
constant 6 Bar supply
CDA filter
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were interrogated in the DoE screen in order to detect any interaction relationships. The input 
factors selected in these experiments were based on previous studies of hA2AR or other GPCRs 
recombinantly produced in yeast. For example, it is known that lower pH values (5.0-6.0) are 
favourable in yeast, therefore the input conditions for pH were 5.0, 5.5 and 6.0 (Fraser, 2006). It 
is also established that lower temperature values (~22°C) are favourable in yeast for hA2AR 
production (Fraser, 2006) therefore the input conditions for temperature were 22, 24 and 26°C. 
The DO input conditions were chosen close to the normal range for a bioreactor set-up which is 
~30% set-point. Therefore the input conditions for DO were 30, 40 and 50%. Finally, in the 
literature there have been reports that the addition of the additive, DMSO has a positive effect 
on recombinant GPCR yield in yeast (Andre et al., 2006, Lundstrom et al., 2006). Therefore this 
was an input factor that was interesting to include in this DoE. This input factor was however, 
included as a qualitative or attribute input factor, where it was either present or absent and did 
not vary in its level (with or without DMSO) and inclusion of this additional factor contributed 
to choosing a d-optimal design.  
In this study, 4 input factors were initially investigated in a screening design where 3 of the 
factors were at 3 levels (low, medium and high; -1, 0 and +1 and therefore constituted a  or 3
3
  
design) and one was at one level but was either present or absent in the experiments. With these 
input factors, the classical full factorial design was considered. However, to run it in full, 162 
separate experiments were defined and this was too large to conduct. Therefore a computer 
derived design called a d-optimal design was selected as this took the 162 runs from the full 
factorial design and selected 24 experiments to be run, which was more practical. A d-optimal 
design is an option when trying to reduce the number of runs in a design when there are 3 levels 
and 3 or more factors to explore.  However, there are compromises on this design such as the 
design being non-orthogonal.  
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Table 3.3 summarises the input factors that were entered into the Minitab
®
 DoE and that 
generated the d-optimal design. In conjunction with these input factors, the output responses 
were also defined. These were cell biomass, total membrane protein yield and specific binding 
activity of hA2AR.  
Table 3.3 Input factors used in the DoE screen for hA2AR production. Temperature (22, 24 
and 26°C), pH (5.0, 5.5 and 6.0) and DO (30, 40 and 50%) of the yeast culture were examined. 
The addition of 2.5% DMSO is either present or absent in the culture media. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Input Factor
Input factor 
type
Low Level
Medium 
Level
High Level
Temperature 
( C)
Quantitative 22 24 26
pH
Quantitative
5 5.5 6
dO (%)
Quantitative
30 40 50
DMSO (%) Qualitative 0 (absent) n/a 2.5 (present)
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3.1.3. Saccharomyces cerevisiae strains  
Screening experiments were carried out using a DoE designed to screen the best growth 
conditions for yeast to produce the highest hA2AR yields. The DoE explored four input variables 
in three different S. cerevisiae yeast strains producing recombinant hA2AR (Table 3.4). These 
strains were chosen as previous studies had shown they were high-yielding (Ferndahl et al., 
2010, Bonander et al., 2009). The hA2AR construct is a full length, glycosylated version with a 
haem-agglutinin tag (HA3) and includes an alpha- factor signal sequence (Figure 3.4) that was 
previously designed and cloned into pYX212 or pYX222 TPI vectors by Dr. Renaud Wagner, 
Université de Strasbourg, France.  Dr. Richard Darby, Aston University subsequently 
transformed these into a wild-type strain of S. cerevisiae (BY4741) in a pYX212 vector with 
uracil selection and into an over-expression mutant, S. cerevisiae BMS1 (BY4741) in a pYX222 
vector with histidine selection.  The third strain was developed by Dr. Cecilia Ferndahl 
(Ferndahl et al., 2010) and this was S. cerevisiae TM6* (KOY-TM6*) and was transformed 
with the pYX212 vector with uracil selection. The strains are referred to as WT-hA2AR, BMS1-
hA2AR and TM6-hA2AR throughout this chapter. The origins of these strains are described in 
1.2.2.3. 
Table 3.4 S. cerevisiae strains producing hA2AR used for DoE research. 
Full name 
S. cerevisiae 
strain 
Vector Selection Short name 
S. cerevisiae 
wild-type hA2AR 
BY4741 pYX212 Uracil WT-hA2AR 
S. cerevisiae 
BMS1 hA2AR 
BY4741 
yTHCBMS1 
pYX222 Histidine BMS1-hA2AR 
S. cerevisiae 
TM6* hA2AR 
KOY-TM6* pYX212 Uracil TM6-hA2AR 
 
 
Figure 3.4 hA2AR construct design schematic for S. cerevisiae transformations. Construct 
includes full-length hA2AR, an alpha-factor signal sequence at the 5′ end and a haem-agglutinin 
tag × 3 at the 3′ end. 
S. cerevisiae was used for these experiments to avoid the need for any media exchange during 
recombinant protein production. The strains chosen produce recombinant hA2AR constitutively 
α-factor hA2AR HA35′ 3′
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in the pYX212 and 222 vectors, with glucose as its sole carbon source. Therefore for the 
purpose of these experiments, it was simpler to use S. cerevisiae strains rather than P. pastoris, 
where methanol feeding is required to induce recombinant production.   
3.2. Execution of the d-optimal DoE design  
When the input factors were entered into the Minitab
® 
software, a d-optimal design was 
selected.  The input factors were temperature (22, 24 and 26°C) pH (5.0, 5.5 and 6.0), DO (30, 
40 and 50%) and the presence or absence of DMSO. The output responses that were measured 
were cell biomass, total membrane protein yield and specific binding activity of hA2AR in three 
different S. cerevisiae strains: WT-hA2AR, BMS1-hA2AR and TM6-hA2AR. This section 
describes the experimental results of the d-optimal DoE screen for all 3 S. cerevisiae strains 
producing recombinant hA2AR. 
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Table 3.5 shows the output of the experiments that were defined by the d-optimal design and 
were to be performed in the Micro-24 microreactor plates. It can be seen that 24 different 
combinations of temperature, pH, DO and DMSO conditions from Table 3.3. The d-optimal 
design output gave 22 different experiment combinations. The grey highlighted rows in the 
table show repeats of certain combinations in the wells to increase the well usage to the full 24. 
Table 3.5 d-optimal design of 4 input factors, 3 numeric factors and 1 attribute factor. The 3 
numeric factors are temperature (22, 24 or 26°C), pH (5.0, 5.5 or 6.0) and DO (30, 40 or 50%). 
The attribute factor is presence/absence of DMSO. The highlighted rows indicate repeated input 
factor combinations. The total number of experiments is 24, to fit one whole Micro-24 plate. 
 
In DoE outputs, a run order is usually stated in the design output return. This means that the 
DoE design can state which order each experiment should be run in order to minimise the error 
due to the effect of lurking variables by using a random sequence (Lendrem et al., 2001). 
However, in these experiments, the run order could not be adhered to due to instrument 
constraints. The temperature in the plate wells had to be ordered so that lowest temperatures 
were at the back of the plate and the highest temperatures were at the front of the plate. This 
was due to the coolant fans in the Micro-24 microreactor being positioned at the rear of the 
instrument (Figure 3.5). Each S. cerevisiae strain, WT-hA2AR, BMS1-hA2AR and TM6-hA2AR 
was inoculated to a starting optical density of 1 from a 50 mL shake flask pre-culture in the 
Micro-24 microreactor well plate. WT-hA2AR, BMS1-hA2AR and TM6-hA2AR were run on the 
Micro-24 microreactor in triplicate with the well plate set-up as illustrated in Figure 3.5, on 
Temperature (°C) pH dO (%) 2.5% DMSO
22 5.5 40 Absent
22 5.5 40 Absent
22 6 50 Present
22 6 50 Present
22 5 50 Present
22 6 30 Absent
22 5 40 Present
22 5.5 30 Absent
24 5 30 Absent
24 5.5 50 Present
24 5.5 50 Absent
24 6 40 Absent
24 5 30 Present
24 5 50 Absent
24 5.5 30 Present
24 6 40 Present
26 6 50 Absent
26 5.5 30 Present
26 5 40 Absent
26 6 30 Present
26 5.5 40 Present
26 5 50 Absent
26 6 30 Absent
26 5 40 Present
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three different days. When the glucose levels reached between 10-30 mM, the cultures were 
harvested and the optical density noted at 600 nm (OD600). The glucose levels were monitored 
by using Accu-Chek Active glucose analyser (Roche Diagnostics). Membrane preparations 
were carried out for each well and the total membrane protein quantified using a BCA assay. 
Finally, single-point radio-ligand binding assays were carried out with [
3
H]ZM241385 on each 
well for each strain.  
 
Figure 3.5 Micro-24 microreactor plate set-up. Each well is shown with specified input factors 
shown in Table 3.3. Yes/No indicates the presence/absence of 2.5% DMSO. 
 
 
 
 
 
 
 
 
 
 
 
1 2 3 4 5 6
A
22°C, 
pH5, 50, 
Yes
22°C, 
pH6, 50, 
Yes
24°C, 
pH5, 30, 
No
24°C, 
pH5, 30, 
Yes
26°C, 
pH6, 50, 
No
26°C, 
pH5.5,40, 
Yes
B
22°C, 
pH5.5, 
40. No
22°C, 
pH5.5, 
30, No
24°C, 
pH5.5, 
50,Yes
24°C, 
pH5, 50, 
No
26°C, 
pH5.5, 
30, Yes
26°C, pH 
5, 50, No
C
22°C, 
pH6, 30, 
No
22°C, 
pH6,50, 
Yes
24°C, pH 
5.5, 50, 
No
24°C, 
pH5.5, 
30, Yes
26°C, 
pH5, 40, 
No
26°C, 
pH6, 30, 
No
D
22°C, 
pH5,40, 
Yes
22°C, 
pH5.5, 
40, No
24°C, 
pH6, 
40,No
24°C, 
pH6, 40, 
Yes
26°C, 
pH6, 30, 
Yes
26°C, 
pH5, 40, 
Yes
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The output data retrieved after the runs had finished were OD600, total membrane protein yields 
and specific binding activity of hA2AR in WT-hA2AR, BMS1-hA2AR and TM6-hA2AR strains. 
The OD600  for all the strains was approximately 5.0 ± 1.0 therefore the effects from the input 
factors were minimal (Figure 3.6). 
 
Figure 3.6 Main effects plots of OD600 values for each hA2AR strain, for each input factor at 
the end of the Micro-24 microreactor run.  OD600 plots for WT-hA2AR are all on the left side, 
plots for BMS1-hA2AR are all in the centre and plots for TM6-hA2AR are all on the right side. 
Values are means of OD600 for triplicate readings of each strain for each input factor. ± 
standard error of the mean (SEM) is displayed as error bars.  
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Total protein yield was also measured in membrane preparations and the SEM between 
replicates was high for some replicates and ranged between 4-79 µg total protein (Table 3.6).  
Table 3.6 Total protein yields of membrane preparations from each input combination and S. 
cerevisiae strain. The input factors and the total protein yield as determined by BCA assay with 
bovine serum albumin as a standard are shown. The data are means from triplicate samples 
and the ± SEM are displayed.  
 
Radio-ligand binding analyses of hA2AR were the main output data of interest for this DoE 
screen, since the objective was to determine how the input factors had an effect or not on hA2AR 
yield for each strain. Specific binding activity data were collected via radio-ligand binding 
assays using the hA2AR antagonist, [
3
H] ZM241385 (Table 3.7). The range of specific binding 
activity was from 0- 500 fmol mg
-1
 for all the strains and all the input conditions indicating the 
overall expression was low for these experiments.  
 
 
 
 
 
Temperature (°C) pH dO (%) 2.5% DMSO WT-hA2AR BMS1-hA2AR TM6-hA2AR
22 5.0 50 Present 193 ± 13 206 ± 21 233 ± 15
22 5.5 40 Absent 162 ± 17 185 ± 58 186 ± 18
22 6.0 30 Absent 217 ± 44 219 ± 53 217 ± 31
22 5.0 40 Present 236 ± 28 217 ± 19 205 ± 19
22 6.0 50 Present 159 ± 6 221 ± 43 192 ± 18
22 5.5 30 Absent 192 ± 32 178 ± 53 191 ± 12
22 6.0 50 Present 198 ± 21 210 ± 35 190 ± 4
22 5.5 40 Absent 200 ± 29 213 ± 47 173 ± 37
24 5.0 30 Absent 162 ± 8 193 ± 37 197 ± 18
24 5.5 50 Present 167 ± 4 201 ± 32 208 ± 15
24 5.5 50 Absent 195 ± 41 214 ± 30 212 ± 35
24 6.0 40 Absent 182 ± 26 248 ± 18 241 ± 48
24 5.0 30 Present 198 ± 5 199 ± 36 172 ± 14
24 5.0 50 Absent 182 ± 41 185 ± 43 195 ± 17
24 5.5 30 Present 199 ± 21 216 ± 40 195 ± 23
24 6.0 40 Present 223 ± 56 204 ± 14 195 ± 32
26 6.0 50 Absent 168 ± 15 177 ± 43 195 ± 37
26 5.5 30 Present 175 ± 5 187 ± 31 237 ± 45
26 5.0 40 Absent 212 ± 49 228 ± 21 161 ± 31
26 6.0 30 Present 204 ± 11 233 ± 20 181 ± 30
26 5.5 40 Present 175 ± 11 228 ± 49 174 ± 25
26 5.0 50 Absent 166 ± 12 163 ± 35 180 ± 15
26 6.0 30 Absent 182 ± 41 231 ± 18 168 ± 46
26 5.0 40 Present 207 ± 34 209 ± 79 193 ± 60
Conditions tested generated from d-optimal DoE screen Total Protein Yield (µg)
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Table 3.7 Specific binding activity from each input combination and S. cerevisiae strain. The 
input factors and specific binding activity as determined by a radio-ligand assay with the hA2AR 
antagonist, [
3
H] ZM241385 . The data are means from triplicate samples and the ± SEM are 
displayed. 
 
These values were entered into the d-optimal design. A linear regression analysis was 
performed on the data. Main effects and interaction plots were generated with the ANOVA 
analyses.  
 
 
 
 
 
 
 
Temperature (°C) pH dO (%) 2.5% DMSO WT-hA2AR BMS1-hA2AR TM6-hA2AR
22 5 50 Present 7.9 ± 5.5 8.1  ± 3.6 4.5 ± 2.1
22 5.5 40 Absent 3.1 ± 1.6 13.8  ± 9.9 9.5 ± 3.0
22 6 30 Absent 320.6 ± 122.1 18.1  ± 6.0 4.6 ± 2.5
22 5 40 Present 9.3 ± 4.8 8.3  ± 2.6 3.9 ± 0.2
22 6 50 Present 28.8 ± 6.8 11.7  ± 4.2 5.9 ± 1.8
22 5.5 30 Absent 12.3 ± 6.4 14.7  ± 4.9 6.1 ± 1.2 
22 6 50 Present 31.4 ± 2.4 16.6  ± 3.3 7.6 ± 1.3 
22 5.5 40 Absent 25.8 ± 3.0 15.9  ± 2.4 7.6 ± 1.3 
24 5 30 Absent 5.8 ± 5.5 9.4  ± 2.5 6.1 ± 0.6
24 5.5 50 Present 17.9 ± 3.9 19.5  ± 8.6 35.5 ± 12.6
24 5.5 50 Absent 14.1 ± 5.9 12.8  ± 3.8 4.6 ± 1.5 
24 6 40 Absent 10.6 ± 6.4 45.6  ± 11.8 5.8 ± 2.3 
24 5 30 Present 12.1 ± 4.9 12.3  ± 6.1 4.1 ± 3.0 
24 5 50 Absent 18.3 ± 2.7 9.4  ± 2.5 4.2 ± 2.6 
24 5.5 30 Present 13.4± 5.8 11.9  ± 3.5 3.9 ± 0.3 
24 6 40 Present 22.8± 2.6 32.5  ± 8.6 3.6 ± 1.2
26 6 50 Absent 55.8 ± 24.3 10.5 ± 6.9 4.5 ± 0.7
26 5.5 30 Present 5.7 ± 8.7 13.4  ± 5.0 4.9 ± 3.5
26 5 40 Absent 7.3 ± 4.9 9.3  ± 3.7 2.9 ± 1.2
26 6 30 Present 7.7± 5.4 12.3  ± 5.4 5.6 ± 1.3
26 5.5 40 Present 14.7 ± 4.7 11.4  ± 4.3 4.1 ± 2.1 
26 5 50 Absent 16.1 ± 4.6 18.4  ± 9.3 7.3 ± 1.1 
26 6 30 Absent 22.6 ± 4.0 19.7  ± 5.7 2.7 ± 1.4 
26 5 40 Present 21.7 ± 4.2 11.5  ± 3.9 3.2 ± 1.8 
Conditions tested generated from d-optimal DoE screen Specific binding (fmol mg
-1
)
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Figure 3.7 shows the main effects plot, the interaction plot and the ANOVA analysis output for 
the d-optimal design performed on WT-hA2AR.  
 
Figure 3.7 Main effects, interaction and ANOVA analysis for WT-hA2AR. A) Main effects plot 
where the horizontal line indicates mean specific binding activity. B) Interaction plot with mean 
specific binding activity as the y axis. C) Analysis of Variance (ANOVA) for specific binding in 
WT-hA2AR. The relationship between the specific binding activity and the input factors was 
analysed using ANOVA where the F statistic is the Fisher’s F-test. The R2 (adj) indicates 
‘goodness of fit’ of the model. Input factors highlighted in grey show a significant p value 
(<0.05, 95% confidence) and a positive co-efficient and marked by * on the graphs (Appendix 
A4). 
For the WT-hA2AR strain, the highest yields of hA2AR were produced when the culture medium 
was at a temperature of 22°C, pH 6.0, with 30% DO and in the absence of DMSO, according to 
the main effects plot (Figure 3.7A). Furthermore, the temperature effect alone of 22°C was 
found to give a significant increase (Figure 3.7C) in specific binding activity (p value = 0.001). 
When considering the interaction effects, the interaction plot (Figure 3.7B) showed that 
interaction were present such as a low temp, high pH interaction; a low temp, low DO 
interaction; a low temp, no DMSO interaction; a high pH, low DO interaction; a high pH, no 
DMSO interaction and finally a low DO, no DMSO interaction. These interactions gave higher 
yields of hA2AR than any other interactions. The adjusted R
2 
value for the WT-hA2AR DoE was 
52.74% (Figure 3.7C). Figure 3.7C also displays the ANOVA output for the input terms to 
determine if they were significant or not. As stated, the temperature at 22°C was significant (p 
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value < 0.05) and also the co-efficient was positive (Appendix A4 for linear regression co-
efficient data).  
Figure 3.8 shows the main effects plot, the interaction plot and the ANOVA analysis output for 
the d-optimal design performed on BMS1-hA2AR. 
 
Figure 3.8 Main effects, interaction and ANOVA analysis for BMS1-hA2AR. A) Main effects 
plot where the horizontal line indicates mean specific binding activity. B) Interaction plot with 
mean specific binding activity as the y axis. C) Analysis of Variance (ANOVA) for specific 
binding in BMS1-hA2AR. The relationship between the specific binding activity and the input 
factors was analysed using ANOVA where the F statistic is the Fisher’s F-test. The R2 (adj) 
indicates ‘goodness of fit’ of the model. Input factors highlighted in grey show a significant p 
value (<0.05, 95% confidence) and a positive co-efficient and marked by * on the graphs 
(Appendix A4).  
The main effects plot (Figure 3.8A) showed that the BMS1-hA2AR strain, gave the highest 
yields of hA2AR when the culture medium was at a temperature of 24°C, pH 6.0, with 40% DO 
and in the absence of DMSO. The 40% DO in the culture gave a significant increase in hA2AR 
yield (p value = 0.018, Figure 3.8C). From the interaction plot (Figure 3.8B), interactions that 
gave higher yields of hA2AR included a mid temperature, high pH interaction; a mid 
temperature, mid DO interaction; a high pH, mid DO interaction; a high pH, no DMSO 
interaction and finally a mid DO, no DMSO interaction. The adjusted R
2 
value for the BMS1-
hA2AR DoE was 28.52% (Figure 3.8C).  
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Figure 3.9 shows the main effects plot, the interaction plot and the ANOVA analysis output for 
the d-optimal design performed on TM6-hA2AR. 
 
Figure 3.9 Main effects, interaction and ANOVA analysis for TM6-hA2AR. A) Main effects 
plot where the horizontal line indicates mean specific binding activity. B) Interaction plot with 
mean specific binding activity as the y axis. C) Analysis of Variance (ANOVA) for specific 
binding in TM6-hA2AR. The relationship between the specific binding activity and the input 
factors was analysed using ANOVA where the F statistic is the Fisher’s F-test. The R2 (adj) 
indicates ‘goodness of fit’ of the model. Input factors highlighted in grey show a significant p 
value (<0.05, 95% confidence) and a positive co-efficient and marked by * on the graphs 
(Appendix A4). 
The main effects plot (Figure 3.9A) revealed that the TM6-hA2AR strain, gave the highest yields 
of hA2AR when the culture medium was at a temperature of 24°C, pH 5.5, with 50% DO and in 
the presence of DMSO. Contrastingly however, there were no significant singular effects for 
this strain. The interaction plot showed (Figure 3.9B) higher yields of hA2AR were obtained 
with either a mid temp, mid pH interaction; a mid temperature, high DO interaction; a mid 
temperature, DMSO present interaction; a mid pH, high DO interaction; a mid pH, DMSO 
present interaction and finally a high DO,  DMSO present interaction. Furthermore, the mid 
temperature, DMSO present and mid pH, DMSO present interactions were significant effects on 
hA2AR yields and gave a p value of 0.008 and 0.035, respectively (Figure 3.9C).  The adjusted 
R
2 
value for the TM6-hA2AR DoE was 39.10% (Figure 3.9C).  
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Residual plots were also retrieved from the analyses. Figure 3.10 displays all three residual plots 
for the yeast strains.  
 
Figure 3.10 Residual plots for WT-hA2AR, BMS1-hA2AR and TM6-hA2AR after linear 
regression analysis from d-optimal design. Visualised in four ways, as a normal probability 
plot, standardised versus fitted plot, a histogram and observed order of residuals. Black circles 
indicate outlier data and black arrows indicate outlier residuals and patterns or trends that do 
not fit the normal residuals.  
The residual plots were examined to determine how well the data fit the model.  It can be seen 
from Figure 3.10A when viewing the normal probability plot that the data points for the WT-
hA2AR did not fit to the model. It can also be seen that there are 3 clear unusual residuals 
present in the versus fits, normal probability and versus order plot indicated by black arrows or 
black circles.  
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These points were replicates of the same input condition, 22°C, pH 6.0, 30% and DMSO absent 
and were also in the same position in the Micro-24 well plate for each replicate (Figure 3.11). 
Upon further investigation, the set-points of these input factors were checked. It was found that 
the temperature was maintained at 22°C (data not shown) as was the pH (6.0) but the DO did 
not reach the set-point of 30% and instead the DO was maintained at 60% (Figure 3.11). In 
general it was found that many of the DO set-points were not reached in the Micro-24 well plate 
and this is further discussed in section 3.4.1. 
 
 
Figure 3.11 Actual set-points for DO and pH for WT-hA2AR replicate 1. Data interrogated 
after residual plot revealed unusual residual for well 1C (highlighted in yellow) in Micro-24 
plate well (left). The actual DO and pH data for well 1C are shown in the graph on the right.  
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This examination of the residuals was also performed for the BMS1-hA2AR and the TM6-hA2AR 
strain (Figure 3.10B and C). It was found that inspecting the residuals (black arrows and black 
circles) and tracing them back to the experiment and the actual set-points, the DO levels were 
not achieved.  Figure 3.12 shows the well position of the input conditions that gave the high 
residuals from Figure 3.10, the input conditions and the actual set-points for the DO and pH for 
the BMS1-hA2AR (Figure 3.12A) and the TM6-hA2AR (Figure 3.12B) experiments.  
 
Figure 3.12 Actual set-points for DO and pH for BMS1-hA2AR and TM6- hA2AR replicate 1. 
A) BMS1-hA2AR data interrogated after residual plot revealed high residual for well 3D 
(highlighted in yellow) in Micro-24 plate well (left). The actual DO and pH data for well 3D are 
shown in the graph on the right. B) TM6-hA2AR data interrogated after residual plot revealed 
high residual for well 3B (highlighted in yellow) in Micro-24 plate well (left). The actual DO 
and pH data for well 3B are shown in the graph on the right. 
Figure 3.12A shows the Micro-24 well plate for BMS1-hA2AR and the input conditions of 24°C, 
pH 6.0, 40% and DMSO absent and the actual DO and pH data. It can be seen that, not unlike 
the WT-hA2AR strain, the pH was maintained at the set-point but the DO did not reach the set-
point of 40%. For the TM6-hA2AR (Figure 3.12B); input conditions (24°C, pH 5.5, 50% and 
DMSO present), the pH was maintained but the DO was not. These findings prompted further 
error investigation discussed in section 3.4. 
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The overall d-optimal analysis showed that specific input factor combinations gave rise to 
favourable conditions for optimal hA2AR yields for all three strains. It was noted however that 
the R
2
 values retrieved from the linear regression were low, overall instrument limitations 
introduced unanticipated error and that a linear model was not optimal. 
3.3. Using response surface methodology (RSM) to improve the statistical outcome of the 
d-optimal data 
Based upon inspection of the residuals data for all the strains the data were fitted to a quadratic 
model instead of a linear one and this was done using response surface methodology (RSM).   
The goal was to improve upon the d-optimal model that was originally generated and used for 
the DoE experiments investigating hA2AR production in 3 yeast strains. After applying a linear 
regression model to the data, it was evident that this was not the best model, since the ANOVA 
analysis revealed high residuals that warranted further investigation. A customised RSM 
analysis was run in Minitab
®
 software on the data set (input factors and output response). Visual 
plots and residuals plot were also generated as before. It is worth noting that the RSM analysis 
carried out on the BMS1-hA2AR and TM6-hA2AR strains gave very poor R
2
 (adj) values (15-
20%), therefore it was decided to not continue with any further analysis for these strains. This is 
discussed further in the main discussion chapter (Chapter 6). Hence, the subsequent experiments 
described and discussed in this section are for WT-hA2AR only. 
A model was derived from the RSM analysis of the WT-hA2AR data which gave an initial R
2
 
(adj) of 63.07%. The model was then reduced to improve the R
2
 (adj) value by removing any 
insignificant terms. This was done by de-selecting a term that was not significant in the 
Minitab
®
 software and re-running the analysis. It was found that the temperature [squared] 
effect was insignificant (p value > 0.05) and therefore was removed and re-analysed with 
ANOVA. The model improved to give a R
2
 (adj) of 63.41%. Removal of other insignificant 
terms did not improve the model further. Table 3.8 shows the statistical output of the ANOVA 
analysis showing the terms that were analysed.  
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Table 3.8 ANOVA analysis output for WT-hA2AR strain after RSM analysis. The relationship 
between the input factors and the output response (specific binding activity of hA2AR) was 
calculated using analysis of variance (ANOVA). F statistic is the Fisher’s test and p value was 
deemed significant if it was <0.05 (95% confidence level). The R
2 
(adj) was 63.41% for this 
reduced model where (Temp*Temp) were removed. The full analysis is shown in Appendix A5. 
 
The analysis also generated co-efficients that could be applied as a predictive model in the form 
of a polynomial equation (Y = βo + β1 X1 + β2 X2+ β3 X3 + β4 X4 + β12 X1 X2 + β23 X2 X3 + β13 X1 
X3 + β14X1 X4 + β24 X2 X4 + β34 X3 X4 + β11 X1
2
 + β22 X2
2+ β33 X3
2
 + β44 X4
2
) where β is the 
regression co-efficient from the ANOVA analysis and X is the input factor. 
Yield (fmol mg
-1
) = 1653.14 + (162.98 × T) – (934.92 × pH) – (56.47 × DO) + (99.12 × DMSO) 
+ (227.77 × pH
2
) + (0.45 × DO
2
) – (49.93 × T × pH) + (2.50 × T × DO) + (10.83 × T × DMSO) 
- (7.35 × pH × DO) - (68.73 × pH × DMSO) + (0.56 × DO × DMSO) 
where T = temperature (°C), DO = dissolved oxygen (%), DMSO = DMSO present in culture.   
From the RSM analysis, a response optimisation plot was generated (Figure 3.13) where a 
theoretical yield is entered and predicted input conditions are returned to achieve this yield. In 
this instance, the theoretical target yield was entered was 250 fmol mg
-1
 (in order for the 
response optimiser to have a low and high limit within capable means). This graphic revealed 
that the optimal input level settings for maximum hA2AR production in the WT strain were 22°C 
for temperature, pH 6.0, DO 30% in the absence of DMSO for a maximum predicted yield of 
240.34 fmol mg
-1
 which was close to the target yield. It was noted that the d-optimal screening 
design also generated the same optimal conditions.  
Source Degree of freedom Adjusted Sum of squares Adjusted mean squares F statistic p value
Regression 12 265920 22160 7.79 0.001
Linear 4 52711 13178 4.63 0.004
Temp  1 11798 11798 4.15 0.049
pH 1 43077 43077 15.14 0.001
DO  1 1779 1779 0.63 0.435
DMSO 1 382 382 0.13 0.716
Square 2 36288 18144 6.38 0.004
pH*pH 1 21091 21091 7.41 0.010
DO*DO 1 19010 19010 6.68 0.014
Interaction 6 155148 25858 9.09 0.001
Temp*pH 1 35284 35284 12.4 0.001
Temp*DO 1 27389 27389 9.62 0.004
Temp*DMSO 1 5809 5809 2.04 0.162
pH*DO 1 23895 23895 8.40 0.006
pH*DMSO 1 27188 27188 9.55 0.004
DO*DMSO 1 619 619 0.22 0.644
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Figure 3.13 Response optimisation plot for WT-hA2AR strain after RSM analysis. The plot is a 
visual tool from Minitab
® 
which shows how factors affect predicted responses. Each column 
corresponds to an input factor. The input factor settings in red represent the predicted 
conditions for the maximum yield possible (blue value in left bottom). The red vertical line can 
be moved (in the software programme) and as the input factor is adjusted, the predicted WT-
hA2AR binding yield will change. The composite desirability is a measure of how good the 
prediction is and a target of 1.000 is desirable. 
 
From the response optimisation plot, it was possible to generate a contour and wire-frame plot 
where the predicted optimal conditions were visualised (Figure 3.14). The contour plot (Figure 
3.14A) shows the green colour deepen as the yield increases, therefore showing that optimal 
yields predicted are at low temperature, high pH, low DO and no DMSO present in the culture 
for the WT-hA2AR strain. The surface plot shows a 3 dimensional representation of the contour 
plot with the same interpretation. These plots are useful as they also give an indication of further 
testing that would be required. For instance, the response area in the contour plot around pH 6.0 
and temperature 22°C shows that further experiments could be carried out to explore input 
conditions lower than 22°C and higher than pH 6.0 to see if the yield could be improved further. 
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Figure 3.14 Contour and surface wire-frame plot for WT-hA2AR strain after RSM analysis. 
A) Contour plot where the darker the green colour, the higher the desired yield. The x axis is 
temperature and the y axis is pH. The DO and DMSO are fixed at 30% and with no DMSO. B) 
Wire-frame or surface plot showing a more 3D view of the contour plot with temperature, pH 
and specific binding activity in the x, y and z axes. The hold values for DO and DMSO are 30% 
and no DMSO as for the contour plot.  
3.3.1. Examination of residuals 
A visual residual analysis after the RSM identified unusual points that did not fit the model as 
had been seen for the d-optimal design (section 3.2). Figure 3.15A shows the residuals plots for 
the RSM for the WT-hA2AR strain. From the plots it can be seen that some points are unusually 
high or low. Also, there is a cyclic trend that is observed in the versus order plot (indicated by a 
black curve super-imposed). This plot illustrates the residuals observed for each experimental 
combination as it was run. The 4 data points that form the peaks and troughs of the curve were 
investigated to see if there was any unusual behaviour in the wells. The  4 data points were 
found to be 2 replicates of the same condition: 22°C, pH 6.0, 30% DO and no DMSO which 
was well 1C in the Micro-24 well plate and 22°C, pH 5.5, 30% DO and no DMSO which was 
well 2B in the Micro-24 well plate. This is a notable observation as these are the optimal 
predicted conditions from the RSM and the d-optimal linear analysis (22°C, pH 6.0, 30% DO 
and no DMSO) for high hA2AR yield. Figure 3.15 shows 1 WT-hA2AR replicate of the actual 
set-point data for pH and DO during the experiment. It is observed that for both wells (Figure 
3.15B), the pH is maintained but the DO does not achieve the target set-points. This is discussed 
further in section 3.4.  
A) B)
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Figure 3.15 Residual plots for WT-hA2AR strain after RSM analysis showing actual DO and 
pH set-points for the whole experiment. A) the plots shown are normal probability, versus fits, 
histogram and versus order. Versus order plot has a black curve super-imposed to highlight 
cyclic behaviour of the observations B) 1C (left) and 2B (right) wells show the actual DO data 
(blue and top) and actual pH data (green and bottom).  
The RSM analysis enabled a predictive equation for the model to be generated and assessed the 
optimal input conditions for hA2AR yield in the S. cerevisiae wild type strain, which were 22°C, 
pH 6.0, 30% DO in the absence of DMSO. The R
2
 (adj) was improved to 63.41% but analysis of 
the residuals still revealed unusual points and a cyclic trend. The unusual residuals were 
associated with DO set-points never reaching the target input condition. Sources of error were 
therefore considered more generally to see if any can explain unusual behaviour in the system. 
3.4. The importance of a robust experimental set-up to minimise error 
For a DoE to be successful in predicting optimal conditions and generating a robust model, 
obtaining and using reliable data is crucial. This was considered briefly in sections 3.2. and 
3.3.1. where actual data set-points of input parameters impacted the residual analysis and 
therefore the statistical robustness of the DoE model. This section explores further the influence 
of instrument and biological error on DoE modelling. 
3.4.1. Instrument challenges 
As with any piece of laboratory equipment or instrument, the Micro-24 comes with constraints 
and restrictions when it is used. This is to ensure that the instrument calibration and controls are 
A)
B)
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working correctly and are within the instrument specifications. However, when carrying out 
certain methods, such as DoE, these can be prohibitive. For example, when setting up the input 
factors for the DoE design, the DoE states which order to run an experiment. In this situation, 
this is difficult to follow, as the temperature parameter is a physical constraint for the Micro-24 
instrument. In order for temperatures to reach the set-point as much as possible, the designs with 
different temperatures must be ordered in a specific way on the Micro-24 well plate. For 
example, in the case of the d-optimal design tested in section 3.2., the temperature input values 
were 22°C, 24°C and 26°C. In order for the temperatures to reach as close to the set point as 
possible, on the Micro-24 well plate, the lowest temperatures were assigned to the back of the 
plate and the highest at the front (Figure 3.5). This was because the coolant fans are positioned 
at the back of the instrument. The impact of this requirement on the DoE is large. This means 
that no randomisation can happen which contributes to the variation in the data when analysis is 
performed.  
The Micro-24 plate wells each include a DO tension sensor, pH optical sensor, a sparging port 
and thermal conduction pads, all of which control and monitor the three parameters 
(temperature, pH and DO). The pH and DO of the culture are controlled by a set-point by 
sparging gas through the medium, in this instance, oxygen for the DO and carbon dioxide or 
ammonium hydroxide gas for the pH.  Figure 3.16 show actual pH and DO data for one 
replicate of the WT-hA2AR experiment for each well. The pH is shown as green points and the 
DO as blue and the graphs are laid out as the Micro-24 well plate would be. For the actual pH 
data during a run, only one well did not meet the expected set-point which was well 2D 
(indicated by red cross on the green pH axis Figure 3.16). For the DO however, most of the 
levels did not reach the set-points (red crosses on DO blue axes), in fact only 3 out of the 24 
experiments had DO set-points that reached the desired level (indicated by black circles). 
Additionally, there were some wells (indicated by green circles) that eventually met the desired 
DO set-point but took most of the run time to achieve it or had high oscillations that spanned 
30-50%. Figure 3.17 shows a successful calibration test of the DO sensors where oxygen is 
applied to each well (containing water only) for 15 min at a 90% set-point. The oxygen is then 
switched off and the actual DO levels returned to between 0-10% within 10 min and these pass 
the calibration specifications of the instrument. This shows that the instrument was calibrated 
correctly which suggests that the failure to reach DO set-points could be due to other factors 
associated with the experiment such as the DO consumption behaviour of the yeast cultures. 
Therefore the DO control was investigated by optimising the PI settings (proportional, integral) 
settings in the system. For future work, a new development from Pall will enable the oxygen 
uptake rate of the cells to be measured and this is an important feature to have for yeast cultures. 
This is because they rely on sufficient oxygen concentrations, especially strictly aerobic yeast 
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such as P. pastoris and hence monitoring the actual uptake rate would be a more meaningful 
parameter. 
 
Figure 3.16 Actual DO and pH data for WT-hA2AR experiment. Data shown are for one 
replicate experiment. The graphs are organised matching the Micro-24 well plate layout (wells 
1A->6A across and 1A->1D down). Each graph shows the actual DO data (blue) and the actual 
pH (green) data. Black circles highlight wells that have reached the set-points for the DO, 
green circles indicate wells that eventually reached the set-point and red crosses indicate that 
the pH or DO did not reach the set-point. 
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Figure 3.17 DO calibration test. 60%:40% oxygen:nitrogen gas mix applied at 2 bar pressure 
to Micro-24 microreactor well plate with water for 15 min at a 90% DO set-point. The oxygen 
supply was switched off and the DO dropped between 0-10% within 10 min. Each line 
represents the actual DO level for a single well in a Micro-24 well plate.  
It is likely that these instrument effects have a very large impact on the DoE data and form part 
of the explanation for the unusual residuals and also the presence of different patterns or trends 
observed in the normal probability plots.  
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3.4.2. Biological sample error  
For the analysis of hA2AR, data measurements were not directly from the culture supernatants 
from each Micro-24 well. Instead, the assays were on membrane-bound protein and therefore 
membrane preparations need to be carried out to remove the yeast cell wall (Figure 3.18).  
 
Figure 3.18. Membrane preparation process for Micro-24 yeast cultures. The flow diagram 
shows the steps required to isolate membranes in order to carry out an assay on the membrane 
protein, for example specific binding activity. See text for detailed description of steps. 
It can be seen that several transfers of the cells to and from tubes are required depending on the 
step. The actual action of the glass bead agitation poses a potential issue with regards to 
membrane protein integrity. There is normally increased heat generation during this process and 
although safeguards (such as carrying out the procedure at 4°C) are in place, little is known as 
to how much the membrane protein is damaged during this process. This process must be 
considered as an additional source of error for the DoE as the output response, the specific 
binding activity, is not directly measured in the culture. For soluble proteins, this is not the case, 
as an assay can be directly applied to the culture supernatant after the Micro-24 run has 
completed.  
 
3.5. Discussion 
The purpose of the work performed in this chapter was to examine the effects of varying several 
input conditions on the specific binding activity of recombinant hA2AR in yeast by employing a 
statistical Design of Experiments (DoE) approach.  
DoE is widely used in industry to minimise the number of experiments carried out whilst 
simultaneously not compromising the quality of the data in an attempt to move away from trial 
Micro-24 cultures transferred to 
centrifuge tubes and cells spun 
down
Cells transferred to appropriate 
tube for glass bead agitation
Cells transferred to new tubes 
for two rounds of centrifugation 
(10,000 x g)
Cells transferred to new tubes 
for ultracentrifugation to isolate 
membranes (100,000 x g)
Membrane protein assay
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and error methods. In this chapter, a DoE screen examined the influence of temperature, pH, 
DO and the presence of an additive (2.5% DMSO) on recombinant hA2AR yield. The input 
condition levels were temperature at 22°C, 24°C and 26°C; pH at 5.0, 5.5 and 6.0; DO at 30, 40 
and 50% and the presence or absence DMSO. Therefore the type of design was a 3
k
 or 3
3 
plus 
one qualitative factor. These experiments were carried out in a small scale, high throughput 
bioreactor system called the Micro-24 microreactor (Pall Corporation). 
The experiments were carried out in three S. cerevisiae strains producing hA2AR, S. cerevisiae 
wild-type hA2AR (WT-hA2AR), S. cerevisiae BMS1 hA2AR (BMS1-hA2AR) and S. cerevisiae 
TM6* hA2AR (TM6-hA2AR). Using S. cerevisiae over P. pastoris was ideal for these 
experiments as there was no fed-batch type phase involved during the cultivation. Therefore it 
was not necessary to halt the Micro-24 microreactor cultivation run in order to add the feed 
manually to each well. Holmes and colleagues (Holmes et al., 2009) used P. pastoris producing 
GFP to run the DoE but had to halt the run in order to add more methanol feed and whilst this 
worked perfectly well, for the purpose of this research, the closed, batch fed system with 
glucose as the sole carbon source was ideal in order to simplify the experiment.  The S. 
cerevisae strains were selected due to prior work carried out by Bonander and colleagues for the 
BMS1-hA2AR strain (Bonander et al., 2005; Bonander et al., 2009) and Otterstedt and 
colleagues for the TM6-hA2AR strain (Otterstedt et al., 2004) where both were found to be high 
yielding for recombinant protein production.  
A d-optimal design was selected, which reduced the required number of experimental runs 
when compared to the classical screening method (full factorial,) which would have demanded 
an impractically large number of experimental runs. The d-optimal design outlined 24 different 
experimental combinations of the 4 input factors at 3 different levels (except the DMSO 
addition which was either present or absent). The output response was defined as the specific 
binding activity of the hA2AR. This was entered back into the d-optimal design. An ANOVA 
analysis was carried out to see if there were any input condition combinations that provided 
optimal hA2AR yields as measured by specific binding activity. Significant effects from the 
input factors were shown and included the WT-hA2AR strain where temperature at 22°C was 
found to give a significant increase in specific binding activity (p value = 0.001). For the 
BMS1-hA2AR strain, DO at 40% was found to give a significant increase in specific binding 
activity (p value = 0.018). Finally, for the TM6-hA2AR strain, it was found that temperature at 
24°C and the presence of DMSO together gave a significant increase in the specific binding 
activity (p value = 0.008), as well as at pH 5.5 and the presence of DMSO, which also gave 
increased specific binding activity (p value = 0.035).  The R
2
 (adj) values for the WT-hA2AR 
was 52.74%, BMS1-hA2AR was 25.82% and TM6-hA2AR was 39.10%. The residual plots 
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further indicated that the linear regression model was not the best fit for these experiments, 
drawing these conclusions into question.  
Applying a quadratic model (RSM) (Montgomery, 2005) to the DoE data helped achieve an 
improved model with optimal conditions for increased hA2AR production. This was done for the 
WT-hA2AR strain only as the R
2
 values for the BMS1-hA2AR and the TM6-hA2AR strains were 
low and therefore were not analysed further. For the WT-hA2AR however, the optimal 
conditions were 22°C, pH 6.0 and DO 30% with no DMSO for hA2AR production. The contour 
plot pointed to areas on the optimal range that could be further improved for optimisation 
studies, where the temperature could be tested lower than 22°C and the pH higher than 6.0. 
These conditions are not unexpected since hA2AR production has been optimal in other studies 
at 22°C but in P. pastoris strains only (Fraser, 2006; Singh et al., 2008; Singh et al., 2010; 
André et al., 2006; Lundstrom et al., 2006). The pH for yeast cultures tends to be between 5.0-
6.0 for optimal growth. Here, the ideal pH was 6.0 for hA2AR production and further hinted at a 
higher pH from the contour plot. This tends to be at the buffered pH value in complex media 
such as BMGY and BMMY (André et al., 2006).  With regards to DO, little work or no work 
has been done to determine the optimal DO for hA2AR production. It is not clear why 30% DO 
was optimal for this strain, however, it could postulated that this wild type strain is not highly 
aerobic like P. pastoris (Cereghino and Cregg, 2000) or S. cerevisiae TM6* (Otterstedt et al., 
2004; Ferndahl et al., 2010) and therefore the lower DO is more amenable to optimal hA2AR 
production. In the case of DMSO, it was found by André and colleagues and Lundstrom and 
colleagues (André et al., 2006; Lundstrom et al., 2006) that when they carried out a GPCR 
screen, the binding activity increased in more than half the GPCRs when produced in DMSO. It 
is thought that the cell membrane permeability increases in the presence of DMSO (Murata et 
al., 2003).  However, the DMSO addition had no effect on the hA2AR production in these 
experiments. These conditions were determined from the RSM DoE and resulted in a predictive 
model or equation. However, it should be considered that the equation may not be very reliable 
since the error being high and especially not being able to maintain the DO adequately.The next 
step would be to carry out validation experiments to test if the predictive model is acceptable.  
Holmes and colleagues demonstrated this for soluble GFP where the line of parity for the 
experimental data versus the predicted data was R
2
 = 0.57 (Holmes et al., 2009).  
The causes of the high variation in the data were investigated globally for all the runs carried 
out by further inspecting the actual set-point values of the input factors in the Micro-24 
instrument and whether they had been achieved. It was found that many of the DO set-points 
were not reached. Another cause of error was the manipulation of the cells before an assay 
could be applied. Carrying out individual membrane preparations on each well sample 
introduced user handling and the potential to lose sample or even affect the receptor protein.  
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These findings show that DoE statistical methods can be used for streamlining optimisation 
experiments. The impact of this is that many growth factor and recombinant protein production 
parameters may be investigated simultaneously. However, issues need to be addressed such as 
reducing the amount of variability within an experimental process. These can be done by 
optimising the downstream processing of the membrane protein preparation methods via 
automated processes.   
The work derived from this chapter is published in a book chapter review (Appendix A9); (Bora 
et al., 2012) and a review article (Appendix A9); (Bawa et al., 2011). 
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Chapter 4: An investigation into the induction phase of P. pastoris 
cultures: production of hA2AR as a case study  
This chapter describes an investigation of the induction protocol in P. pastoris cultures 
producing hA2AR at both laboratory and pilot scale. The construct used in this chapter was 
selected in collaboration with the industrial sponsor, AstraZeneca Ltd, on account of its 
immediate availability at Aston University; in Chapter 5, a second, multiply-tagged construct is 
investigated that was designed with AstraZeneca‘s input. A major finding of the work described 
in Chapter 4 is the detection of pre-induction recombinant protein production, which was also 
confirmed for soluble green fluorescent protein (GFP). When glucose, which has been shown to 
repress AOX expression, was the pre-induction carbon source, GFP was still produced in the 
pre-induction phases. GFP yields were higher and biomass yields were lower than in an 
equivalent glycerol-grown culture. Both hA2AR and GFP were also produced in methanol-free 
cultivations; functional protein yields were maintained or increased after depletion of the carbon 
source. Analysis of the pre-induction phases of 10 L pilot scale cultivations also demonstrated 
that pre-induction yields were at least maintained after methanol induction, even in the presence 
of cytotoxic concentrations of methanol. 
4.1. Analysis of growth rates during methanol induction in pilot-scale bioreactors 
This section describes the work performed to investigate methanol induction feeding regimes in 
hA2AR producing P. pastoris in 35 L pilot-scale bioreactors.  
4.1.1. Expression strain 
The human 2A adenosine receptor (hA2AR) construct considered for this study was designed by 
Dr. Niall Fraser, University of Glasgow, United Kingdom (Fraser, 2006). A de-glycosylated 
version of the sequence was used where the N-linked glycosylation site at Asn154 was mutated 
to Gln; it is referred to as dG- hA2AR in this chapter. The hA2AR sequence is tagged with FLAG 
and His10 tags on the N-terminus of the receptor and includes an α-factor leader sequence 
(Figure 4.1).  
  
                          5′          α-factor           FLAG    His10                   dG-hA2AR          3′ 
 
Figure 4.1 Schematic diagram for dG - hA2AR construct. Construct design schematic for dG- 
hA2AR designed by Dr. Niall Fraser. Design includes a FLAG and His10 tag and α-factor leader 
sequence. 
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The sequence was cloned into the pPICZαA vector (Life Technologies Corporation) and 
transformed into the P. pastoris X33 strain by electroporation; and the transformed cells were 
grown on increasing concentrations of zeocin containing plates. Three colonies (clones 26, 27, 
28) were selected from 250 µg mL
-1
 zeocin selection plates and were cultured in YPD broth 
with 250 µg mL
-1
. When the cells reached exponential growth, glycerol stocks of the cells were 
prepared for storage at -80°C. This work was previously carried out by Dr. Richard Darby, 
Aston University, United Kingdom. These clones (26, 27 and 28) were screened for dG-hA2AR 
expression by culturing them in BMGY flasks (50 mL culture volume) overnight at 30°C. The 
cells were then transferred to BMMY (0.5% methanol) media shake flasks and cultured to 
anOD600 of 1. Samples were taken at 24 h and 48 h post-induction and membrane preparations 
and immuno-blot analyses were performed.  Figure 4.2 shows expression of dG-hA2AR from all 
the clones selected; clone 26 at 48 h post-induction in BMMY medium showed the strongest 
signal at about 50 kDa along with other fainter bands demonstrating a mixture of degraded 
forms of the receptor and where the Kex2 protease was unable to cleave the alpha mating factor 
signal sequence.  
 
Figure 4.2 Immuno-blot from X33-dG-hA2AR colony screen. Immuno-blot of dG-hA2AR 
production from colony screening of BMMY cultures (0.5% methanol) in shake flasks. Lanes 
labelled Clone 26 (24 and 48) are membrane fraction preparations for clone 26 P. pastoris cells 
harvested at 24 h and 48 h from the BMMY cultures. Lanes labelled Clone 27 (24 and 48) are 
membrane fraction preparations for clone 26 P. pastoris cells harvested at 24 h and 48 h from 
the BMMY cultures. Lanes labelled Clone 28 (24 and 48) are membrane fraction preparations 
for clone 26 P. pastoris cells harvested at 24 h and 48 h from the BMMY cultures. Ladder is 250 
kDa with 70, 50, 35 and 25 kDa indicated on figure. The primary antibody used in the method 
was anti-His antibody (Serotec).  
Since colony 26 gave the strongest band, this colony was selected for subsequent cultivations. 
Before the strain was used for a 35 L pilot-scale cultivation, the strain was cultured using a 2 L 
50
35
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24 48 24 48 24 48
Clone 26 Clone 28Clone 27
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bench-top bioreactor to ensure growth in (BSM) minimal medium, to retrieve information about 
growth rates for this strain and also to test methanol induction and hence, hA2AR production at a 
larger scale. Figure 4.3 shows a 2 L bioreactor cultivation for the X33-dG-hA2AR colony 26 
strain. The bioreactor set-points were 30°C, pH 5.0, 30% DO and stirrer speed at 500 rpm. The 
cultivation shows the glycerol batch phase (I), the glycerol fed-batch phase (II), the transition 
phase (III) and the methanol induction phase (IV) where the phases are separated by blue 
vertical lines. The batch phase (I) started off with 40 g L
-1
 glycerol in the bioreactor and as that 
was consumed by the cells, the DO (green line) started to decrease and the carbon dioxide (red 
line) started to increase, indicating that the cells were growing. This was also reflected in the 
optical density measurements (black line). After about 20 h, the fed- batch phase (II) was started 
by adding a constant feed of 50% glycerol at 12 mL h
-1
 for 4 h. The transition or starvation 
phase was for about 2 h, where the temperature was lowered to 22°C, since it is established that 
lowering the temperature to 22°C during induction increases the functional yield of hA2AR 
(Singh et al, 2008; Singh et al, 2010 and Fraser, 2006) and the fed-batch phase was stopped. 
Within this phase, a DO spike was detected indicating that the glycerol had been consumed and 
therefore methanol induction could begin. The methanol induction phase (IV) was run for the 
duration of the cultivation at 2 mL h
-1
 at 50% methanol. However, at about 45 h, the DO levels 
started to rise (cells not demanding oxygen) and the carbon dioxide levels started to decrease, 
indicating that the cells had stopped growing. This also showed that the methanol feed rate 
probably exceeded the rate of consumption of the cells. Samples were taken throughout the 
cultivation and stored at -80°C for further use.  
 
Figure 4.3 Bioreactor cultivation of P. pastoris X33 dG-hA2AR. Optical density (black line), 
carbon dioxide off-gas (red line) and DO (green line) are shown for P. pastoris X33 dG-hA2AR 
cultivation in BSM media with PTM1 salts. The batch phase (I) was with 40 g L
-1
 glycerol, the 
fed-batch phase (II) was with 50% glycerol constant feed of 12 mL h
-1
 and the methanol 
induction phase (IV) was carried out with 50% methanol at 2 mL h
-1
. The phases are marked by 
vertical blue lines. The bioprocess set-points were at 30°C, pH 5.0 and 30% DO. The 
I II III IV
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temperature was lowered to 22°C for the induction phase at the beginning of the transition 
phase (III).  
From the optical density measurements, the specific growth rate (µ) was calculated for the 
second half of the glycerol batch phase (I) since the growth was exponential; µ= 0.21 h
-1
.  Two 
of the samples were taken at 42 h and at 90 h during the methanol induction phase (IV) where 
membrane preparations and immuno-blot analysis was performed.  Figure 4.4 shows expression 
of dG-hA2AR from clone 26 from a minimal medium bioreactor run with a band at about 50 kDa 
for both time-points. The blot shows fainter, larger bands which could suggest forms of the 
receptor where the Kex2 protease was unable to cleave the alpha factor sequence. This could be 
confirmed by extracting this band from the gel and after suitable purification and performing 
mass spectrometry analysis. A single point radio-ligand binding assay was performed on clone 
26 to give specific activity of 4.0 ±0.2 pmol mg
-1
 which confirmed expression of correctly-
folded dG-hA2AR. 
 
Figure 4.4 Immuno-blot from X33-dG-hA2AR 2 L bioreactor cultivation (clone 26). Immuno-
blot of dG-hA2AR from X33-dG-hA2AR 2 L bioreactor cultivation (clone 26). Lanes are for 
Clone 26 membrane fraction preparations of P. pastoris cells harvested at 42 h and 90 h during 
the methanol induction phase. Ladder is 250 kDa with 70, 50, 35 and 25 kDa indicated on 
figure. The primary antibody used in the method was anti-His antibody (Serotec).  
From these cultivations, clone 26 of the P. pastoris X33-dG-hA2AR strain was used for the 
subsequent 35 L pilot-scale bioreactor studies at the AstraZeneca fermentation facility. 
4.1.2. Methanol feed regimes 
Selecting optimal culture conditions such as temperature, pH, and the amount of DO in the 
culture medium as well as the addition of chemical additives and ligands for optimal GPCR 
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production in P. pastoris cultivations is often desired, since achieving high yields is a 
requirement for downstream structural analysis (Andre et al., 2006, Mattanovich et al., 2009, 
Cereghino and Cregg, 2000, Cos et al., 2006b). Furthermore, Holmes and colleagues showed 
that along with culture conditions influencing protein production, the induction feeding strategy 
of P. pastoris is also important (Holmes et al., 2009) and this is particularly relevant when 
growing cultures at a large scale (10 – 2000 L bioreactors). Detailed studies examining specific 
growth rates (µ) during the methanol induction phase of P. pastoris cultures have shown that µ 
influences recombinant protein yields and cell biomass (Potvin et al., 2012).  In particular, this 
could be achieved by applying exponential feeding strategies to maintain cell growth at a 
constant specific and desired growth rate (µset) (Jahic, 2002). This is a common strategy 
employed in industry where large bioreactors are used for recombinant protein production and 
where controlled addition of the nutrient feed is essential in order minimise ‗over-flow‘ 
metabolism (side metabolites) which could affect the quality of the product (Lee et al., 1999; 
Wlashin et al., 2006). Exponential feeding follows the empirical model of cell growth to 
regulate the feeding rate i.e. in the correct nutrient and operating conditions; the cells grow 
exponentially thereby achieving high cell biomass (Aulicino et al., 2010). This method has been 
used in previous studies and is termed ‗feed forward strategy‘ since a theoretical specific growth 
rate (µset) of an organism can be achieved by feeding the cells in an exponential manner and 
hence will influence recombinant protein production and cell biomass (Potvin et al., 2012). This 
is described as an equation and can therefore be programmed into specialised software to 
deliver the exponential feed via the bioreactor controllers and feed pumps: 
 
F(t) is the feed rate (g h
-1
) at time, t (h); Fo is the initial feed rate and µset is the desired 
theoretical constant specific growth rate (h
-1
). 
 
Several studies have been published on the influence of µset for soluble proteins (Çelik et al., 
2009; Çelik et al., 2010; Jungo et al., 2007; Kobayashi et al., 2000; Zhang et al., 2000), 
however, no detailed studies are available for membrane protein production and feed forward 
strategies. This chapter therefore describes the effect of exponential feeding of methanol at two 
different µset on hA2AR production in P. pastoris in 35 L pilot-scale cultivations. The two µset 
were 0.01 h
-1
 which was termed µlow and 0.03 h
-1
 which was termed µhigh. These µset were chosen 
as the literature had suggested that µset of 0.03 h
-1
 for soluble proteins such as human EPO and 
human growth hormone had resulted in high yields (Çelik et al., 2009; Çelik et al., 2010). A low 
µset was also selected (0.01 h
-1
) as studies have also shown that for soluble proteins the 
productivity decreased but the cell biomass increased at lower µset than 0.03 h
-1
. It was therefore 
interesting to see if this was the same for membrane protein production.  
161 
 
4.1.3. Pilot-scale cultivations 
Two simultaneous pilot scale bioreactor cultivations (10 L starting volume) of P. pastoris X33 
strain expressing dG - hA2AR were compared following the same batch, fed-batch and transition 
feeding regimes. During the induction phase, different methanol feed profiles were applied; a 
low methanol feed profile was devised to give μset = 0.01 h
-1
, while a higher methanol feed 
profile was devised to achieve μset = 0.03 h
-1
 followed by 0.05 h
-1
. Cultures were monitored for 
optical density at 600 nm (OD600), dry cell weight (DCW), residual glycerol and methanol 
concentrations in the culture supernatant, total membrane protein yield and the yield of correctly 
folded dG - hA2AR, as measured by radio-ligand binding with the tritiated antagonist, 
ZM241385.  
Table 4.1 shows the phases of the two simultaneous bioprocesses examined in this study. A total 
cultivation time of 91.2 h included the following phases: batch (phase I), fed-batch (phase II), 
transition (phases IIIA and IIIB) and induction (phase IV and V). An identically conducted 
batch phase (I) on 10 g L
-1
 glycerol lasted for 19.1 h for both bioprocesses. The IIA phase had 
an exponential glycerol feed of µset = 0.15 h
-1
 and IIB was at µset = 0.03 h
-1
. The transition (III) 
phase consisted of a short starvation period (IIIA) followed by a brief pre-induction constant 
methanol feed at 4 g L
-1
 h
-1
 (IIIB), for both bioreactors. During the induction (IV) phase, one 
cultivation (µlow) was subjected to a 46 h exponential methanol feed rate, predicted to achieve 
µset = 0.01 h
-1
. The second cultivation (µhigh) was subjected to µset = 0.03 h
-1
 for 41 h (phase IV) 
and then µset = 0.05 h
-1
 for a further 5 h (phase V). At this point, the characteristic DO spike 
indicated full consumption of the glycerol carbon source and the stirrer speed decreased as 
result of the DO control (Fig. 4.5A). In the subsequent 20 h fed-batch phase (II), the same 
exponential, growth rate-limiting glycerol feed profile of 4 g L
-1
 h
-1
 was applied to both 
bioprocesses, increasing exponentially at a rate of 0.15 h
-1
 for 10 h and then 0.03 h
-1
 until the 
end of this phase. The transition phase had two different sections (IIIA and IIIB): in phase IIIA, 
no feed was applied to the cultivations for 1 h; in phase IIIB a constant methanol feed of 4 g L
-1
 
h
-1
 was applied. At the end of phase IIIB, the induction phase commenced differently for the 
two cultivations.  
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Table 4.1 Bioprocess events during two simultaneous P. pastoris cultivations producing recombinant dG - hA2AR with different exponential methanol 
feed rates (µset). I denotes batch phase; IIA and B denotes fed-batch phase; IIIA and B denotes transition phase and IV denotes the induction phase. The µhigh 
cultivation has another induction phase, V where the µset was adjusted to 0.05 h
-1
. 
 
Age of Cultivation (h) Temperature (°C)
0.0
14.4
16.4
18.4
19.1
20.4
22.4
23.6
28.8
38.4
40.6
42.2
42.9
44.4
µlow µhigh µlow µhigh
45.4
46.4
47.4
62.4
64.4
66.4
68.4
70.4
86.4
86.4
87.4
88.9
90.4
91.2
Phase
Glycerol Batch (10 g)
Transition (Methanol pre-induction constant feed at 46 g L 
-1 
h
 -1
 )
IIIA
IIIB
I
Transition (No feed)
Feed Event
IIA
IIB
Glycerol Fed-batch (Exponential feed at µset = 0.15 h 
-1
Glycerol Fed-batch (Exponential feed at µset = 0.03 h 
-1
22
Induction (Methanol exponential feed at µset = 0.05 h 
-1
)
Induction (Methanol exponential feed at µset = 0.03 h 
-1
)
Induction (Methanol exponential feed at µset = 0.01 h 
-1
) IV
IV
V
30
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4.2. A low methanol induction feed profile increases biomass yield leading to improved 
overall volumetric dG-hA2AR yields 
Applying a µset of 0.01 h
-1
 during the methanol induction phase for a pilot-scale cultivation of P. 
pastoris gave an overall increase in cell biomass and recombinant dG-hA2AR yield when 
compared to the cultivation with a µset of 0.03 h
-1
 during the methanol induction phase (Table 
4.2). 
4.2.1. The µlow P. pastoris cultivation yields increased biomass when compared to the µhigh P. 
pastoris cultivation 
Correct control of the required bioprocess settings is verified in Figure 4.5. The DO set-point 
was maintained at 30%, the pH set-point was maintained at 5 and the temperature set-points 
were maintained at 30°C for phases I, II and III and 22°C for phases IV and V for both the µlow 
(Figure 4.5A) and µhigh (Figure 4.5B) cultivations. Stirrer speed was set in cascade mode; for the 
µlow cultivation it increased to its maximum value as the DCW increased, demonstrating an 
increasing cellular demand for aeration (Figure 4.5A). In contrast, the stirrer speed decreased as 
the cells ceased to grow in phase IV of the µhigh cultivation (Figure 4.5B); in phase V, the stirrer 
speed decreased at a slightly lower rate as the DCW increased in response to a change in µset to 
0.05h
-1
. 
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Figure 4.5 Bioprocess parameters for the µlow and µhigh cultivations. The bioprocess 
parameters, DO (red), pH (blue), temperature (green) and stirrer speed (grey), were monitored 
during the entire duration of the µlow (A) and µhigh (B) cultivations. DO and pH were maintained 
at 30% and 5, respectively; the temperature set-points were maintained as defined in Table 4.1. 
Stirrer speed (grey) increased as the dry cell weight (DCW; closed circles) increased for the 
µlow cultivation during phase IV (A). A decrease in stirrer speed for the µhigh cultivation was 
observed as the DCW (closed squares) decreased in phases IV and V (B). 
 
Figure 4.6A shows the OD600 and DCW data throughout both cultivations. During phases I and 
II, the biomass yield remained almost identical, as expected, while differences were apparent in 
the induction phase (IV and V), most notably around 70 h duration. DCW and OD600 increased 
throughout the methanol feeding phase for the µlow cultivation (µset = 0.01h
-1
). For the µhigh 
cultivation (µset = 0.03h
-1
), the DCW and OD600 values increased slightly in the first half of 
phase IV then decreased after 70 h duration. When µset was increased to 0.05 h
-1
, DCW and 
OD600 increased slightly. At 91 h, the final biomass yields were 1,057.2 g for the µlow cultivation 
and 589.8 g for the µhigh cultivation. This is apparent in harvest flasks after centrifugation to 
sediment the cells (Figure 4.6B).  
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Figure 4.6 Biomass yield of the µlow and µhigh cultivation. A) Cell biomass (OD600; squares and 
DCW; circles) was monitored throughout the µlow (closed symbols) and µhigh (open symbols) 
cultivations for all phases. Measurements were made in triplicate. 
†
Phase V indicates a µset 
setting change for the µhigh cultivation only. At 91 h, cell biomass for the µlow cultivation was 
approximately double that of the µhigh cultivation. B) Photograph of centrifuge flasks with 1 L 
culture showing P. pastoris cells for µhigh (left) and µlow (right) at the end of the cultivations. 
 
4.2.2. Increased volumetric dG-hA2AR yields are achieved in the µlow cultivation  
Table 4.3 shows Bmax estimates and the amount of biomass generated (DCW and total 
membrane protein) for both cultivations during the transition and induction phases. Overall, 
when the cell biomass is taken into account, the µlow cultivation produces improved volumetric 
yields of dG - hA2AR. In fact, it the µlow cultivation yields 7 times more active receptor in 1 L of 
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P. pastoris culture when compared to the µhigh cultivation (38522 pmol versus 5573 pmol). This 
finding suggests that the slower feeding of methanol has a positive effect on cell biomass 
generation and hence increased production of cell membranes leading to increased production 
of the desired recombinant receptor. 
Table 4.2 The yield of dG - hA2AR is higher in the µlow cultivation than the µhigh cultivation. 
The total yield of dG - hA2AR (pmol) and the specific yield of dG - hA2AR per gram of DCW 
(pmol g
-1
) were derived from the Bmax estimates and total membrane protein measurements. 
Values are calculated per L of culture for the transition and induction phases of the µlow and 
µhigh cultivations and are the mean of triplicate determinations, with the standard error of the 
mean. Triplicate measurements were from three different membrane preparations. Bmax 
estimates were calculated from single-point radio-ligand binding analysis using 
[
3
H]ZM241385. 
  
Phase Age (h) DCW (g L
-1
) 
Total 
membrane 
protein yield 
in 1 L culture 
(mg) 
Bmax 
estimate 
(pmol 
mg
-1
) 
Total 
dG-
hA2aR 
yield in 1 
L culture 
(pmol) 
Specific 
yield 
(pmol g-1) 
µlow 
IIIA 42.2 41.91 ± 0.6 764.4 4.4 ± 0.1 3363.6 80.3 
IIIB 44.4 42.10 ± 0.4 2791.1 7.1 ± 0.6 19816.9 470.7 
IV 66.4 50.53 ± 0.5 4084.4 4.5 ± 0.2 18380.0 363.7 
IV 89.0 71.82 ± 0.2 7704.4 5.0 ± 0.2 38522.2 536.4 
µhigh 
IIIA 42.2 46.71 ± 0.5 813.3 4.4 ± 0.2 3578.7 76.6 
IIIB 44.4 46.66 ± 0.7 3060.0 4.0 ± 0.0 12240.0 262.3 
IV 66.4 45.76 ± 0.5 3277.8 3.8 ± 0.1 12455.5 272.2 
V 89.0 37.64 ± 0.8 1797.8 3.1 ± 0.1 5573.1 148.1 
 
4.3. Increased dG-hA2AR yields correlate with low residual methanol in the cultivation but 
cytotoxic levels of residual methanol maintain baseline levels of active dG-hA2AR 
Table 4.3 shows the binding activity of dG - hA2AR during the transition (IIIA and IIIB) and 
induction (IV and V) phases for both the µlow and µhigh cultivations. The amount of residual 
methanol and the cumulative addition of methanol in the cultivations is also shown. Membranes 
isolated from the µlow cultivation had higher binding activity than those from the µhigh 
cultivation; notably, the highest binding activity (7.1 ± 0.6 pmol mg
-1
) was measured in 
membranes of cells that had been subjected to constant methanol feeding (phase III; 4 g L
-1
 h
-1
). 
The residual methanol concentration in the µlow cultivation remained below 5 g L
-1
. 
Furthermore, the activity was at its highest only when the residual methanol was at 0.5 g L
-1
 in 
the system. The activity then decreased from 7.1 ± 0.6 pmol mg
-1 
to 4.5 ± 0.2 pmol mg
-1 
when 
the residual methanol increased by another 0.5 g L
-1
. Interestingly, the activity increased slightly 
to 5.0 ± 0.2 pmol mg
-1
as the entire residual methanol in the system was consumed by the cells 
after 23 h of cultivation. For the µhigh cultivation, the highest level of binding activity reached 
167 
 
was 4.4 ± 0.2 pmol mg
-1
 during the transition phase (IIIA) where no methanol feeding had 
occurred and the cells were in starvation phase. The binding activity decreased gradually as the 
residual methanol in the system increased. During phases IV and V, the residual methanol levels 
remained above 5 g L 
-1
 which is considered to be cytotoxic (Guarna et al., 1997). Moreover, the 
residual methanol reached levels that were about 17 times the cytotoxic concentration (84.7 g L
-
1
). While it is not unexpected that the binding activity was low, it was surprising that any 
activity was present at all. More methanol was added and at a faster rate for the µhigh cultivation 
when considering the cumulative addition of the methanol to the bioreactor. Methanol was 
added at a slower rate for the µlow culture and hence less was added in total at the end of the 
cultivation. At 66.4 h when the exponential feeding began (phase IV), for the µlow culture 0.8 kg 
methanol was added but for the µhigh culture1.3 kg was added and by 89 h, the µlow cultivation 
had 2.2 kg added whereas for the µhigh cultivation had 3.8 kg of methanol added by the end of 
the run (89 h), (Table 4.3). Figure 4.7 illustrates the difference in rate of addition of the 
methanol for both cultivations. The trend lines show that an exponential addition is achieved in 
both cultivations. 
Table 4.3 dG-hA2AR activity, residual methanol and cumulative methanol values for µlow and 
µhigh cultivations. Values are for Bmax estimates which were calculated from single-point radio-
ligand binding analysis using [
3
H]ZM241385, residual methanol analysis and cumulative 
methanol measurements for the transition phase of carbon source starvation (IIIA), transition 
phase of constant methanol feeding of 4 g L
-1
 h
-1
(IIIB) and the methanol induction phase of 
either µlow or µhigh (IV and V). Measurements are the mean of triplicate determinations, with the 
standard error of the mean. Cumulative methanol addition values are from a single reading.  
 
Phase Age (h) Estimated Bmax (pmol mg
-1
) Residual methanol (g L
-1
) Cumulative methanol added (kg)
IIIA 42.2 4.4 ± 0.1 0 ± 0.0 0
IIIB 44.4 7.1 ± 0.6 0.5 ± 0.1 0.2
IV 66.4 4.5 ± 0.2 1.0 ± 0.1 0.8
IV 89 5.0 ± 0.2 0 ± 0.0 2.2
IIIA 42.2 4.4 ± 0.2 0 ± 0.0 0
IIIB 44.4 4.0 ± 0.0 2.1 ± 0.2 0.2
IV 66.4 3.8 ± 0.1 39.1 ± 9.0 1.3
V 89 3.1 ± 0.1 84.7 ± 0.5 3.8
µlow
µhigh
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Figure 4.7 Cumulative addition of methanol to µlow and µhigh cultivations. Cumulative 
methanol addition values are from a single reading and fit an exponential curve (solid trend 
line). For µlow the exponent is 0.0537 (open circles) and for µhigh the exponent is 0.0659 (closed 
circles).  
4.4. Yield co-efficients differ between µlow and µhigh cultivations during induction 
Table 4.4 shows the calculated yield co-efficient for each phase for both the µlow and µhigh 
cultivations.  For phases I, IIA, IIB and III the values were similar, as expected. In the induction 
phase (phase IV), however, the yield co-efficient (0.23) was higher for the µlow cultivation than 
the corresponding value (0.02) for the µhigh cultivation; the yield co-efficient for the µhigh 
cultivation increased (to 0.30) in phase V. 
Table 4.4 Calculated yield co-efficients for the µlow and µhigh cultivations. Yield co-efficients 
for each phase of the µlow and µhigh cultivations. There was no phase V in the µlow cultivation. 
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Phase Age (h) µlow µhigh
I 18.4 0.51 0.59
IIA 28.8 0.17 0.17
IIB 40.6 1.60 1.27
III 42.2 0.75 0.76
IV 86.4 0.23 0.02
V 91.2 0.30
Yield co-efficients
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4.5. Calculated specific growth rates versus set growth rates for µlow and µhigh cultivations  
To determine whether the theoretical constant specific growth rates had been achieved, the 
actual specific growth rates were calculated (Table 4.5). As expected, both cultivations had 
similar specific growth rates in the batch and fed-batch phases (I, IIA and IIB). In the transition 
(III) and induction (IV) phases, the specific growth rate of the µlow cultivation was 0.012 h
-1
, in 
agreement with µset = 0.01h
-1
. However, the µhigh cultivation achieved a negative specific growth 
rate of -0.001 h
-1
, which was unexpected as µset = 0.03 h
-1
. During phase V of the cultivation for 
the µhigh cultivation, µset = 0.05h
-1
 and the specific growth rate increased to 0.012 h
-1
. 
Table 4.5 Calculated specific growth rates for the µlow and µhigh cultivations. Specific growth 
rates (h
-1
) were calculated from the DCW data. The R
2
 value shows the fit to the rate equation. 
There was no phase V in the µlow cultivation. 
 
4.6. Pre-induction activity in P. pastoris cultivations  
Observations of pre-induction activity in the µlow and µhigh cultivations prompted further 
investigation into these unexpected findings (Table 4.6).  
4.6.1. dG - hA2AR binding activity is present in the pre-induction glycerol phases of the µlow 
and µhigh cultivations 
Even in the absence of methanol, dG - hA2AR receptor expression (i.e. binding activity) was 4.4 
pmol mg
-1
 for both µlow (SEM = ± 0.1 pmol mg
-1
) and µhigh (SEM = ± 0.2 pmol mg
-1
) 
cultivations (Table 4.6). For the µlow cultivation, in phase IIIB, where a constant methanol feed 
was initiated and glycerol was still present at 1.1 g L
-1
, binding activity was present. In phases 
IV and V of the µlow cultivation, no glycerol was present and binding activity was present. For 
the µhigh cultivation during the transition and induction phases (IIIB and IV), glycerol was 
present in the culture medium and binding activities were 4.0 and 3.8 pmol mg
-1
, respectively. 
In phase V, there was no residual glycerol in the culture medium and binding activity was 3.1 
pmol mg
-1
.  
Phase Specific Growth Rate (h
-1
) R
2
Specific Growth Rate (h
-1
) R
2
I 0.246 0.97 0.256 0.99
IIA 0.122 0.99 0.108 0.96
IIB 0.035 0.99 0.041 0.99
III & IV 0.012 0.93 -0.001 0.47
V 0.012 0.92
µlow µhigh
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4.6.2. dG - hA2AR binding activity is also present in the pre-induction glycerol phases of a 
2 L bench-top bioreactor cultivation 
Following on from the 35 L pilot-scale work, 2 L bench-top cultivations were carried out for 
further investigations of pre-induction binding activity. The influence of glycerol on the yield of 
dG - hA2AR, in a 2 L cultivation was analysed throughout phases I-IV. Figure 4.8 shows the 
residual glycerol measurements, DCW and Bmax estimates for the recombinant P. pastoris 
culture expressing dG - hA2AR. Residual glycerol peaked during phase II at ~ 2 g L 
-1
 and was 
not present during the transition and induction phases (III and IV). Binding activity between 1.1 
and 3.1 pmol mg
-1
 was measured during the batch and fed-batch phases (I and II), suggesting 
leaky expression. During the transition phase (III), binding activity increased to 4.1 pmol mg
-1 
and during the induction phase (IV) it was 3.7 – 4.4 pmol mg-1.  The measured specific growth 
rates during this cultivation were 0.08 h
-1
 during phases I and II and zero during phases III and 
IV. The specific yield from the 1L cultivation was 122.2 pmol g
-1
, comparable to that of the µhigh 
cultivation (148.1 pmol g
-1
) rather than that of the
 
µlow cultivation (536.4 pmol g
-1
). Notably, the 
impact of the methanol feed was minimal since the pre-induction specific yield was not 
substantially increased (Figure 4.8). hA2AR was also produced in all phases of a methanol-free 
cultivation of glycerol-grown P. pastoris (Figure 4.9). During the batch phase (I), glycerol was 
present at 1.9 g L
-1
 and the recombinant hA2aR yield was 1.1 pmol mg
-1
, reaching a final yield of 
1.6 pmol mg
-1 
at the end of the cultivation. The specific yield from the 1L cultivation was 90.3 
pmol g
-1
 and the total yield was 5,598.3 pmol. This was lower than the yield achieved in the 
corresponding induced culture (Figure 4.8; 122.2 pmol g
-1
 and 12,986.3 pmol at the end of 
phase IV) indicating the positive impact of the methanol feed on total yield. The DCW reached 
a maximum of 62.0 g L
-1
 in contrast to that of 106.3 g L
-1
 for the corresponding induced culture 
(Figure 4.8). 
 
 
Table 4.6 Residual glycerol in the culture medium does not repress dG - hA2AR expression. 
Bmax estimates and residual glycerol values were measured. Samples were tested from the 
transition (III) and induction (IV and V) phases for both the µlow and µhigh cultivations. 
†
Phase V 
indicates µset setting change for µhigh cultivation only. Values are the means of triplicate 
determinations, with the standard error of the mean (SEM) given in parentheses. Student’s t-test 
was used to compare corresponding Bmax estimates from the µlow and µhigh cultivations; * = P ≤ 
0.01 and ** = P ≤ 0.001.  
  
Bmax estimate (pmol mg
-1
) Residual glycerol (g L
-1
) 
Cultivation phase Age (h) µlow µhigh µlow µhigh 
IIIA 42.2 4.4 (0.1) 4.4 (0.2) 0 (0) 2.9 (0.1) 
IIIB 44.4 7.1 (0.6) ** 4.0 (0.0) 1.1 (0.2) 4.2 (0.2) 
IV 66.4 4.5 (0.2) * 3.8 (0.1) 0 (0) 1.1 (0.2) 
†
V 88.9 5.0 (0.2) ** 3.1 (0.1) 0 (0) 0 (0) 
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Figure 4.8 dG - hA2AR binding activity is present in all phases of a subsequent 2 L 
cultivation. A 2 L cultivation was analysed for dG - hA2AR binding activity (pmol mg
-1
; red 
symbols), DCW (g; circles), residual glycerol concentration (g L
-1
; triangles) and residual 
methanol concentration (g L
-1
; squares). Measurements were made in triplicate. dG - hA2AR 
binding activity was measured in all the phases, including pre-induction phases I and II. The 
residual glycerol concentration was at its highest during phase II, dropping to zero in phase II 
and for the duration of the cultivation. DCW increased during phases I and II and plateaued 
during phases III and IV. Residual methanol ranged from 1.25 – 7.66 g L-1 during the induction 
phase.  
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Figure 4.9 dG - hA2AR binding activity is present in all phases in a methanol-free cultivation.  
A 2 L cultivation was analysed for the same strain and construct cultured previously (Figure 
4.8). dG - hA2AR binding activity (pmol mg
-1
; red symbols), DCW (g; circles) and residual 
glycerol concentration (g L
-1
; triangles) are shown. Measurements were made in triplicate. dG - 
hA2AR binding activity was measured in all the phases, glycerol batch phase (I); glycerol fed-
batch phase (II) and carbon source starvation phase (III). The residual glycerol concentration 
was at its highest during phase I, dropping to zero in phase II and for the duration of the 
cultivation. DCW increased during phases I and II and plateaued during phases III.  
4.6.3. Soluble GFP is produced in all phases of P. pastoris bioreactor cultivations 
In order to assess whether these observations were specific to dG - hA2AR as the recombinant 
target protein, the production of recombinant soluble GFP was also examined. Figure 3.9A 
shows a 2 L bioreactor cultivation with glycerol as the pre-induction carbon source. During the 
batch phase (I), glycerol was present at 3.0 g L
-1
 and the recombinant GFP yield was 2.6 mg L
-1 
prior to methanol addition. This increased to 2.7 – 3.5 mg L -1 in the fed-batch phase (II; the 
glycerol was consumed 3 h into this fed-batch phase), reaching a final yield of 4.7 mg L
-1
 in the 
induction phase (IV). The low impact of the methanol feed was confirmed in a subsequent 
experiment: when glycerol replaced methanol in the induction phase, the final yield was 3.6 mg 
L
-1
.  
 
As glucose has been shown to repress AOX1 even in the presence of methanol (Potvin et al, 
2012), a second cultivation containing glucose as the pre-induction carbon source was analysed 
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(Figure 4.9B). During the batch phase (I), when the glucose concentration was 6 mM, the yield 
of recombinant GFP was 2.5 mg L
-1
 prior to methanol addition. This increased to 2.5 – 3.5 mg 
L
-1
 in the fed-batch phase (II; the glucose was consumed 3 h into this fed-batch phase), reached 
a plateau in the transition phase (III) and then increased during the induction phase (IV) to a 
maximum value of 13.6 mg L
-1
. Methanol-free induction (with glucose replacing methanol in 
the induction phase) in a subsequent experiment gave a final yield of 2.2 mg L
-1
. This confirmed 
the higher impact of methanol induction on glucose-grown cells. 
 
Following methanol-induction, DCW values for glycerol-grown cells were approximately 5 
times higher than for glucose-grown cells in the equivalent pre-induction phase, while glucose-
grown cells produced 3 times the yield of GFP compared with glycerol-grown cells. 
Since GFP was present in the pre-induction phases of both glycerol- and glucose-grown P. 
pastoris bioreactor cultivations (Fig. 4.10), its production was analyzed in the absence of a 
methanol induction step (Fig. 4.11). GFP yield was measured in the culture supernatant in all 
phases of two 1 L P. pastoris cultivations, one grown on glycerol (Fig. 4.11A) and one grown 
on glucose (Fig. 4.11B). In these cultivations, the transition phase (III) was extended from 2 h to 
30 h. During the batch phase (I) of the glycerol-grown culture (Fig. 4.11A), glycerol was 
present at 2.9 g L
-1
 and the recombinant GFP yield was 2.1 mg L
-1
 in line with the earlier 
glycerol-grown cultivations (2.6 mg L
-1
 prior to methanol addition, Fig. 4.10A). The total GFP 
yield remained stable in the fed-batch phase (II) and reached a final yield of 8.4 mg L
-1
 at the 
end of the cultivation. This was higher than the yield achieved in the corresponding induced 
cultures (4.7 mg L
-1
 at the end of phase IV; Fig. 4.10) indicating the negative impact of the 
methanol feed on total yield. The DCW for the methanol free cultivation reached a maximum of 
92.5 g L
-1
 (Fig. 4.11A) in contrast to that of 175 g L
-1
 for the corresponding induced culture 
(Fig. 4.10). 
 
During the batch phase (I) of the glucose-grown culture (Fig. 4.11B), glucose was present at 3.4 
mM  and the recombinant GFP yield was 1.8 mg L
-1
, which was lower than that for the earlier 
glucose-grown cultivation (2.5 mg L
-1
; Fig. 4.10B). The total GFP yield increased in the fed-
batch phase (II), remained stable in the transition phase and reached a final yield of 5.6 mg L
-1
 
at the end of the cultivation. This was lower than the yield achieved in the corresponding 
induced culture (13.6 mg L
-1
 at the end of phase IV; Fig. 4.10B) indicating the positive impact 
of the methanol feed on total yield. The DCW reached a maximum of 46.5 g L
-1
 in contrast to 
that of 30 g L
-1
 for the corresponding induced culture (Fig. 4.10B). 
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Figure 4.10 Recombinant GFP is produced in the pre-induction phases of two independent 2 
L cultivations. GFP yield (mg L
-1
; circles) was measured in the culture supernatant in all 
phases of two 2 L P. pastoris cultivations, one grown on glycerol (A) and one grown on glucose 
(B). The residual glycerol concentration (A; squares) was at its highest during phase I, 
eventually dropping to zero in phase II. The DCW (A; triangles) for this cultivation reached a 
maximum of 175 g L
-1
. For the glycerol cultivation, residual methanol (B; open squares) ranged 
from 3.01 to 8.52 g L
-1
. For the glucose cultivation, the residual methanol (B; open squares) 
ranged from 2.83 to 8.69 g L
-1
. The residual glucose concentration (B; squares) was at its 
highest during phase I, eventually dropping to zero in phase II. The DCW (B; triangles) for this 
cultivation reached a maximum of 30 g L
-1
.  All measurements were made in triplicate. 
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Figure 4.11 Recombinant GFP is produced in methanol-free cultivations of P. pastoris 
grown on either glycerol or glucose as the carbon source. GFP yield (mg L
-1
; circles) was 
measured in the culture supernatant in all phases of two 1 L P. pastoris cultivations, one grown 
on glycerol (A) and one grown on glucose (B). The residual glycerol concentration (A; g L
-1
; 
squares) was at its highest during phase I, eventually dropping to zero in phase II. The DCW 
(A; g L
-1
; triangles) for this cultivation reached a maximum of 92.5108 g L
-1
. The residual 
glucose concentration (B; mM; squares) eventually dropped to zero in phase II. The DCW (B; g 
L
-1
; triangles) for this cultivation reached a maximum of 46.5 g L
-1
.  All measurements were 
made in triplicate.  
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4.7. Discussion 
The experiments performed in this chapter addressed the effect of applying two methanol feed 
profiles during induction on the cell biomass and recombinant hA2AR yields in P. pastoris. The 
study used 35 L pilot-scale bioreactors with software that enabled pre-programming a desired 
feeding regime; previous studies had shown that applying exponential feeding of methanol to P. 
pastoris cells to control the specific growth rate can be beneficial for recombinant protein 
production. The cultivations were regulated to reach a theoretical specific growth rate (µset) by 
controlling the feeding strategy at the methanol induction phase. The µset chosen were 0.01 h
-1 
termed µlow and 0.03 h
-1 
termed µhigh. Two separate P. pastoris cultivations were set-up to 
recombinantly produce a de-glycosylated version of the human adenosine A2A receptor (dG-
hA2AR) with either the µlow or the µhigh set growth rate applied at the methanol induction phase.  
 
A central finding in this study was that recombinant hA2AR yields in P. pastoris could be 
improved by controlling the methanol feeding regime. The µlow cultivation gave overall hA2AR 
yields of 536.4pmol g
-1
 compared to the µhigh cultivation, which yielded 148.1 pmol g
-1
. This 
was attributed to the doubling in cell biomass in the µlow cultivation (71.82 g L
-1
) when 
compared to the µhigh cultivation (37.64 g L
-1
). In the µlow and µhigh cultivations, the methanol 
feed influenced the biomass yield and particularly increased the total membrane protein yield in 
the µlow cultivation (7,704 mg for µlow compared to 1,798 mg for µhigh). Notably, a similar 
increase in total membrane protein yield has previously been reported to increase total 
volumetric yields of GPCRs in a respiratory yeast strain of S. cerevisiae (Ferndahl et al., 2010). 
As a consequence of increased total membrane protein yield, the yield per unit volume of the 
µlow cultivation was approximately 40 times higher than shake flask cultivations of the same 
hA2AR construct (Fraser, 2006); total membrane protein yields from shake flasks are 200 mg 
compared with almost 7704 mg in bioreactors. This yield improvement compares very 
favourably with that achieved by Singh and colleagues using an optimised hA2AR construct 
(Singh et al., 2010): on transferring from shake flasks to bioreactors a yield improvement of 
approximately 25 times was achieved on account of both an increase in specific productivity (25 
pmol mg
-1
 in a shake flask; 100 pmol mg
-1
 in a bioreactor) and biomass yield (OD600 = 13 in a 
shake flask; OD600 = 80 in a bioreactor). Furthermore, this increase in yield in the µlow 
cultivation suggested that a slowed metabolism may be desirable in maximising yields. This is 
consistent with previous reports demonstrating that improvements in GPCR yield can be 
achieved by lowering the culture temperature (André et al., 2006; Singh et al., 2008; Lundstrom 
et al., 2006; Fraser., 2006); under low temperature conditions, cells have a reduced flux through 
the TCA cycle, reduced levels of oxidative stress proteins and lower levels of molecular 
chaperones (Dragosits et al., 2010). 
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When considering the Bmax estimate data for hA2AR, (where overall biomass is not considered) 
there is a significant but less dramatic increase in pmol of hA2AR per milligram of total protein 
(for µlow 7.1 ±0.6 pmol mg
-1
 and for µhigh 4.0 ±0.0 pmol mg
-1
 at phase IIIB and 5.0 ±0.2 pmol 
mg
-1
 for µlow and 3.1 ±0.1 pmol mg
-1
 for µhigh at the end of phase V). From these findings, it 
could be hypothesised that growing the cells at a higher density may have had a negative effect 
on the hA2AR being produced at the cellular level. Jahic and colleagues (Jahic et al., 2003) 
showed that high cell density P. pastoris cultures exhibit increased in proteolysis and that 
cultures between OD600 100-500 are at risk of this. There is further evidence in the literature that 
high yeast culture cell densities tend to be under osmotic stress (Mattanovich et al., 2004). 
Osmotic stress occurs when the salt concentrations in the media formulations rise and fall 
during consumption by the yeast cells. In particular relation to membrane proteins, it is thought 
that the yeast cell surface assembly is sensitive to osmotic stress (Gasch et al., 2000) and that 
major structural changes occur such as adjustment of the cell wall organisation during 
hyperosmotic conditions (Mager and Siderius, 2002).  For different protein targets, different 
residual methanol concentrations have been found for optimal productivity, ranging from 0.4-30 
g L
-1
 (Hellwig et al., 2001, Zhang et al., 2000). Overall, this suggests that applying an 
exponential methanol feeding regime at a low set growth rate yields high biomass for P. 
pastoris and leads to higher membrane protein yields than are achieved in a high set growth 
rate.  
 
The slight increase in dG- hA2AR activity for the µlow cultivation was probably due to the lack of 
residual methanol that was present in the cultivation and that it never exceeded the reported 
cytotoxic level of 5 g L
-1
. However in stark contrast, the µhigh cultivation contained residual 
methanol levels of 84.70 g L
-1
 which gave rise to a cytotoxic environment. The effect of this 
was reflected in the cell biomass yields as they did not increase once this (µhigh) methanol 
feeding regime was applied. Interestingly however, dG-hA2AR activities were only slightly 
lower than the activities achieved from the µlow cultivation and therefore it was quite unexpected 
to achieve any activity in such a cytotoxic methanol environment. 
Another notable finding from this study was the presence of dG-hA2AR activity prior to 
methanol induction. For both the µlow and µhigh cultivations, binding activity was present at 4.4 
pmol mg
-1
 prior to any induction. Furthermore, it was found that residual glycerol was still 
present in some phases indicating that glycerol did not repress the AOX1 gene. This finding 
warranted further investigation and therefore several 2 L bench-top bioreactor cultivations were 
performed on P. pastoris and the pre-induction phases were studied in more detail.  
In one bioreactor experiment, dG- hA2AR was recombinantly produced in P. pastoris and it was 
found that the activity was present regardless of the presence of glycerol.  
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This was assessed further by carrying out bench-top bioreactor cultivations for another 
recombinant protein, in order to rule out any protein specific phenomena. Soluble GFP was 
recombinantly produced in P. pastoris cultivations with either glycerol or glucose as the batch 
and fed-batch carbon source. This was done to test if the carbon source was also a factor.  
It was found that there was indeed a pre-induction production of GFP with either glycerol or 
glucose present in the cultivation. This could suggest that the leaky expression phenomena are 
present in all of the tested systems in this chapter but would require further testing. This is 
reported in the literature for some P. pastoris AOX1 leaky promoter behaviour (Lombardi et al., 
2010) and also in E. coli systems (Ham et al., 2006, Guzman et al., 1995). 
 
These findings show that against the general consensus, pre-induction production of hA2AR and 
GFP are present. The impact of this finding is that this adds insight into the importance of 
controlling and optimising culture conditions during all the phases of P. pastoris cultivations 
and not just the induction phase. There are however unanswered questions such as: is this true 
for other protein targets? Future work would therefore be to select several more recombinant 
protein targets and perform the same bioreactor and comparative shake flask cultivations to see 
if this is true. This information could then be useful when planning P. pastoris recombinant 
protein cultivations.  
 
This chapter forms the basis of an original research manuscript currently in submission and also 
a published book chapter titled ‗Optimising P. pastoris induction‘ by Zharain Bawa and Richard 
Darby (Bawa, 2012) ;(Appendix A9). 
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Chapter 5: The use of novel polymers to extract recombinant hA2AR 
from P. pastoris membranes 
Extracting membrane proteins from their native membranes to enable structural studies is 
challenging due to their heavy dependence on the membrane lipid bilayer for their integrity.  
The first step of extracting the membrane protein from the membrane is termed solubilisation, 
followed by purification of the protein to enable further biophysical studies such as circular 
dichroism (CD), analytical ultra-centrifugation (AUC) and dynamic light scattering (DLS). 
Eventually, x-ray crystallography techniques are used to achieve crystal structures. The 
solubilisation process typically uses compounds such as surfactants or detergents as discussed in 
Chapter 1. These may cause denaturation of the membrane protein or formation of aggregates if 
not optimised. In this chapter solubilisation of hA2AR from P. pastoris membranes using poly 
(maleic anhydride-styrene) polymers (PMAS) is described with the goal of making 
solubilisation a quick and cheap alternative to employing traditional detergents. The hA2AR 
construct described in Chapter 5 was designed in collaboration with the industrial sponsor, 
AstraZeneca Ltd, in order to use their standard tagging protocol.  This was done to render the 
hA2AR construct amenable to different downstream applications within AstraZeneca that would 
not be possible for the hA2AR construct used in Chapter 4.  
5.1. Design of a novel hA2AR construct 
An improved construct design was investigated for hA2AR. The goal was to use a truncated 
version of the hA2AR sequence. Fraser (Fraser, 2006) used a full length version of the sequence 
even though it was mutated for de-glycosylation. The new construct illustrated in Figure 5.1 
kept the de-glycosylation but also introduced a truncated version of the protein (A316) as in 
Singh et al., 2010.  
5.1.1. Construct design 
The new hA2AR construct was designed with multiple tags which included 10× histidine, FLAG 
and biotin tags. It was also designed with a bovine pancreatic trypsin inhibitor (BPTI) sequence 
(Parekh et al., 1995) which replaces the commonly used alpha factor leader peptide sequence in 
yeast vector-construct designs (Waters et al., 1988, Tashiro et al., 1993). A thrombin cleavage 
site was designed into the construct where thrombin proteases are highly specific for cleavage 
between Arg and Gly residues (Vu et al., 1991). Another cleavage site included was the TEV 
cleavage site. Two Gly-Ser linkers were designed either side the hA2AR ORF. Finally a Kozak 
sequence was included at the beginning of the construct (Kozak, 1999). A synthesised XbaI was 
included to allow flexibility of the construct to be used in other projects. Figure 5.1 shows the 
design, DNA and amino acid sequence for the new construct with the new name: MT-hA2AR. 
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The construct was synthesised and cloned into the pPICZB vector (Life Technologies) by 
GeneArt Life Technologies Corporation (Figure 5.2). 
A) 
  
B) Coding sequence for new construct: 
GAAACGATGAGAATGAAGGTTTTGATCGTTTTGTTGGCTATCTTCGCTGCTTTGCCATTG 
GCTTTGGCTTTGGTTCCAAGAGGTTCTCATCACCATCACCATCATCACCACCATCACGAG 
AACTTGTACTTCCAAGGTTCTGGTTCCGGTTCTGGATCTGGTTCCATGCCAATTATGGGT 
TCCTCCGTTTACATCACTGTTGAGTTGGCTATCGCTGTTTTGGCTATCTTGGGTAACGTT 
TTGGTTTGTTGGGCTGTTTGGTTGAACTCCAACTTGCAGAACGTTACAAACTACTTCGTT 
GTTTCCTTGGCTGCTGCTGACATTGCTGTTGGAGTTTTGGCTATTCCATTCGCTATCACT 
ATCTCCACTGGTTTCTGTGCTGCTTGTCACGGTTGTTTGTTCATTGCTTGTTTCGTTTTG 
GTTTTGACTCAGTCCTCTATCTTCTCCTTGTTGGCTATTGCTATCGACAGATATATCGCT 
ATCAGAATCCCATTGAGATACAACGGTTTGGTTACTGGTACTAGAGCTAAGGGTATTATC 
GCTATCTGTTGGGTTTTGTCCTTCGCTATCGGTTTGACTCCAATGTTGGGTTGGAACAAC 
TGTGGTCAGCCAAAAGAGGGTAAGCAACACTCTCAAGGTTGTGGTGAGGGTCAGGTTGCT 
TGTTTGTTCGAGGACGTTGTTCCAATGAACTACATGGTTTACTTCAACTTTTTCGCTTGT 
GTTTTGGTTCCTTTGTTGTTGATGTTGGGTGTTTACTTGAGAATCTTCTTGGCTGCTAGA 
AGACAGTTGAAGCAGATGGAATCCCAGCCATTGCCAGGTGAAAGAGCTAGATCCACATTG 
CAGAAAGAGGTTCACGCTGCTAAGTCCTTGGCTATCATCGTTGGTTTGTTCGCTTTGTGT 
TGGTTGCCATTGCACATCATCAACTGTTTTACTTTCTTCTGTCCTGACTGTTCCCACGCT 
CCATTGTGGTTGATGTACTTGGCTATCGTTTTGTCCCACACTAACTCCGTTGTTAACCCA 
TTCATCTACGCTTACAGAATCAGAGAGTTCAGACAGACTTTCAGAAAGATCATCAGATCC 
CACGTTTTGAGACAGCAAGAGCCATTCAAGGCTGACTACAAGGATGATGACGACAAGGGT 
TCCGGATCAGGTTCTGGATCAGGATCAGGTCAATTCGGTGGTGGTACTGGTGGTGCTCCA 
GCTCCAGCTGCTGGTGGTGCTGGTGCTGGTAAAGCTGGTGAAGGTGAAATTCCAGCTCCA 
TTGGCTGGTACTGTTTCCAAGATCTTGGTTAAGGAAGGTGACACTGTTAAGGCTGGTCAG 
ACTGTTTTGGTTTTGGAGGCTATGAAGATGGAAACTGAGATCAACGCTCCAACTGACGGT 
AAGGTTGAGAAGGTTTTGGTCAAAGAAAGAGATGCTGTTCAGGGAGGTCAGGGTTTGATT 
AAGATCGGTTCTAGA 
 
C) Translated amino acid sequence with same colour code key as in B): 
ETMRMKVLIVLLAIFAALPLALALVPRGSHHHHHHHHHHENLYFQGSGSGSGSGSMPIMGSSVYITVELAIA
VLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAAADIAVGVLAIPFAITISTGFCAACHGCLFIACFVLVLTQ
SSIFSLLAIAIDRYIAIRIPLRYNGLVTGTRAKGIIAICWVLSFAIGLTPMLGWNNCGQPKEGKQHSQGCGEGQ
VACLFEDVVPMNYMVYFNFFACVLVPLLLMLGVYLRIFLAARRQLKQMESQPLPGERARSTLQKEVHAAK
SLAIIVGLFALCWLPLHIINCFTFFCPDCSHAPLWLMYLAIVLSHTNSVVNPFIYAYRIREFRQTFRKIIRSHVLR
QQEPFKADYKDDDDKGSGSGSGSGSGQFGGGTGGAPAPAAGGAGAGKAGEGEIPAPLAGTVSKILVKEGD
TVKAGQTVLVLEAMKMETEINAPTDGKVEKVLVKERDAVQGGQGLIKIGSR 
Figure 5.1 MT-hA2AR construct design and sequence. A) Schematic diagram of a multi-tag, 
truncated (tr.), de-glycosylated (dG) hA2AR construct, named MT- hA2AR. B) Coding DNA 
sequence of MT- hA2AR that was cloned into pPICZB vector (Life Technologies) using 
EcoRI/NotI cloning sites present in multiple cloning region of vector backbone. C) Amino acid 
sequence translated from DNA coding region. 
Colour code key: 
Kozak sequenceBPTI signal (bovine pancreatic trypsin inhibitor)Thrombin cleavage site10x 
histidine tagTEV cleavage siteGly-Ser linker (5x)FLAG tag (with internal enterokinase 
cleavage site)Truncated (A316) (Singh et al., 2010) and de-glycosylated (N154Q) hA2AR 
(Fraser, 2006) Biotin tagSynthesised XbaI site 
 
Kozak BiotinFLAGHis10BPTI Thrombin TEV tr. dG. hA2AR5′ 3′
5× GS
5× GS
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Figure 5.2 pPICZB-MT-hA2AR vector map. Vector map of the MT-hA2AR cloned into the 
pPICZB vector multiple cloning sites using EcoRI/NotI. Notable features of the vector include 
the AOX1 promoter region used for inducing recombinant protein production with methanol 
and the Zeocin resistance gene (Zeo (R), used for colony selection after transformations into the 
desired strain are performed. Appendix A2 and A3 contains the alignment sequencing 
performed at Life Technologies for the pPICZB-MT-hA2AR vector. 
5.1.2. Validation of construct design 
The MT-hA2AR construct was tested further and sub-cloned out of the pPICZB vector and 
cloned into a mammalian vector (pCDNA3.1) and transfected into human embryonic kidney 
(HEK) cells. This work was performed and analysed by Dr. Sarah Routledge, Aston University, 
United Kingdom. The purpose of this investigation was to observe if any of the tags in the MT-
hA2AR construct interfered with the specific binding activity by comparing it to HEK cells 
transfected with His tagged hA2AR and an untagged construct of hA2AR. Figure 5.3 shows the 
competition binding curves performed where cold ZM241385 competed with [
3
H] ZM241385. 
The pKd values were derived from the Ki values where the untagged hA2AR construct gave the 
highest pKd of 8.2. Both the His-tagged and MT-hA2AR construct gave a pKd of 8.9 suggesting 
good affinity and that the tags did not interfere with hA2AR binding.  
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Figure 5.3 Competition binding curves for untagged, His- tagged and MT-hA2AR from HEK 
cell membranes. Competition binding curves were performed where cold ZM241385 competed 
with [
3
H] ZM241385. The curve was fitted to a one site binding model and data points were 
triplicate over 3 separate experiments with the standard error of the mean (SEM) shown. pKd 
values were derived from the EC50 values from the curves. 
The novel hA2AR construct (MT- hA2AR) was therefore transformed into a protease-deficient 
strain (SMD1163) and was verified for growth and expression. This allowed it to be used for 
studies of novel hA2AR solubilisations. Subsequent experiments used the SMD1163- MT- 
hA2AR grown in FM22 minimal medium. 
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5.1.3. Generation of a high yielding P. pastoris strain for production of recombinant MT-
hA2AR 
The pPICZB-MT-hA2AR vector was transformed into E.coli XL 10-Gold® ultra-competent cells 
(Stratagene) and the vector purified using a mini-prep method. Figure 5.4 shows the agarose gel 
of the purified vector from the propagated XL 10-Gold® ultra-competent E.coli cells and the 
vector after linearisation with PmeI. The vector was linearised so that it could integrate with the 
P. pastoris genome via homologous recombination.  
 
 
Figure 5.4 Agarose gel (1%) showing purified pPICZB-MT-hA2AR before and after 
linearization. A) pPICZB-MT-hA2AR purified after mini-preparation technique, lanes 1-6. 
Supercoiled plasmid DNA is indicated at~ 5000 kb. Open circular plasmid DNA is also 
indicated in the upper part of the gel. B) pPICZB-MT-hA2AR after linearization with PmeI with 
a size estimated between 10-20 kb. 
Once the pPICZB-MT-hA2AR DNA was linearized and the sequence verified, the chosen P. 
pastoris strain for transformation was prepared. The SMD1163 (his4 pep4 prb1) protease 
deficient strain (White et al.,1995 and Brierley, 1998) was selected and was the kind gift of Dr. 
Shweta Singh, Imperial College, London, United Kingdom. After electroporation of the 
pPICZB-MT-hA2AR DNA into the SMD1163 P. pastoris cells, they were grown on zeocin 
selection plates of increasing concentrations. Figure 5.5 illustrates the colony selection process 
for expression screening. 
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Figure 5.5 Scheme for screening MT-hA2AR expression. Diagram shows YPDS culture plates 
with 4 concentrations of zeocin. Colonies grew on 100 µg mL
-1
 and 250 µg mL
-1 
plates and were 
taken forward for expression screens. No colonies were observed on the 500 µg mL
-1 
and 1000 
µg mL
-1
 plates. 
Before the expression screen began, a few colonies from the 100 µg mL
-1
 and 250 µg mL
-1 
plates were grown in BMGY complex medium in shake flasks to determine their growth rates 
and hence to determine at which time point the induction of recombinant MT-hA2AR should 
approximately begin (around late log phase) by changing the medium to BMMY during the 
expression screen experiments. The mean growth rate (µ) of the colonies was 0.36 h
-1
 and their 
doubling time for growth was about 67 min. These calculations were done at the logarithmic 
phase of growth. The late log phase occurred at 5-10 h and therefore induction started at this 
time (Figure 5.6). 
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Figure 5.6 Growth curves for several colonies of SMD1163- MT-hA2AR in BMGY cultured in 
shake flasks. 5 colonies (3 from 100 µg mL
-1
 plates and 2 from 250 µg mL
-1 
plates) were 
cultured in BMGY in shake flasks and grown at 30°C for 48 h. Optical density measurements 
were taken at 600 nm. The specific growth rates (µ) were calculated from the exponential part 
of the curve for each colony and averaged. The doubling times (DT) were calculated from µ. 
The optimal time for starting induction is between 5-10 h.  
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Immuno-blot analysis showed expression of the MT-hA2AR from a selection of colonies from 
both concentrations of zeocin (colony A3 and A7 from the 100 µg mL
-1
 plates and colony B1 
and B4 from the 250 µg mL
-1 
plates). The main band was approximately 38-40 kDa (Figure 
5.7). There were other larger bands seen in the immuno-blot and this may be attributed to 
uncleaved thrombin signal peptides and the smaller bands may be attributed to degraded 
products of the receptor..  
 
Figure 5.7 Immuno-blot from SMD1163-MT-hA2AR colony screen. Immuno-blot of MT-hA2AR 
from colony screening in BMMY shake flasks. Lanes labelled A3 and A7 correspond to colonies 
A3 and A7 from the 100 µg mL
-1
 zeocin YPDS plates. Membrane preparations were made from 
cells that were harvested at the end of methanol (0.5%) induction after 24 h from the BMMY 
shake flask experiments. Lanes labelled B1 and B4 correspond to colonies B1 and B4 from the 
250 µg mL
-1
 zeocin YPDS plates. Membrane preparations were also from cells that were 
harvested at the end of methanol (0.5%) induction after 24 h from the BMMY shake flask 
experiments. The primary antibody used in the method was anti-His antibody (Serotec). 
5.1.4. Analysis of functional recombinant MT-hA2AR in P. pastoris 
Radio-ligand binding analysis was carried out on all the colonies selected (Figure 5.8). Single- 
point binding analysis was performed on the membrane preparations of the colonies. It can be 
see that colony A7 gave the highest specific binding (~ 7.0 pmol mg
-1
) to the hA2AR antagonist 
[
3
H] ZM241385 hence this colony was selected for subsequent experiments. SMD1163 P. 
pastoris transformed with the pPICZB vector only were also grown on the zeocin selection 
plates. Colonies grew on the 100 µg mL
-1
, 250 µg mL
-1
 and 500 µg mL
-1
 zeocin plates and were 
selected for single-point radio-ligand binding. There was no activity detected in these cells with 
the vector only control. 
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Figure 5.8 Specific binding activities from SMD1163 MT-hA2AR colony expression screen. 
Single-point radio-ligand binding analysis using [
3
H] ZM241385 on membrane preparations of 
8 selected colonies from 100 µg mL
-1
 zeocin YPDS plates (after growth in BMGY shake flask 
and induction with BMMY) and 5 selected colonies from 250 µg mL
-1
 zeocin YPDS plates (after 
growth in BMGY shake flask and induction with BMMY). Colony A7 gave the highest specific 
binding activity and was chosen for all subsequent experiments. A vector only control was also 
grown on the 100, 250 and 500 µg mL
-1
 zeocin YPDS plates where the pPICZB vector was 
transformed into SMD1163 P. pastoris cells with no insertion of the construct. The no binding 
activity was present for all colonies and the figure shows this for the 500 µg mL
-1
 zeocin only.   
As the purpose of the work described in this chapter was to study novel solubilising compounds, 
it was necessary to generate large amounts MT-hA2AR membranes to enable this research. The 
most efficient and controlled method was to run a 2 L bioreactor of SMD1163 MT- hA2AR cells. 
This also tested if the cells could be scaled-up from 25 mL culture volume to 2 L culture 
volume and also to see if the cells could grow on minimal medium (FM22 media) and not just 
complex medium (BMGY and BMMY). The results were compared to a 2 L bioreactor run for 
the X33-dG -hA2AR in FM22 media. Membrane preparations were carried out at the final 
induction time-point (90 h) for both constructs. For both construct types and strains, the total 
wet cell biomass was recorded (Figure 5.9, inset table). The wet cell biomass was similar in all 
situations, where the X33-dG -hA2AR wet cell mass was 125 g and SMD1163 MT- hA2AR was 
120 g at the end of the runs. The specific growth rate was calculated for the exponential part of 
the growth curves for both constructs and they were similar in value, 0.086 for X33-dG -hA2AR 
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and 0.082 for SMD1163 MT- hA2AR. Radio-ligand binding analysis with [
3
H] ZM241385, a 
saturation binding curve, was carried out for both constructs and the Bmax and pKd values 
calculated (Figure 5.9). Both constructs gave similar pKd values of 8.3 (X33-dG -hA2AR) and 
8.5 for (SMD1163 MT- hA2AR). However, the Bmax was slightly increased for SMD1163 MT- 
hA2AR (6.4 pmol mg
-1
) when compared to X33-dG -hA2AR (4.4 pmol mg
-1
). This suggested that 
the SMD1163 MT- hA2AR strain yielded more expression of the receptor than the X33-dG -
hA2AR strain-construct combination. 
 
Figure 5.9 Saturation binding curve and  summary of wet cell weight, specific growth rates 
(µ), Bmax and pKd data for X33-dG - hA2AR and SMD1163-MThA2AR in FM22 minimal media. 
Saturation binding of [
3
H] ZM241385 to membrane bound dG - hA2AR grown in FM22 media 
(closed triangles), MT-hA2AR grown in FM22 media (closed squares) at a single time-point 
during the induction phase (91h). Data were all from triplicate sampling. Inset table shows wet 
cell biomass weighed at end of bioreactor runs (91 h). The specific growth rates (µ) were 
derived from the exponential section of the growth curve for both constructs. The Bmax and pKd 
values were calculated from the saturation binding curve using non-linear regression. Radio-
ligand binding assays were carried out on membrane preparations of cells harvested at the final 
time-point of 91 h during the induction phase for both constructs. 
5.2. Solubilisation of MT-hA2AR from SMD1163 P. pastoris membranes with the detergent, 
n-dodecyl-β-d-maltopyranoside (DDM) 
Typically, n-dodecyl-β-d-maltopyranoside (DDM) is used for solubilising hA2AR from native 
membranes (yeast or mammalian); (le Maire et al., 2000). Figure 5.10 shows the saturation 
binding profile for DDM solubilised MT- hA2AR from SMD1163 P. pastoris cells. The Bmax 
value is 5.6 ± 2.3 pmol mg
-1 
 and the pKd is 8.3 ± 0.1 which was comparable to the membrane 
bound MT- hA2AR and gave values of Bmax = 6.4 ± 0.5 pmol mg
-1 
 and pKd = 8.5 ± 0.1. This 
confirmed that the SMD1163 MT- hA2AR strain was able to be solubilised via detergents and 
hence the PMAS solubilisations were initiated.  
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Figure 5.10 Saturation binding curve for DDM solubilised MThA2AR from SMD1163 P. 
pastoris cells. Saturation binding of [
3
H] ZM241385 to DDM solubilised MThA2AR.  Data are 
the mean of triplicate experiments ± SEM The Bmax and pKd values were derived from non-linear 
regression of the curve.  
5.3. Solubilisation of MT-hA2AR from SMD1163 P. pastoris membranes with responsive 
hydrophobically associating polymers  
In an alternative approach, MT-hA2AR was solubilised from SMD1163 P. pastoris membranes 
with responsive hydrophobically associating polymers, in particular, poly (maleic anhydride-
styrene) or PMAS. Figure 5.11 shows the generic chemical structure of poly (maleic anhydride–
styrene) (Figure 5.11A) and poly (maleic acid-styrene) (Figure 5.11B) after hydrolysis (addition 
of NaOH) which opens the anhydride rings to form maleic acid molecules in order to make the 
polymer soluble. The styrene molecules form the hydrophobic regions of the polymer and 
maleic acid is the hydrophilic part. The number of styrene to maleic anhydride/acid can vary. As 
there are many forms of poly (maleic anhydride–styrene), a sub-set of PMAS was chosen with 
different molecular weights in order to test whether these variations improved the 
solubilisations. For the same reason, one PMAS was esterified with methanol. 
Bmax (pmol mg
-1
)  5.6 ± 2.3 
pKd (nM)      8.3 ± 0.1 
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Figure 5.11 Chemical structure of poly (maleic anhydride-styrene) and poly (maleic acid-
styrene) A) is the chemical structure of poly (maleic anhydride-styrene) showing the styrene 
benzene ring and the anhydride group in the polymer. The number of styrene molecules and 
anhydride groups can vary denoted by m and n. B) shows poly (maleic acid-styrene) after 
hydrolysis with NaOH. When the pH reaches above 6 when the NaOH is added, the carboxyl 
(COOH) group is ionised to COO
- 
 with Na
+
 in solution.    
 
Detergents have always been a popular choice for solubilising membrane proteins (Seddon et 
al., 2004) however; they come with their challenges including the formation of unstable protein-
detergent micelles, loss of membrane protein function due to aggregation and the disordered 
nature of detergent molecules leading to the lack of crystal lattice formation (Alguel et al., 
2010). Therefore, research into finding more robust agents such as modified detergents and 
polymers for solubilising membrane proteins is a current objective (Jamshad et al., 2011). It was 
recognised by Tonge and Tighe (Tonge and Tighe, 2001) that PMAS (mixed with a 
phospholipid), have properties that can be exploited in biomedical science, such as drug 
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delivery, to target areas of the body including the lung (Tonge and Tighe, US Patent number 
6,436,905) and also as a contact lens fluid to prevent dry eye syndrome (Tighe et al., 2013, 
Patent application number GB 1312343.5, Appendix A6). It was later recognised that by mixing 
the PMAS with a phospholipid and cell membranes, membrane proteins were solubilised in a 
polymer-membrane protein-lipid complex (Knowles et al., 2009). Moreover, the typical DDM 
solubilisation protocol of membrane proteins from P. pastoris membranes was modified with 
PMAS as the solubilising agent instead of DDM and DMPC instead of CHS as the 
supplementary lipid and the buffers and protease inhibitors remained unchanged in the 
solubilisation mixture. This initial work was performed by Knowles and colleagues and 
Jamshad and colleagues with the membrane proteins, PagP and bacteriorhodopsin. Furthermore, 
the results led to successful biophysical experiments (Knowles et al., 2009; Jamshad et al., 
2011). In these studies, the polymer used was was called styrene maleic acid (SMA) which is 
the same as PMAS 2000P used in this thesis (Chapter 1); (Tighe et al., 2013, Patent application 
number GB 1312343.5, Appendix A6). The aim was to look for improvements on 2000P by 
changing its structure and also by optimising the actual solubilisation protocol.  
Table 5.1 shows the PMAS that were used in this study. These were chosen based on 
commercial availability of the raw material. 2000P has a molecular weight of approximately 
7500 g mol
-1
 and consists of a chain of two styrene to every one maleic anhydride/acid. It is the 
largest polymer that was tested. In terms of size, 1000F was next largest (5500 g mol
-1
) followed 
by the smallest, 1600 and 1600ME (both 1600 g mol
-1
). These PMAS were all 1:1 for styrene : 
maleic anhydride/acid. The four PMAS solutions were prepared using hydrolysis and reflux 
reactions by Dr. Anisa Mahomed, Aston University, United Kingdom. Reflux reactions were 
carried out for the higher molecular weight and more hydrophobic PMAS where the anhydride 
rings were more difficult to open and hydrolysis was not sufficient.  
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Table 5.1 Four PMAS solutions used for testing solubilisation of hA2AR in P. pastoris 
membranes. The number of styrene :  maleic anhydride/acid in the polymer chain were 2 : 1 for 
2000P. All others were 1:1. For 1600ME, esterification of the 1600 PMAS was performed with 
methanol. The molecular weights differed for each PMAS. P denotes powder of the raw 
material, F denotes flakes of the raw material.  
 
PMAS name 
m(number of 
styrenes) 
n(number of maleic 
anhydride) 
Approximate 
molecular weight  
(g mol
-1
) 
2000P 2 1 7500 
1000F 1 1 5500 
1600 1 1 1600 
1600ME 1 1 + methyl group 1600 
 
Each PMAS solution (final concentration of 3%) was prepared at pH 7.0 and pH 11.0 and was 
used for the solubilising experiments. These pHs were selected because pH 11.0 is the final pH 
once the hydrolysis procedure is complete while pH 7.0 is more physiological pH. Therefore, 
pH 11.0 was tested to see if the polymer could be used directly to solubilise the membrane 
protein. The actual pH was also measured when the membrane and lipid were added to the 
solubilisation mixture to see how much it altered. It was found that when any of the pH 7.0 
PMAS were added to the P. pastoris SMD1163-MT-hA2AR membranes plus the DMPC lipid, 
the pH altered in the range of 7.1-7.2. For the pH 11.0 PMAS the pH altered in the range of 8.2-
8.5.  
 
 
 
 
 
 
  
193 
 
5.3.1. Preliminary optimisation of PMAS solubilisation conditions 
Initially work was done with SMA co-polymer (PMAS 2000P equivalent) and P. pastoris 
expressing hA2AR (unpublished results) in collaboration with Dr. Yu-pin Lin, University of 
Birmingham, United Kingdom using Knowles and colleagues specified protocol (Knowles et 
al., 2009). However, there was an opportunity to improve upon the solubilisation protocol and 
therefore the main solubilisation conditions (solubilisation buffer composition, time period of 
solubilisation incubation and temperature of the solubilisation) were tested for the PMAS 
2000P. The optimal conditions retrieved were used for all subsequent experiments. 
Knowles and colleagues had included a buffer in the solubilisation mixture similar to that used 
in DDM solubilisations (50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 10% glycerol, 10% DMPC 
and membrane (40-80 mg mL
-1
)); (Knowles et al., 2009). Therefore, this was an opportunity to 
investigate whether this buffer was necessary in the solubilisation as the P. pastoris membranes 
were already suspended in 50 mM Tris-HCl, 5% glycerol, 2mM EDTA and 0.2% protease 
inhibitors. If the solubilisation reaction could be kept simple, without the buffer, it would be 
more user-friendly and less expensive. In this section the solubilisation reactions are therefore 
referred to as ‗standard‘ or ‗simple‘. The standard reaction includes: MT-hA2AR SMD1163 P. 
pastoris membranes; 10% DMPC, 50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 10% glycerol and 
the PMAS. The simple reaction includes: MT-hA2AR SMD1163 P. pastoris membranes; 10% 
DMPC, and the PMAS. Table 5.2 summarises the results from testing the type of solubilisation, 
the time of incubation and the temperature on the Bmax estimate. From this test, it can be seen 
that the best condition was a simple solubilisation, incubated overnight at room temperature. 
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Table 5.2 Summary of solubilisation condition tests using PMAS 2000P pH 7.0 and DDM. 
Table shows Bmax estimate values of solubilised MT-hA2AR from SMD1163 P. pastoris 
membranes using PMAS 2000P pH 7.0 or DDM. The simple versus standard buffer recipe was 
tested, the time of the incubation and the temperature of the incubation. RT denotes room 
temperature and O/N denotes overnight (~16 h). Data are from at least 2 replicates and SEM 
are shown ±. 
 
   Standard solubilisation buffer for DDM solubilisations are 20 mM HEPES, pH 7.4, 50% glycerol, 250 mM NaCl, 1 
µL protease inhibitors, 5% (w/v) DDM and 0.5% (w/v) cholesteryl hemi-succinate (CHS) plus membrane fraction. 
Simple solubilisation buffer for DDM solubilisations are 5% (w/v) DDM and 0.5% (w/v) CHS plus membrane 
fraction.  Standard solubilisation buffer for PMAS 2000P pH 7.0 solubilisations are 10% glycerol, 500 mM NaCl, 
2.3% (w/v) PMAS, 1% (w/v) DMPC, 50 mM Tris-HCl, pH 8.0 and membrane fraction.  Simple solubilisation buffer 
for PMAS 2000P pH 7.0 solubilisations are 2.3% (w/v) PMAS, 1% (w/v) DMPC plus membrane fraction as outlined 
in Chapter 2 section 2.2.10 and 2.2.12. 
Figure 5.12 displays the solutions in the solubilisation protocol at each step. It is important to 
note the clarity of the final solubilisation mixture as this gives a preliminary indication if any 
hyper-coiled structures have been formed (Tonge and Tighe, 2001) and hence if the 
solubilisation has worked. It can be seen that the membrane and the membrane plus the DMPC 
are quite cloudy when mixed together. But when the PMAS is added to the mixtures, some 
became clear. It was noted that some would turn clear immediately but some took longer and 
hence the overnight rocking incubation period was necessary. 
  
Time of incubation
Temperature of 
incubation
DDM PMAS 2000P pH 7.0 
Standard solubilisation buffer 1 h RT 2.4 ± 0.6 2.1 ± 0.1
Simple solubilisation buffer 1 h RT 1.2 ± 0.8 3.9 ± 0.3
Simple solubilisation buffer O/N RT 1.1 ± 1.3 4.9 ± 0.1
Simple solubilisation buffer O/N 4°C 5.3 ± 0.3 4.7 ± 0.1
Bmax estimate (pmol mg
-1
)
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Figure 5.12 Clarity of solutions in solubilisation experiments. A) Shows the SMD1163 P. 
pastoris membrane with MT-hA2AR only. B) Shows the SMD1163 P. pastoris membrane with 
MT-hA2AR only with DMPC. C) Shows the 2000P pH 11.0 PMAS solution only. D) Shows the 
SMD1163 P. pastoris membrane with MT-hA2AR plus DMPC and PMAS after overnight, room 
temperature incubation. 
5.3.2. Screening PMAS solutions for solubilisation of MT-hA2AR from SMD1163 P. 
pastoris membranes 
This section describes the screening process carried out to observe which PMAS were the best 
at solubilising functional MT-hA2AR from SMD1163 P. pastoris membranes and therefore, 
which ones were suitable to move forward with more detailed experiments. Radio-ligand 
binding assays were carried out on the supernatant fraction obtained via ultra-centrifugation 
(solubilised material). Table 5.3 summarises the Bmax and pKd data (if applicable). In the first 
instance, single point radio-ligand binding was performed with the [
3
H]ZM241385 and if no 
saturation binding curves were performed due to poor performance of the PMAS, these data 
were considered as Bmax estimates. It can be seen that the 1000F (pH 7.0 and 11.0) and the 1600 
(pH 7.0 and 11.0) PMAS solubilisations did not give any radio-ligand binding activity, 
suggesting that they failed to solubilise any intact MT-hA2AR at all. Therefore, these polymers 
were eliminated from any further study. It is interesting to point out that the 1000F pH 11.0 
solubilisation mix cracked and broke the ultracentrifugation tube after being subjected to a 
SMD1163 MT-hA2AR 
membrane only
SMD1163 MT-hA2AR membrane
plus DMPC only
PMAS solutions at pH 7.0 or 11.0
SMD1163 MT-hA2AR 
membrane plus DMPC and PMAS 
after overnight incubation
A)
D)
B) C)
196 
 
100000 ×g spin. This occurred on two occasions but did not happen in the 1000F pH 7.0 
samples (Figure 5.13). It was unclear why this occurred but it renders the polymer unsuitable for 
further study.  
 
Figure 5.13 Cracked ultracentrifugation tubes with 1000F pH 11.0 solubilisation mixture 
after 1 h spin at 100000 ×g. Tubes are from 2 separate experiments. 
   
 
 
Bubbles 
Bubbles 
Hairline crack 
Hairline crack 
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The pKd of the MT-hA2AR was evaluated for remaining solubilisations (DDM, 2000P pH 7.0 
and 11.0 and 1600ME pH 7.0 and pH 11.0) and were compared to the membrane-bound MT-
hA2AR via saturation or competition binding curves. Table 5.3 shows that there was no 
significant difference between the pKd calculations suggesting that the receptor did not alter in 
affinity as a consequence of the solubilisations. The Bmax values were different when compared 
to the membrane-bound MT-hA2AR which gave the highest Bmax value of 6.4 ± 0.5 pmol mg
-1
. 
The other solubilisations (DDM, 2000P pH 7.0, 1600ME pH 7.0 and pH 11.0) gave lower Bmax 
or Bmax estimates ranging from  4.9-5.6 pmol mg
-1
 which were lower than membrane-bound 
MT-hA2AR . 
Table 5.3 Bmax and pKd values for DDM and PMAS solubilisations. Saturation binding curves 
were performed on DDM solubilisations and membrane-bound MT-hA2AR previously and the 
Bmax and pKd values were calculated from non-linear regression and recorded in this table. For 
the PMAS solubilisations, single point radio-ligand binding assays were carried out in the first 
instance with 10 nM [
3
H]ZM241385 and if no binding activity was observed, no further radio-
ligand binding analysis was performed, as was the case for the 1000F and 1600 PMAS. For the 
remaining PMAS (2000P pH 7.0 and 11.0 and 1600ME pH 7.0 and pH 11.0), competition 
binding curves with ZM241385 were constructed and the pKd values were derived from the EC50 
values once the curve was best fit to a one site binding model. All data are means from at least 3 
separate experiments including the ± SEM nd indicates ‘not determined’. † indicates Bmax 
estimate from homologous competition binding curves. p < 0.05 when compared to native 
membrane (ANOVA with Bonferroni’s post hoc test). 
Solubilisation reagent 
Bmax or Bmax estimate† 
(pmol mg
-1
) 
pKd 
None, native SMD1163- 
MT-hA2AR membrane 
6.4 ± 0.5 8.5 ± 0.1 
DDM pH 7.0 plus CHS 5.6 ± 2.3 8.3 ± 0.4 
2000P pH 7.0 plus DMPC 4.9† ± 1.0 8.3 ± 0.2 
2000P pH 11.0 plus DMPC 6.4† ± 0.7 8.9 ± 0.4 
1000F pH 7.0 plus DMPC 0.0  nd 
1000F pH 11.0 plus DMPC 0.0 nd 
1600 pH 7.0 plus DMPC 0.0 nd 
1600 pH 11.0 plus DMPC 0.0 nd 
1600ME pH 7.0 plus DMPC 5.4† ± 1.6 8.3 ± 0.2 
1600ME pH 11.0 plus 
DMPC 
5.2† ± 1.8 8.4 ± 0.3 
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This activity data seemed to relate with the physical clarity of the solubilisation solution for the 
DDM and PMAS experiments. Figure 5.14 shows a representation of clarity of the 
solubilisation solution versus Bmax values and relative clarity of the solution. It can be seen that 
the very cloudy solutions of 1000F and 1600 PMAS, at both pH values tested, gave zero Bmax 
values, whereas the other solutions were clearer and correlated with increased Bmax values.  
 
 
Figure 5.14 Graphical representation of clarity of solubilisation solution versus MT-hA2AR 
activity. The Bmax values versus relative clarity of the solution are plotted. The relative clarity 
values were calculated using ImageJ software where a PMAS solution with no membrane or 
lipid added was used as background to calculate the intensity values. A photograph of the 
PMAS and DDM solubilisations is shown above the bar graph. Tubes are shown after overnight 
incubation at room temperature and before ultra-centrifugation. Visual comparison of clarity 
versus Bmax shows a trend where the clearer the solubilisation, the better the activity and vice 
versa. 
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The final analysis into the PMAS screen was to calculate percent recovery of MT-hA2AR from 
each solubilisation. Therefore, single-point binding assays were performed on the supernatant 
(expected solubilised material) and also the pellet (expected non-solubilised material) after the 
ultra-centrifugation step. Figure 5.15 shows that 1000F and 1600 pH 7.0 and 11.0 polymers 
solubilised zero or almost zero MT-hA2AR as the activity remained in the pellet. 1600ME pH 7 
and 11 gave higher activity in the supernatant (32.5-46.1%) than in the pellet (29.4-29.9%). For 
2000P pH 7.0, a higher amount of activity was retained in the pellet (62.6%) than in the 
supernatant (31.2%) which was noteworthy. This was the opposite for 2000P pH 11.0 as most 
of the activity was found in the supernatant (72.0%) rather than in the pellet (23.3%) and was 
comparable to the DDM recovery (supernatant, 70.9%, pellet 15.3%). Compared to all the other 
PMAS, 2000P pH 11.0 performed the best at this screening stage. For all samples however, 
there was activity that was lost and unaccounted for, suggesting loss of sample during the 
process of solubilisation ranging from 3.0-48.2%. 
 
Figure 5.15 Percent recovery of MT-hA2AR from PMAS solubilisations. MT-hA2AR activity 
measured in the supernatant and pellet fractions of the solubilisation mixtures after ultra-
centrifugation. Dark grey bars are % recovery values for supernatant fraction of the 
solubilisation mixture, light grey bars are for the pellet fraction of the solubilisation mixture. 
All values calculated are from means from at least 3 experiments and their SEM shown in the 
graph. 
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5.3.3. Comparative pharmacology of PMAS solubilised MT-hA2AR  
It is important with any receptor research, that its pharmacology is examined when investigating 
techniques that could alter it using competition radio-ligand binding assays. In this instance, the 
MT- hA2AR from the PMAS and DDM solubilisations was interrogated with established 
agonists and antagonists to hA2AR. The molecules used in the assays were the agonist N-
ethylcarboxamidoadenosine (NECA) and the antagonists, xanthine amine congener (XAC); 
theophylline and ZM241385. Table 5.4 shows the pKi values for each assay derived using the 
Cheng-Prusoff equation. For all solubilisations the pKi values showed the general order of 
affinity for each agonist and antagonists was ZM241385 > XAC and NECA >theophylline 
which is in agreement with the literature (Fraser, 2006; Singh et al., 2010).  There were some 
significant differences detected upon statistical examination (ANOVA analysis) of the pKi 
values from the various solubilisations when compared to membrane-bound MT- hA2AR. For 
the ZM241385, the competition binding curve showed that the solubilisation with the 1600ME 
pH 7.0 PMAS gave a pKi that was significantly lower (p value <0.05) than the membrane bound 
MT- hA2AR for ZM241385 and XAC (p value <0.01). The solubilisation with the 2000P pH 7.0 
PMAS gave a pKi that was significantly lower (p value <0.05) than the membrane bound MT- 
hA2AR for NECA. There were no significant differences with any other pKi values when 
compared to the membrane bound MT- hA2AR suggesting no alterations in the receptor during 
the solubilisations.Figures 5.16 shows the full competition binding curves achieved from these 
assays. The figure shows the four curves (panel A, B, C and D) for each molecule (ZM241385, 
XAC, theophylline and NECA) for each solubilisation that passed the screening process carried 
out in section 5.3.2. Therefore the data are for the DDM, 2000P pH 7.0, 2000P pH11.0, 
1600ME pH 7.0 and 1600ME pH 11.0 solubilisations against each molecule. The membrane-
bound MT- hA2AR competition binding curve is also included.  
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Table 5.4 Summary of pKi values as an indication of the pharmacological properties of MT-
hA2AR after PMAS and DDM solubilisations. The pKi values are means of two separate 
experiments and their SEM shown. Competition binding assays were performed using 
[
3
H]ZM241385 as the competitor to ZM241385, NECA, XAC and theophylline. Data were fit to 
a one site binding model and the Ki (and pKi) values were calculated from the EC50 values and 
using the Cheng-Prusoff equation. p < 0.05 indicated by * and  p < 0.01 indicated by ** when 
compared to native membrane (ANOVA with Dunnett’s post hoc test 
 
 
 
 
 
ZM241385 XAC NECA Theophylline
Membrane-bound MT-hA2AR 8.4 ±  0.2 6.5 ± 0.1 6.1 ± 0.1 4.3 ± 0.3
DDM 8.2  ± 0.2 6.6 ± 0.1 5.9 ± 0.1 4.5 ± 0.3
2000P pH 7.0 7.8 ± 0.2 6.3 ± 0.2 5.7 ± 0.1* 4.5 ± 0.3
2000P pH 11.0 8.2 ± 0.4 6.9 ± 0.1 6.1 ± 0.1 4.8 ± 0.3
1600ME pH 7.0 7.5 ± 0.1* 5.8 ± 0.1** 6.4 ± 0.1 3.8 ± 0.3
1600ME pH 11.0 7.6 ± 0.1 6.4 ± 0.1 6.2 ± 0.1 4.0 ± 0.2
Solubilisation type of MT-hA2AR
pKi
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Figure 5.16 Competition binding curves for MT-hA2AR (membrane bound, DDM solubilised, 
2000P pH 7.0 solubilised, 2000P pH 11.0 solubilised, 1600ME pH 7.0 solubilised and 
1600ME pH 11.0 solubilised) with ZM241385, XAC, NECA and theophylline agonist and 
antagonists. Binding curves of NECA, ZM241385, XAC and theophylline were determined 
using [
3
H]ZM241385 as the competitor for A)membrane bound MT-hA2AR, B)DDM solubilised, 
C)2000P pH 7.0 solubilised, D)2000P pH 11.0 solubilised, E)1600ME pH 7.0 solubilised and 
F)1600ME pH 11.0 solubilised MT-hA2AR. The general trend of affinity for all the drugs and the 
solubilisations were ranked as ZM241385 > XAC and NECA >theophylline. The data were fit 
to a one site binding model and the pKi values were determined from the EC50 values from the 
curves. Data shown are from 2 separate experiments. ANOVA analysis with Dunnett’s post hoc 
tests were performed on the pKi values and the data summarised in Table 5.6.   
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5.3.4. Investigation of the lipid composition in PMAS solubilisation mixtures 
A typical DDM detergent solubilisation of hA2AR includes cholesteryl hemisuccinate (CHS) as 
it has been shown to stabilise the receptor (Jaakola et al., 2008). In the PMAS solubilisations 
and the previous SMA solubilisations, the phospholipid, 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) is present in the solubilisation mixture. In previous work, no 
explanation was given as to why this phospholipid was used instead of CHS. Tests were 
therefore carried out on whether using CHS or DMPC in the solubilisation mixture has an effect 
on the recovery of functional protein. DDM and 2000P (pH 7.0 and pH 11.0) solubilisations 
were carried out using the simple buffer format described in section 5.3.1. CHS or DMPC were 
added to the solubilisations. The DDM solubilisation was tested further with a mixture of 
DMPC and CHS and another reaction where no lipid was added at all. After the incubation and 
the ultra-centrifugation steps, single-point binding assays were carried out and the Bmax values 
were estimated. Binding was observed for the DDM plus CHS solubilisation (5.6 ± 2.3 pmol 
mg
-1
), which was expected. However, when the lipid was switched to DMPC, no binding was 
observed at all. Furthermore, the DDM solubilisation without any lipid had less of a detrimental 
effect as some binding was observed (0.1 ± 0.1 pmol mg
-1
). A mixture of DMPC and CHS gave 
a little more binding (0.2 ± 0.1 pmol mg
-1
). The Bmax estimates for the 2000P pH 7.0 and pH 
11.0 gave different results. The DMPC gave expected binding results (2000P pH 7.0; 4.9 ± 1 
pmol mg
-1 
and 2000P pH 11.0; 6.4 ± 0.7 pmol mg
-1
). When CHS was added instead of DMPC, 
the binding was decreased slightly (2000P pH 7.0; 4.2 ± 1.8 pmol mg
-1 
and 2000P pH 11.0; 6.1 
± 1.3 pmol mg
-1
) but not as dramatically as in the case of the DDM experiments suggesting that 
CHS has a minimal impact on the PMAS solubilised MT-hA2AR (Table 5.5). 
Table 5.5 Summary of lipid (DMPC and CHS) composition in PMAS and DDM solubilisation 
experiments. Data shown are for Bmax estimates from single-point binding assays. DDM 
solubilisations were carried out with CHS, with DMPC, with CHS and DMPC or with no 
additional lipids. 2000P pH 7.0 and pH 11.0 solubilisations were carried out with CHS or with 
DMPC. Data are means from triplicate separate experiments with the SEM shown. 
 
Type of solubilisation Estimated Bmax (pmol mg
-1
) SEM ±
DDM with CHS 5.6 2.3
DDM with DMPC 0 0
DDM with CHS and DMPC 0.2 0.1
DDM with no added lipid 0.1 0.1
2000P pH 7 with DMPC 4.9 1
2000P pH 7 with CHS 4.2 1.8
2000P pH 11 simple DMPC 6.4 0.7
2000P pH 11 simple CHS 6.1 1.3
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The 2000P pH 11.0 solubilisation was explored further since it gave the higher Bmax result when 
CHS was used as the lipid (Table 5.5) and when it was compared to the 2000P pH 7.0 
solubilisation. A homologous competition binding curve to [
3
H] ZM241385 was carried out to 
determine the pKd values when a solubilisation was carried out with CHS and DMPC and 
compared to the DDM plus CHS solubilisation (Figure 5.17). The 2000P pH 11.0 solubilisation 
with CHS gave a higher pKd of 9.5 ± 0.6 when compared to the solubilisation with DMPC 
which gave a pKd of 8.9 ±0.4 and the DDM with CHS solubilisation which gave 8.2 ± 0.2. This 
was an interesting result and suggests that the presence of CHS in the 2000P pH 11.0 
solubilisations increases the affinity of the MT-hA2AR receptor. 
 
 
Figure 5.17 Competition binding curve after solubilisation in (i) 2000P pH 11.0 with CHS 
and DMPC and (ii) DDM with CHS. Binding curves of ZM241385 for 2000P pH 11.0 CHS or 
DMPC and DDM with CHS solubilisations were determined using [
3
H]ZM241385 as the 
competitor. The data were fit to a one site binding model and the pKd values were determined 
from the EC50 values from the curves. Data shown on curve are from 3 separate experiments.  
  
pKd
9.5  0.6
8.9  0.4
8.2  0.2
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5.3.5. Preliminary purification tests of MT-hA2AR after 2000P pH 11.0 solubilisation 
compared to DDM solubilised membrane. 
After solubilisation, the next step is to purify the isolated receptor. This is often difficult as the 
receptor may change structure or fold differently once the lipid-like environment has been 
removed (Serebryany et al., 2012). Therefore, the purification procedure itself requires 
optimisation. In this section, a preliminary purification test was carried out on a 2000P pH 11.0 
solubilised MT-hA2AR sample and a DDM solubilised sample. Table 5.6 illustrates the 
percentage activity calculated from the starting native membrane material derived from pmols 
per 1 L culture for each step of the solubilisation and manual purification process.  The data 
show similar solubilisation and purification profiles for both the DDM and 2000P pH 11.0.  For 
the DDM solubilisation, the total eluted material comprised 41.72% of the total input of the 
native membrane compared to 36.51% for the 2000P pH 11.0 solubilised material. For 
[
3
H]ZM241385 binding, the Bmax value of the elution for the DDM solubilisation was 7.9 ± 0.8 
pmol mg
-1
 and 7.9 ± 1.0 nmol mg
-1
 for the 2000P pH 11.0 solubilisation. The theoretical hA2AR 
specific activity maximum is 24 nmol mg
-1
 and therefore this purification corresponded to only 
0.03% of the theoretical maximal value. This suggests that most of the receptor population was 
not active for both solubilisations where protein aggregation or denaturation may have occurred 
during the purification process. It is possible that technical issues with the protocol were 
responsible for these results. Future experimentation would enable protocol optimisation using 
the DDM solubilisation as a positive control. Due to technical issues, a silver stain gel of the 
purified samples was not successful and therefore not shown.  
 
Table 5.6 MT-hA2AR activity of native membrane, solubilised with either DDM or 2000P pH 
11.0 and at each purification step. Data are expressed as percentage of total volumetric pmol 
where starting material (native membrane) is 100% activity. SEM are from duplicate samples. 
 
 
% SEM % SEM
Native membrane 100.00 0.32 100.00 0.32
Solubilised 77.96 1.04 69.06 3.22
Flow-through 35.14 0.34 32.16 0.31
Wash 1 0.00 0.00 0.00 0.00
Wash 2 0.00 0.00 0.00 0.00
Elution 1 0.02 0.00 0.01 0.00
Elution 2 0.24 0.01 0.26 0.01
Elution 3 20.71 0.44 16.98 0.36
Elution 4 20.75 0.00 19.26 0.00
DDM 2000P pH 11.0Treatment and 
purification steps
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5.4. Discussion 
 The research in this chapter is concerned with solubilising hA2AR from P. pastoris membranes 
and investigating the use of novel compounds as replacements for detergents in that process. 
It was first necessary to design and develop a novel, more updated, working hA2AR construct for 
these studies. The construct designed was a de-glycosylated, truncated (A316) multi-tag version 
of hA2AR, named MT-hA2AR that was transformed into a protease deficient P. pastoris strain 
(SMD1163). It was compared to a previously used construct (a full-length, de-glycosylated 
form with two tags (dG-hA2AR) in a non-protease deficient strain (X33)) for activity. The 
specific binding activity for the MT-hA2AR was 6.4 pmol mg
-1
 and for the dG-hA2AR was 4.4 
pmol mg
-1
. The pKd values were comparable (8.5 for MT-hA2AR and 8.3 for dG-hA2AR). The 
MT-hA2AR construct was also cloned into a mammalian vector and transfected into HEK cells. 
An untagged version of the hA2AR construct was compared for activity, and it was verified that 
the multiple tags did not interfere with the binding assays. The MT-hA2AR construct in 
SMD1163 was therefore suitable to be used in the subsequent solubilisation experiments. The 
hA2AR construct used in the design terminated at A316 which removed the intracellular C-
terminal tail and the intracellular loop 3 (ICL3). This version was used for the structural 
determination of hA2AR by Jaakola and colleagues in 2008 by modifying it with a T4 lysozyme 
(T4L) to make the structure more stable (Jaakola et al., 2008) as it was previously reported that 
the C-terminal tail  degrades during recombinant production (Weiß and Grisshammer, 2002, 
Singh et al., 2008, Singh et al., 2010). This design was therefore perfect for the needs of this 
thesis research. The hA2AR A316 was further modified to contain no glycosylation site via a 
mutation (N154Q) (Fraser, 2006). The construct inlcuded three tags to allow flexibility when 
detecting or purifying the construct. The tags were His10, FLAG and a biotin tag. These tags are 
excellent for detection (with antibodies for immunoblot studies) and also for purification of 
recombinant proteins (Terpe, 2003). It has been debated however if these tags cause altered 
solubility or increase aggregation or even hinder crystallisation (Derewenda, 2004). Therefore 
the general method is to cleave off the tags (Carson et al., 2007), and hence in this design, a 
tobacco etch virus (TEV) protease cleavage site and an enterokinase cleavage site present in the 
FLAG tag sequence were included. A bovine pancreatic trypsin inhibitor (BPTI) was used as a 
signal sequence instead of an α-factor sequence in the construct which could be cleaved off by 
the presence of a thrombin cleavage site. 
Expression screens of the new construct were successful and when compared to a previously 
used hA2AR strain, gave good specific binding activity and the affinity of the receptor was 
similar. This was further elaborated upon where the construct was sub-cloned into mammalian 
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vector. Here the goal was to test if the tags were an issue and therefore specific activity was 
tested against an unlabelled hA2AR. The results showed that the tags did not interfere with the 
binding activity. As discussed earlier, the tags may influence the binding activity and even 
downstream crystallisation and therefore it was necessary to design cleavage sites in the 
construct. 
A set of four poly (maleic anhydride/acid-styrene) (PMAS) solutions prepared at pH 7.0 and pH 
11.0 were tested as solubilising agents on MT-hA2AR SMD1163 membranes and compared with 
the detergent, DDM. These varied in molecular weight, the ratio of styrene : maleic 
anhydride/acid and esterification. It was found that after optimisation, the most favourable 
solubilisation conditions were room temperature, at least 16 h or overnight and using a simple 
combination of membrane, DMPC lipid and PMAS. The MT-hA2AR SMD1163 membranes 
were subjected to DDM solubilisations as a control. For the membrane-bound MT-hA2AR, the 
Bmax was 6.4 ±0.5 pmol mg
-1
 and the pKd was 8.5 ±0.1 and the results of the solubilisations were 
compared to the membrane bound receptor. The pKd did not differ significantly for PMAS when 
compared to the membrane-bound MT-hA2AR. The PMAS solubilisations which gave no or 
little activity, were 1000F pH 7.0 and 11.0 and also 1600 pH 7.0 and 11.0, therefore they were 
not tested further. It was also noteworthy that the clarity of the solubilisation solution was 
related to the binding activity of the MT-hA2AR. The PMAS which gave the highest recovery 
most % recovered material in the correct fraction of the solubilisation (supernatant) was 2000P 
pH 11.0 (72.0%) which was comparable to the DDM solubilisation (70.9%). 
The PMAS that were included for further testing were 2000P pH 7.0 and 11.0 and 1600ME pH 
7.0 and 11.0, along with DDM and membrane-bound MT-hA2AR. The receptor after each of 
these solubilisations was pharmacologically characterised with hA2AR agonist and antagonists. 
For all solubilisations, the pKi values gave a rank order of affinity for the agonist and 
antagonists of ZM241385 > XAC and NECA >theophylline which were in agreement with 
literature findings (Fraser, 2006) and was the case for each solubilisation and membrane-bound 
MT-hA2AR. Furthermore, it was found that for the 1600ME pH 7.0 PMAS solubilisation, the 
pKi was significantly lower (p value < 0.05) for ZM241385 and XAC (p value <0.01) when 
compared to the MT-hA2AR. Also, the 2000P pH 7.0 PMAS solubilisation gave a pKi that was 
significantly lower (p value <0.05) than the membrane bound MT- hA2AR for NECA. However 
there were no further significant differences with any other solubilisations when competition 
binding curves were performed, suggesting no major changes in hA2AR receptor binding.The 
type of lipid present in the solubilisation reaction was further investigated. It was found that the 
presence of CHS in the solubilisation mixture of 2000P pH 11.0 gave higher pKd result than 
with DMPC as the lipid. This suggests that the presence of CHS increases the affinity of the 
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MT-hA2AR with the 2000P pH 11.0 solubilisation, and is in line with a CHS dependence on 
activity for other GPCRs (Jaakola et al., 2008, Rasmussen et al., 2007). 
In general, the PMAS agents are more beneficial to use over detergent methods because they are 
inexpensive to prepare, a range of PMAS with differing properties may be prepared easily, 
DMPC or CHS can be used as the lipid in the solubilisation mixture and they are simple to use. 
With further optimisation, the aim would be to exceed the functional yield obtained with classic 
detergents such as DDM but in a more native environment for hA2AR since the polymer retains 
the native lipid. These findings show that PMAS agents can be used for solubilising MT-hA2AR 
and the data are comparable with DDM solubilisation.  The impact of this work using this class 
of polymers has provided an insight into different system to detergents for membrane protein 
solubilisation.  For future work, some unanswered questions need to be addressed: would this 
system work for any other membrane proteins? Is the polymer suitable for downstream 
biophysical work and crystallisation trials? Therefore it would be useful to perform experiments 
to investigate these questions. 
The results in the chapter are currently in preparation for publication as an original research 
article and these results have also contributed to a filed patent (application number GB 
1312343.5, Appendix A6). 
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Chapter 6: General discussion 
The objectives of this thesis were to increase recombinant hA2AR production in yeast by 
investigating bioprocess conditions at large (pilot-scale) and small (micro-bioreactors) scale and 
also extract functional receptor from P. pastoris membranes using novel polymers.  
A volumetric yield increase in hA2AR produced in P. pastoris was achieved by investigating the 
methanol feeding regime of P. pastoris. By applying a slow, exponential feed of methanol 
during induction in 35 L pilot-scale bioreactors. This type of bioprocess improvement (feed 
forward strategy) has not been applied or tested for any GPCR work prior to the submission of 
this thesis.  Small-scale bioreactor work (Micro-24 microreactor) showed that a statistical DoE 
could be applied to screen for bioprocess conditions such as temperature, pH and DO to give 
optimal hA2AR yields in yeast. Optimal conditions could be retrieved but data with high error 
needed to be addressed.  
Another focus of this thesis was the extraction of hA2AR from the yeast membrane with novel 
polymers. Here, PMAS was successful in solubilising hA2AR from P. pastoris membranes as 
well as or better (in some cases) than the DDM detergent. Furthermore, the 2000P pH 11.0 
PMAS worked well as a solubilising agent with either DMPC or CHS. Table 6.1 outlines the 
thesis objectives, how the objectives were met and in which chapter of the thesis they were 
addressed. The table also summarises the major outcomes and other interesting findings from 
this thesis.  
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Table 6.1 Thesis objectives, optimal conditions and major findings. 
Thesis objectives proposed 
How objective met and in which 
thesis chapter 
Optimal conditions Major findings 
Increase hA2AR production by 
investigating bioprocess conditions 
at a large scale (pilot-scale 
bioreactors) 
Large (pilot-scale) P. pastoris 
X33-dG-hA2AR cultures; 
controlled exponential feeding 
(µset) of methanol during induction 
phase (Chapter 4) 
µset = 0.01 h
-1 
for methanol induction 
at 22°C for large (pilot-scale) P. 
pastoris X33-dG-hA2AR cultures 
Cytotoxic levels of methanol in the 
cultivation is not a hindrance to 
maintaining protein production levels; 
pre-induction levels of recombinant 
protein are present in a methanol 
inducible system 
Increase hA2AR production by 
investigating bioprocess conditions 
at a small scale (micro-bioreactors) 
Small (micro bioreactors) S. 
cerevisiae WT-hA2AR cultures, 
temperature, pH, DO and additive 
presence tested via DoE;  response 
surface methodology (RSM) for 
optimal conditions and predictive 
equation generated (Chapter 3) 
22°C, pH 6.0, 30% DO, no DMSO 
culture conditions for small (micro 
bioreactors) S. cerevisiae WT-hA2AR 
cultures 
High error suggests complete process 
requires optimisation for membrane 
protein research 
Extract the hA2AR from P. pastoris 
membranes using novel polymers 
Medium (bench-top) P. pastoris 
SMD1163-MT-hA2AR cultures; 
Poly (maleic anhydride-styrene) 
PMAS 
(Chapter 5) 
2000P pH 11.0 PMAS plus DMPC 
for solubilisation of MT-hA2AR for 
large (bench-top) P. pastoris 
SMD1163-MT-hA2AR cultures 
CHS with 2000P pH 11.0 PMAS  and 
esterification of PMAS  increases 
MT-hA2AR affinity, suggesting both 
may have a stabilising effect of the 
receptor 
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Ever since scientists began to work with recombinant proteins, the field has strived to increase 
target protein yields in order for more quality product to be available for commercial and 
therapeutic use. This has been the case for soluble proteins such as hEPO, insulin and hGH 
(Schmidt, 2004) In the case of membrane proteins, especially GPCRs, achieving crystal 
structures is the main goal (Tate, 2001). Once this goal is met, GPCR structure-function studies 
invariably lead to drug discovery programmes which interest the pharmaceutical and clinical 
industries greatly. Therefore, increasing the yield and extracting the membrane protein without 
disturbing the integrity of the protein is highly desired by researchers.  
6.1. Controlling methanol feeds during membrane protein induction in P. pastoris to 
increase yields 
It is established that both the concentration and rate of addition of methanol to P. pastoris 
cultures can substantially affect recombinant soluble protein yields (Potvin et al., 2012, Celik et 
al., 2009, Celik et al., 2010, Jungo et al., 2007, Kobayashi et al., 2000, Zhang et al., 2000). In 
contrast, the effect on recombinant membrane protein yields, particularly on GPCRs, had not 
been examined as systematically. Therefore in this study, the application of two methanol-phase 
feed profiles on the yield of recombinant hA2AR was analysed in two pilot-scale 35 L P. 
pastoris cultivations, µlow and µhigh. The set-growth rates were applied via exponential feeding of 
methanol to the P. pastoris cells in order to reach a desired specific set growth rate (µset).  These 
were 0.01 h
-1
 for the µlow and 0.03 h
-1
 for the µhigh. The major findings of this study were that the 
µlow cultivation yielded higher amounts of hA2AR compared to the µhigh cultivation when the 
amount of biomass was taken into account (536.4pmol g
-1
 for the µlow cultivation compared to 
148.1 pmol g
-1 
for the µhigh cultivation). Moreover, hA2AR levels were still present in cytotoxic 
residual methanol concentrations and pre-induction levels of hA2AR (and another recombinant 
protein from an additional cultivation) were detected. 
 
6.1.1. Cytotoxic levels of methanol in the cultivation are not completely detrimental to 
hA2AR activity 
 
The residual methanol concentration in the µlow cultivation did not exceed 3 g L
-1 
and was zero 
for most of the induction phase. In contrast, the residual methanol concentration in the µhigh 
cultivation increased throughout the bioprocess to > 80 g L
-1
. Nonetheless, pre-induction hA2AR 
levels were maintained even under these cytotoxic methanol concentrations, however this is not 
fully understood.  In the literature, although detailed research on protein production in cytotoxic 
methanol conditions is lacking, there have been a few studies examining the benefits of high 
methanol concentrations in P. pastoris cultivations on recombinant protein production. One 
notable study was by Khatri & Hoffman, where they examined the impact of methanol 
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concentration on single-chain antibody fragment (scFv) in oxygen-limited P. pastoris cultures. 
They found that high methanol concentrations (30 g L
-1
) were required in order to fully induce 
recombinant protein production. However, this was in an oxygen-limited system and also the 
temperature of the cultivation was reduced. The decrease in temperature is thought to reduce 
proteolysis. Moreover, they found that accumulation of degraded versions of their product 
(scFv) was less prevalent in the high methanol concentrated cultures, thereby simplifying 
downstream processing of their protein (Khatri and Hoffmann, 2006). Similar findings were 
established with Katakura and colleagues with their work on human β2-glycoprotein I domain 
V, where production of that recombinant protein was increased in P. pastoris at methanol 
concentrations of 30 g L
-1
 (Katakura et al., 1998). 
 
Most of the literature however, demonstrated that optimal protein production is in the lower 
range for residual methanol concentrations of 2-3 g L
-1
. Examples include, Cunha and 
colleagues (Cunha et al., 2004) and Schenk and colleagues (Schenk et al., 2008) where they 
showed that residual methanol concentrations between 2 g L
-1 
and 3.5 g L
-1
 were optimal for 
soluble protein production, while methanol concentrations between 3.7 g L
-1 
and 20 g L
-1 
were 
cytotoxic and inhibited growth (Cunha et al., 2004; Schenk et al., 2007), consistent with our 
findings. In a recent study, Barrigón and colleagues carried out cultures for Rhizopus oryzae 
lipase production in P. pastoris. They found that biomass yields and productivities were very 
low for methanol concentrations lower than 2 gL
-1
 and that they had a significant increase in 
yield and product when the methanol was between 2-3 g L
-1
. This was the case for the µlow 
cultivation, however, biomass still increased in the presence of no methanol which was 
contrasting to Barrigón‘ data (Barrigón et al., 2013). 
 
Concomitantly, it is becoming established that mixed feeding (methanol together with another 
carbon source) is the preferred P. pastoris induction regime. It was previously reported that 
residual methanol levels below 2.98 g L
-1
 gave optimal yields of recombinant GFP (3.74 g) 
when following a mixed 60% methanol and 40% sorbitol induction regime. In contrast, a 100% 
methanol induction regime, where the residual methanol reached a maximum level of 182.25 g 
L
-1
, gave a poor recombinant GFP yield (0.09 g); (Holmes et al., 2009). More recently, Jordà 
and colleagues were able to develop a 
13
C-labelled metabolic flux analysis system where they 
characterised the central metabolism of P. pastoris when grown on a mixed feed of methanol 
and glucose. They were able to ascertain that during recombinant production of Rhizopus oryzae 
lipase that a significant redistribution of carbon fluxes occurred in the central carbon 
metabolism that adds stress on certain pathways such as the glycolytic, TCA cycle and methanol 
dissimilation rates. Furthermore, in this study, methanol played a role as a supporting substrate 
to compensate for the increased energy demands of the recombinant protein production 
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secretion processes. This could explain why mixed feeding can increase protein production and 
reduce metabolic burden in P. pastoris (Jordà et al., 2012).  
 
6.1.2. Pre-induction activity is present in pilot-scale and bench-top bioreactors 
 
A significant finding emerging from this work is that hA2AR and, subsequently GFP, were 
produced prior to induction with methanol. In both the µlow and µhigh cultivations, hA2AR binding 
activity was already measurable before induction with methanol had begun. This is consistent 
with a previous observation by Singh and colleagues during their bioreactor study using 
minimal medium (Singh et al., 2008). In a bioreactor study by Çelik and colleagues, 
recombinant hEPO appeared to be produced prior to the onset of the methanol feed, a finding 
that was not further elaborated (Çelik et al., 2009). In contrast, pre-induction hA2AR binding 
activity was not apparent in shake flasks using complex medium in studies by Singh and 
colleagues (Singh et al., 2012) or by Fraser (Fraser, 2006). The demonstration of protein 
production prior to induction is especially noteworthy due to the presence of glycerol, which is 
a known repressor of the AOX promoter. Glycerol, glucose, ethanol and acetate have all been 
shown to support growth of P. pastoris cells without inducing the AOX promoter (Inan & 
Meagher, 2001). For example, Hellwig and colleagues (Hellwig et al., 2001) demonstrated 
glycerol in the culture medium inhibited production of a recombinant single-chain antibody by 
causing ethanol and acetate to accumulate.  
 
The data in Chapter 4 further demonstrated that methanol induction did not substantially 
increase the pre-induction specific yield, measured in the transition phase, for cells initially 
cultured on glycerol. In both the µlow and µhigh cultivations, the total yield of hA2AR was at least 
maintained once the methanol feed commenced during the induction phase (IV). However, the 
increase in total yield was not substantial, being only approximately double that of the pre-
induction yield of the µlow cultivation. A subsequent P. pastoris cultivation also produced 
recombinant GFP in the pre-induction phases, with similar results following induction with 
methanol. These increases in yield are similar to those seen by Çelik and colleagues in their 
hEPO cultivations (Çelik et al., 2009).  
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Previously, it was demonstrated that high yields of recombinant GFP (3.74 g) but low biomass 
yields (OD595 = 64) were produced when P. pastoris was grown at a low induction phase growth 
rate (µ = 0.006 h 
-1
). In contrast, a higher induction phase growth rate (µ = 0.015 h 
-1
)
 
resulted in 
a higher biomass yield (OD595 = 74), but a lower total GFP yield (0.98 g) (Holmes et al., 2009). 
Çalık and colleagues (Çalık et al., 2010) applied three different growth rates in the methanol 
induction phase of P. pastoris cultures expressing soluble human growth hormone: 0.02, 0.03 
and 0.04 h 
-1
 using a mixed sorbitol and methanol feed. The highest biomass yield (48 g L
-1
) was 
obtained at a growth rate of 0.04 h 
-1
, but the highest yield of recombinant human growth 
hormone (270 mg L
-1
) was produced at 0.03 h 
-1
. The authors suggested that this might be due to 
the lower growth rate producing lower biomass and therefore lower extracellular proteases 
being present in the cultivation. Similar trends were also observed for GFP, hEPO, human 
serum albumin, heavy-chain fragment C of Botulinum neurotoxin, serotype A and avidin (Çelik 
et al., 2009; Jungo et al., 2007; Kobayashi et al., 2000; Zhang et al., 2000).  
 
In order to examine the balance between increased biomass yields and specific productivity, the 
glucose as a pre-induction carbon source was examined. Glucose has previously been shown to 
support growth of P. pastoris, but at a lower specific growth rate and yielding lower amounts of 
biomass than that achieved by cells grown on glycerol (Inan & Meagher, 2001).  Following 
induction with methanol, DCW values for glycerol-grown cells were approximately 5 times 
higher than for glucose-grown cells in the equivalent pre-induction phase. However, the 
glucose-grown cells produced 3 times the GFP yield of the glycerol-grown cells. The data in 
this thesis suggests that specific productivity may not necessarily be solely dependent on 
methanol induction and can be increased at the expense of improvements in biomass yields in 
the methanol induction phase. 
 
In summary, the application of a low methanol feed profile to a pilot-scale P. pastoris 
cultivation resulted in higher biomass and hA2AR yields (536.4 pmol g
-1
) than a cultivation to 
which a high feed profile had been applied (148.1 pmol g
-1
). Production of hA2AR (and GFP) 
was detected prior to methanol induction. Furthermore, the transition phase yield was not 
substantially increased following methanol induction. Using glucose as a pre-induction carbon 
source demonstrated that in the subsequent methanol induction phase, specific productivity can 
be increased at the expense of improvements in biomass yield. These data provide a platform to 
rationalise the production of recombinant proteins, such as GPCRs, in bioreactor cultivations.   
To further investigate the exponential feeding work set in Chapter 4, it would be interesting to 
see if a lower µset would yield higher biomass and therefore total hA2AR yields. Furthermore, 
would the biomass have continued to increase further after 92 h since it was still rising for the 
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0.01 h
-1
 µlow growth rate at the end of that cultivation? Finally, it would be useful for these 
growth rate experiments to be tested on other GPCRs. 
 
6.2. Using novel polymers to extract hA2AR from P. pastoris membranes 
The hA2AR receptor and all other membrane proteins are not soluble in water or aqueous buffers 
due to their hydrophobic regions when correctly folded. Therefore, detergents are usually used 
extract membrane proteins from the lipid bilayer whilst maintaining their native structure.  
n-dodecyl-β-d-maltopyranoside (DDM) has been widely used for the extraction of GPCRs 
which have been heterologously produced in eukaryotic systems and some have had crystal 
structures resolved. Examples include the model GPCR used for this thesis research, the human 
adenosine A2A GPCR (Jaakola et al, 2008);  the human β2 adrenergic GPCR (Cherezov et al., 
2007), the mammalian voltage-dependent Shaker family K+ channel (Long et al., 2005) and 2 
recently resolved structures from P. pastoris hosts, the human histamine H1 GPCR complex 
with doxepin (Shimarmura et al., 2011) and the human M2 muscarinic acetylcholine GPCR 
bound to an antagonist (Haga et al., 2012).   
The issue with DDM and other detergents is that many membrane proteins will either aggregate 
or denature during the solubilisation process, thereby leading to unsuccessful structural 
downstream studies; it is thought that membrane proteins that remain stable in detergent 
micelles tend to render better ordered crystals (Sonoda et al., 2011; Prive, 2007, le Maire et al., 
2000).  More specifically, as discussed in Chapter 1, detergents can only provide an 
approximate environment to that of the natural lipid bilayer. Neutron-scattering studies have 
shown that the membrane consists of layers that run perpendicular to each other (Wiener & 
White, 1992), the constituents of the membrane layers themselves are highly variable in 
phospholipid head-groups and acyl chains (Debnath et al., 2011, Damianoglou et al., 2010) and 
the theory of lipid rafts, states that certain lipids help maintain the function of the membrane 
protein in localised areas of the membrane bilayer (Lee, 2011a, Coskun and Simons, 2011, 
Grossmann et al., 2006)  Moreover, the aim has been to mitigate the harmful effect of stripping 
away lipid from intimate contact with proteins. One approach has been to solublise with a 
normal detergent but then to replace the detergent with a less aggressive surfactant. This may 
help restore some function, but it cannot replace important lipids. Therefore there has been a 
drive to move away from detergent solubilisation towards using other compounds. Research is 
being carried out using modified detergents such as such as calix[4]arene based detergents 
(C4C[n]). These were briefly investigated as part of a collaboration (Calixar SAS, France) 
where successful solubilisation of the hA2AR was carried out with a range of C4C[n] 
compounds. However, the results showed that further optimisation was required as the data 
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were not as good as for DDM solubilisations and the purification methods needed to be further 
optimised. As a consequence, this research is currently on-going. 
In this thesis however, the focus was to investigate non-detergent, novel compounds called 
PMAS in the solubilisation of hA2AR from P. pastoris membranes. PMAS experience 
modifications in structural conformation when the pH changes in the environment. The 
alternating co-polymers of maleic anhydride, which is hydrolysed to maleic acid, and styrene 
changes its shape from an extended chain to a secondary structure and the hydrophobic and 
hydrophilic groups shift to separate domains when below or above a critical pH. This is known 
as hydrophobic association or hyper-coiling which results in a more compact formation of the 
polymer (Tonge and Tighe, 2001). The properties of these types of polymers include adsorption 
at the air-water interface, a reduction of the surface tension of water and as a surface active 
agent or surfactant. The co-polymer itself can self-associate above a certain concentration to 
form a micellar structure where the carboxylic pendant groups appear at the outer surface and 
the aromatic styrene pendant groups cluster within the inner core of spherical micelles (Tonge 
and Tighe, 2001). 
Four PMAS solutions at pH 7.0 and pH 11.0 were used to solubilise the MT-A2AR produced in 
SMD1163 P. pastoris cells. The PMAS included 2000P (molecular weight approximately 7500 
g mol
-1
, with 2 styrenes : 1 maleic anhydride);  1000F (molecular weight approximately 5500 g 
mol
-1
, with 1 styrene : 1 maleic anhydride); 1600 (molecular weight approximately 1600 g mol
-
1
, with 1 styrene : 1 maleic anhydride); 1600ME (molecular weight approximately 1600 g mol
-1
, 
with 1styrene : 1 maleic anhydride and modified with methyl group), all at pH 7.0 and pH 11.0 
(Patent pending, application number GB 1312343.5, Appendix A6). 
Initial tests were carried out to determine the optimal solubilisation conditions for MT-hA2AR 
from P. pastoris (3% PMAS, 1% DMPC, 20 mg mL
-1
 membrane, at room temperature and for 
at least 16 h). 1000F and 1600 PMAS at both pHs, gave little or no specific binding activity 
(and the most turbid solutions) for MT-hA2AR when compared to the other PMAS, DDM-
solubilised material and membrane bound MT-hA2AR. It is unclear why these two PMAS did 
not give solubilised material. One reason could be related to the molecular weights. The 1000F 
PMAS is lower in mass compared to 2000P (5500 g mol
-1
 vs 7500 g mol
-1
), so the responsive 
hyper-coiled structure may not be large enough for the membrane protein to be solubilised. 
Alternatively, further optimisation may be required for this PMAS. The 1600 PMAS molecular 
weight (≈1600 g mol-1) is also low when compared to the 2000P PMAS. However, the 1600ME 
molecular weight is almost the same as the 1600 yet the 1600ME PMAS gave better specific 
binding activity results, as discussed below. 
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The PMAS that were carried forward for further investigations were the 2000P and 1600ME at 
both pHs. The 2000P has the same chemical structure as the styrene maleic acid (SMA) co-
polymer (Tonge and Tighe, 2001; Knowles et al., 2009; Rajesh et al., 2010; Jamshad et al, 
2011) used as a solubilising agent by others. The protocol in previous studies relies on a pH 
change from acidic (pH 6.5) to basic (pH 8.0) and it is postulated that a doughnut like structure 
forms around the membrane protein and the lipid bilayer. However, this speculation is unlikely 
as it is more likely to hypercoil forming a more irregular shape. 
The 2000P PMAS was prepared at two pHs, 7.0 and 11.0. The pH 11.0 solution is the pH after 
hydrolysis with 1 M NaOH. Therefore, tests were carried out to see if the pH 11.0 PMAS could 
be used directly for successful membrane protein solubilisation without the need to adjust the 
pH first. The pH 7.0 PMAS version was also examined to provide a solution more typical for 
biological experiments. By measuring the actual pH in the solubilisation mixture, it was found 
that it dropped from 11.0 to 8.2 (PMAS pH 11.0, membrane and DMPC lipid). For the pH 7.0 
PMAS, the pH did not alter very much (7.0 to 7.1). Therefore for the pH 11.0 PMAS, the pH 
remained in the basic region even after the membrane and DMPC were added. The receptor was 
active and furthermore gave the best results from all the PMAS tests (Bmax value of 6.4 ±0.7 
pmol mg
-1
, pKd of 8.9 ±0.4 and 72% recovery of solubilised MT-hA2AR). Interestingly, the 
2000P PMAS at pH 7.0 gave results with a lower Bmax of 4.9 ±1.0 pmol mg
-1
. Moreover, 
pharmacological characterisation of the receptor showed that the solubilised MT-hA2AR in 
2000P pH 11.0 had activity comparable to both the membrane-bound receptor and previous 
literature results: NECA>ZM241385>XAC>theophylline (Singh et al, 2010; Fraser, 2006). The 
affinity for NECA was significantly increased for all PMAS and DDM solubilisations when 
compared to the membrane-bound MT-hA2AR and for theophylline, the 2000P pH 11.0 was the 
only PMAS to increase the affinity of the MT-hA2AR. This suggests that the 2000P pH 11.0 did 
not reduce the affinity of the hA2AR to any of the antagonists or agonist. 
The 1600ME (pH 7.0 = 5.4 ±1.6 pmol mg
-1 
and pH 11 = 5.2 ±1.8 pmol mg
-1
) gave Bmax results 
not dissimilar to the DDM solubilisation (5.6 ±2.3 pmol mg
-1
). This PMAS was the lowest in 
molecular weight (~1600) and partial esterification was performed where the anhydride rings 
were opened with methanol and NaOH. The esterification of the PMAS (1600ME pH 7.0 and 
pH 11.0) made a notable difference in the solubilisation capability in these experiments as 
without the functionalising with methanol; the PMAS (1600 pH 7.0 and pH 11.0) was not able 
to solubilise the membrane. This was an expected result as the introduction of methyl ester 
moieties increased the number of hydrophobic regions of the polymer chain. Consequently, it is 
thought that more hydrophobic binding sites for the lipids are present and therefore can de-
stabilise the lipid assemblies within the cell membrane more readily (Ladaviere et al., 2002, 
Thomas and Tirrell, 2000).  Longer polymer chain lengths are also thought to increase the 
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hydrophobic regions and thereby increase the chance of disrupting the cell membrane lipids. 
However, from these data, it can be seen that the addition of methyl ester groups had more of an 
effect (1600ME, molecular weight ≈ 1600 g mol-1) than chain length 1000F (no methyl ester 
groups, molecular weight ≈ 5500g mol-1). The 2000P however, did not have any esterification 
modifications, yet gave the best (2000P pH 11.0) solubilising results. This could be due to the 
ratio of styrene to maleic anhydride, where the ratio is 2 styrene : 1 maleic anhydride, therefore 
there are twice as many hydrophobic moieties than hydrophilic ones in the polymer chain. 
Hence, these polymers could have more hydrophobic binding sites for the lipids and therefore 
more chance of disruption of the cell membrane (Ladaviere et al., 2002, Thomas and Tirrell, 
2000).  
Investigating the type of lipid in the 2000P pH 11.0 PMAS solubilisations revealed that DMPC 
and CHS gave differing affinities for the MT-hA2AR receptor (2000P pH 11.0 plus DMPC pKd 
= 8.9 ±1.4 and 2000P pH 11.0 plus CHS pKd = 9.5 ±0.6) but the Bmax values were similar 
(2000P pH 11.0 plus DMPC Bmax = 6.4 pmol mg
-1
 and 2000P pH 11.0 plus CHS Bmax = 6.1 
pmol mg
-1
). The lipid type was tested because previously (Knowles et al, 2009; Rajesh et al, 
2010; Jamshad et al, 2011) no explanation was given why DMPC was chosen as the lipid to 
supplement the solubilisation reaction. Also in DDM solubilisations, the cholesterol derivative, 
cholesteryl hemisuccinate (CHS) is routinely used. Cholesterol is known to interact with 
membrane proteins directly (Paila and Chattopadhyay, 2010). In mammalian cells, it is a major 
component of the outer cell membranes constituting about half of the total lipids (Lee, 2011). It 
is known that cholesterol affects the ligand binding to many GPCRs and also increase their 
thermal stability. Hanson and colleagues (2008) resolved the structure of the β2-adrenergic 
receptor with a specific cholesterol binding site where 2 cholesterol molecules were bound in a 
cleft. The side of the cleft comprised helices I and IV and the back of the cleft was made of 
helices II and III (Hanson and Stevens, 2009). Contrastingly in the same year, Jaakola and 
colleagues resolved the structure of the human adenosine A2A receptor and showed that 
phospholipid was bound in the same area instead of cholesterol (Jaakola et al., 2008). However, 
cholesterol is still deemed to be a major stabiliser for hA2AR as a molecular dynamics 
simulation revealed that the binding of cholesterol in the cleft affects function by changing the 
conformation of helix II (Lyman et al., 2009). Yet its precise interaction with GPCRs is 
ambiguous; it is not clear whether it is attributed to indirect bilayer effects or to specific 
receptor binding and putative non-annular binding sites (Paila and Chattopadhyay, 2010).  The 
literature however suggests that the presence of cholesterol modifies GPCR activity and the 
associated specific response appears to be receptor dependent. Additionally, some experiments 
have shown that both up-regulation and down-regulation are possible as are both direct and 
indirect actions (Oates and Watts, 2011). The experimental evidence is unclear as a number of 
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GPCRs can be produced in host systems that do not produce native cholesterol such as E. coli 
(Weiß and Grisshammer, 2002, Attrill et al., 2009), the GPCRs are stable, as determined by 
ligand binding and some are able to activate G proteins (Grisshammer and Hermans, 2001). 
This was certainly the case for the data in this thesis where correctly folded MT-hA2AR was 
produced in P. pastoris membrane in the absence of cholesterol (ergosterol is present instead in 
the P. pastoris membranes) and moreover, the receptor remained stable during PMAS 
extraction supplemented with only phospholipid (DMPC). This was also the case with PMAS 
and CHS as well, however, the pKd increased from 8.9 ±1.4 (PMAS plus DMPC) to 9.5 ±0.6 
(PMAS plus CHS) suggesting the affinity of the receptor had increased and therefore an 
alteration had occurred during this solubilisation. Contrastingly, when the DDM plus DMPC 
solubilisation was explored, Bmax was zero for MT-hA2AR, whereas DDM plus CHS gave a Bmax 
of 5.2 pmol mg
-1
 and a pKd of 8.2 ±0.2. Here the data suggest that the detergent-lipid and 
polymer-lipid combinations are influencing the stability of the receptor and furthermore the 
PMAS solubilisation seems to be more flexible in terms of using either DMPC or CHS as the 
supplementing lipid for MT-hA2AR solubilisations.  
For future considerations regarding this work, it would be important to optimise the purification 
of 2000P pH 11.0 for down-stream biophysical analysis such as circular dichroism (CD), 
analytical ultra-centrifugation (AUC) and NMR studies.  It would be valuable to retrieve 
transmission electron microscopy (TEM) images, to observe exactly the types of structures that 
are formed with the hA2AR, the lipid and PMAS. Further work on the type of lipid 
(phospholipid or cholesterol or both) for the PMAS solubilisations and testing whether this is a 
receptor-dependent phenomenon would be fruitful. Moreover, developing modified PMAS with 
lipid molecules already present may even simplify and improve the solubilisation further. For 
example, functionalising the 2000P PMAS with a cholesterol molecule may improve the 
solubilisation further. There is also a necessity for performing thermostability experiments for 
the polymers and the solubilisation mixtures themselves. 
6.3. Using DoE for hA2AR production improvement in yeast 
In industry, the DoE approach is widely used in order to improve upon product quality and 
process efficiency (Mandenius and Brundin, 2008). Recently DoE has been increasingly applied 
to the biotechnology industries especially concerning bioprocess development - specifically 
recombinant protein production. Although the approach has made the transition to recombinant 
protein production, so far it has been applied to soluble proteins only (Bora et al., 2012) and to 
date, there is a lack of evidence in the literature that membrane proteins have been studied in 
this way. 
220 
 
This thesis applied DoE methodology to improve production of the membrane protein, hA2AR in 
S. cerevisiae strains. The main difference between soluble proteins and membrane proteins is 
that a direct assay can be used to measure the soluble protein product, while membrane proteins 
such as hA2AR are assayed indirectly (membrane fractions must be prepared). DoE relies on an 
accurate output response to be fed back into the model (Montgomery, 2006). Each extra stage 
between production and assay has the potential to introduce error into the output response, 
which is a challenge when working with membrane proteins and perhaps this is a reason why 
DoE has previously been confined to soluble proteins research only. 
However, work in this thesis demonstrated that DoE can be applied to membrane protein 
research. Optimal conditions were retrieved for hA2AR production in a wild type strain of S. 
cerevisiae that were 22°C, pH 6.0, 30% DO and no DMSO additive in the culture. These 
conditions are typical growth and induction conditions for hA2AR production (Fraser, 2006; 
Singh et al., 2008) and it was interesting that the input conditions did not deviate from these 
standard levels despite the significant errors associated with the DoE approach that were 
identified in this thesis. This work should be improved upon to in order to reduce the error and 
therefore generate a more robust DoE model.  
Some future considerations to enable this would be to minimise the user handling as much as 
possible. This could be achieved with the use of automation and robotic platforms. Such 
systems are already in place for other biological assays in the genomics field for DNA 
microarray work (Illumina Inc. and Affymetrix Inc.). Of course, one limitation is that these 
systems require sophisticated engineering and are very expensive. However, the cost of the 
experiment may be equal to or even cheaper than repeating highly variable experiments. Figure 
6.1 shows a proposed schematic of what an automated system should be capable of doing for 
optimal, high throughput screening of membrane protein production in yeast. 
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Figure 6.1 Schematic for proposed automation on of membrane protein production using 
DoE and Micro-24 microreactor. The scheme is a flow diagram of all the major processes 
required from the concept of DoE to obtaining the output radio-ligand binding assay. These 
include the choice of membrane protein, the choice of input factors, to running the Micro-24 
microreactor, carrying out the membrane preparations, total protein quantification and radio-
ligand binding assays all with automated capabilities. 
A further improvement for the Micro-24 microreactor, making it more comparable to larger 
scale bioreactors, would be to introduce fed-batch systems of feeding via a multiple pump. This 
would be specifically applicable to P. pastoris for feeding methanol into the wells at a known 
amount and rate. Figure 6.2 shows a sketch of a possible set-up. The caps of the Micro-24 wells 
would be fitted with micro-tubing whilst maintaining their valve capacity. The tubing could be 
attached to one or several pumps which are connected to the desired feeds in separate vessels. 
This approach negates the need to stop a run and manually feed each well in a batch style. 
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Figure 6.2 Sketch of Micro-24 well plate with modifications. Each well cap would have an 
inserted micro-tubing for the correct volume. This will be connected to a variable pump speed 
which would pump the feed into wells without the need to open the wells.  
In conclusion, this thesis met the objectives set out for increasing hA2AR yields in two species of 
yeast, P. pastoris and S. cerevisiae, by investigating large and small scale cultivations and also 
examining the use of novel polymers for extracting hA2AR in a stable manner. 
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8. Appendices 
A1. Classification of GPCRs 
Since the GPCRs comprise of a ‗super-family‘ of membrane proteins, there have been many 
efforts to classify them into classes and groups on the basis of sequences, mutation data and 
ligand binding data (Schioth and Fredriksson, 2005). In spite of this, there still is no 
international standardised system to classify them. The two most common systems that are 
currently used to classify GPCRs are the A–F system developed in 1994 by Attwood and 
Findlay and also Kolakowski (Kolakowski Jr, 1994, Attwood and Findlay, 1994) and the 
GRAFS (Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, Secretin) system developed by 
Fredriksson and colleagues in 2003 (Fredriksson et al., 2003). The A-F system includes: 
 Class A = Rhodopsin-like 
 Class B = Secretin receptor family 
 Class C = Metabotropic glutamate  
 Class D = Fungal mating pheromone receptors 
 Class E = Cyclic AMP receptors 
 Class F = Frizzled/Smoothened 
This system developed by Attwood, Findlay and Kolakowski (Attwood and Findlay, 1994, 
Kolakowski Jr, 1994), grouped GPCRs into six families for both vertebrates and invertebrates 
based on >20% amino acid homology within the transmembrane helix domains. However, the 
shortcomings of this type of classification include no categorisation for mammalian GPCRs 
such as adhesion and vomeronasal 1 and taste 2 receptors. This is main reason why the GRAFS 
system is becoming more popular for studying the taxonomy of GPCRs.  
The Glutamate (metabotropic) receptor family are typically characterised by a ―venus fly trap‖ 
amino acid N – terminus which is extremely large (~ 600 amino acids in length) and also a very 
short intracellular loop. The family includes eight metabotropic glutamate receptors, two γ 
aminobutyric acid (GABA) receptors, a single calcium sensing receptor (CaSR) and taste 
receptor type 1. There is a recognized disulphide bridge between TM3 and ECL2, and no other 
defining signatures or motifs for this family.of GPCRs (Schioth and Fredriksson, 2005). 
The Rhodopsin receptor family are the largest family of GPCRs in vertebrates. The GRAFS 
system further classifies this family into four smaller groups: α, β, γ and δ. The α group include 
amine binding GPCRs, several peptide binding and prostaglandin receptors. The β group 
include receptors that bind peptides as long as the ligands are known. The γ group consists of 
peptide binding receptors such as chemokine receptors and ones that may bind to neuropeptides 
such as somatostatins and opioids. The final group, δ, these receptors are olfactory, purine and 
glycoprotein receptors (Schioth and Fredriksson, 2005). This family has highly conserved 
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residues such as NSxxNPxxY motif in TM7, the DRY motif or D(E)-R-Y(F) at the border 
between TM3 and IL2, (N/S)LxxxD in TM2, the CWXP motif in TM6, GN in TM1 and finally 
HX in the cytoplasmic helix. There is also the presence of a palmitoylated cysteine in the 
carboxyl tail (Fredriksson et al., 2003).  
The Adhesion family are a small group of GPCRs and in general tend to have long N-termini 
containing a high amount of serine and threonine residues that can function as O- and N- 
glycosylation sites. They are thought to form rigid structures on the surface of cells due to the 
mucin-derived domains present (Schioth and Fredriksson, 2005). 
The Frizzled/Taste2 family include a relatively recent group of GPCRs. Frizzled receptors are 
thought to be involved in cell fate and proliferation by mediating signals from secreted 
glycoproteins. They are about 200 amino acids residues in length with a long N- termini and 
conserved cysteines. The Taste2 receptors are thought to be ‗bitter taste‘ receptors. They share 
several common features among the human consensus sequences with the frizzled receptors and 
hence are in the same group despite their quite different downstream physiological function 
(Schioth and Fredriksson, 2005). 
The Secretin family has structural similarities with the adhesion family, and in the A-F system, 
they are classed the same. The GRAFS separates them due to major differences in the N-
termini. The N-termini are very long, between 60 and 80 amino acids with cysteine bridges 
(Schioth and Fredriksson, 2005). 
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A2. MT-hA2AR DNA and amino acid sequence alignment 
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A3. MT-hA2AR sequence alignment 
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A4. Linear regression analysis for d-optimal DoE (Minitab
®
 output data) 
General Linear Model: BMS1 binding versus Temp, pH, dO, DMSO  
 
Factor  Type   Levels  Values 
Temp    fixed       3  22, 24, 26 
pH      fixed       3  5.0, 5.5, 6.0 
dO      fixed       3  30, 40, 50 
DMSO    fixed       2  Present, Absent 
 
 
Analysis of Variance for BMS1 binding, using Adjusted SS for Tests 
 
Source     DF  Seq SS  Adj SS  Adj MS     F      P 
Temp        2   540.2    28.1    14.1  0.14  0.872 
pH          2  1477.0  1465.8   732.9  7.15  0.002 
dO          2   784.3   677.0   338.5  3.30  0.044 
DMSO        1    96.8    67.6    67.6  0.66  0.420 
Temp*DMSO   2    17.2    15.1     7.5  0.07  0.929 
pH*dO       4  1204.6  1168.9   292.2  2.85  0.032 
pH*DMSO     2    88.1    68.8    34.4  0.34  0.716 
dO*DMSO     2    69.7    69.7    34.9  0.34  0.713 
Error      54  5538.2  5538.2   102.6 
Total      71  9816.0 
 
 
S = 10.1271   R-Sq = 43.58%   R-Sq(adj) = 25.82% 
 
 
Term            Coef  SE Coef      T      P 
Constant      16.250    1.307  12.44  0.000 
Temp 
22             0.933    4.318   0.22  0.830 
24            -1.916    4.318  -0.44  0.659 
pH 
5.0           -4.412    2.050  -2.15  0.036 
5.5           -2.229    2.349  -0.95  0.347 
dO 
30            -2.979    2.050  -1.45  0.152 
40             4.520    1.853   2.44  0.018 
DMSO 
Present       -1.020    1.256  -0.81  0.420 
Temp*DMSO 
22   Present  -1.062    2.926  -0.36  0.718 
24   Present   0.578    1.864   0.31  0.758 
pH*dO 
5.0 30         3.880    4.256   0.91  0.366 
5.0 40        -6.466    3.228  -2.00  0.050 
5.5 30         1.470    3.007   0.49  0.627 
5.5 40        -7.054    3.469  -2.03  0.047 
pH*DMSO 
5.0 Present    0.125    2.333   0.05  0.957 
5.5 Present    1.383    2.671   0.52  0.607 
dO*DMSO 
30 Present     0.018    2.333   0.01  0.994 
40 Present    -1.504    1.860  -0.81  0.422 
 
 
Unusual Observations for BMS1 binding 
 
        BMS1 
Obs  binding      Fit  SE Fit  Residual  St Resid 
 13  65.1400  42.4705  5.4832   22.6695      2.66 R 
 37  24.2100  42.4705  5.4832  -18.2605     -2.14 R 
 
R denotes an observation with a large standardized residual. 
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General Linear Model: WT binding versus Temp, pH, dO, DMSO  
 
Factor  Type   Levels  Values 
Temp    fixed       3  22, 24, 26 
pH      fixed       3  5.0, 5.5, 6.0 
dO      fixed       3  30, 40, 50 
DMSO    fixed       2  Present, Absent 
 
 
Analysis of Variance for WT binding, using Adjusted SS for Tests 
 
Source     DF  Seq SS  Adj SS  Adj MS      F      P 
Temp        2   23706   69002   34501  14.00  0.000 
pH          2   35748   66068   33034  13.40  0.000 
dO          2   17938   13732    6866   2.79  0.071 
DMSO        1   12744   12484   12484   5.07  0.028 
Temp*DMSO   2   44983   49351   24675  10.01  0.000 
pH*dO       4   23547   31295    7824   3.17  0.020 
pH*DMSO     2   59891   70268   35134  14.26  0.000 
dO*DMSO     2   18633   18633    9316   3.78  0.029 
Error      54  133078  133078    2464 
Total      71  370267 
 
 
S = 49.6428   R-Sq = 64.06%   R-Sq(adj) = 52.74% 
 
 
Term             Coef  SE Coef      T      P 
Constant       32.550    6.405   5.08  0.000 
Temp 
22              93.68    21.17   4.43  0.000 
24             -44.12    21.17  -2.08  0.042 
pH 
5.0             10.17    10.05   1.01  0.316 
5.5            -51.90    11.52  -4.51  0.000 
dO 
30              -4.68    10.05  -0.47  0.643 
40            -19.007    9.082  -2.09  0.041 
DMSO 
Present       -13.855    6.156  -2.25  0.028 
Temp*DMSO 
22   Present   -64.17    14.34  -4.47  0.000 
24   Present   24.456    9.140   2.68  0.010 
pH*dO 
5.0 30          15.02    20.86   0.72  0.475 
5.0 40          19.93    15.83   1.26  0.213 
5.5 30         -30.54    14.74  -2.07  0.043 
5.5 40         -25.20    17.00  -1.48  0.144 
pH*DMSO 
5.0 Present    -28.55    11.44  -2.50  0.016 
5.5 Present     66.05    13.09   5.04  0.000 
dO*DMSO 
30 Present      14.54    11.44   1.27  0.209 
40 Present     19.402    9.117   2.13  0.038 
 
 
Unusual Observations for WT binding 
 
Obs  WT binding      Fit  SE Fit  Residual  St Resid 
  7     421.300  279.780  26.604   141.520      3.38 R 
 31     462.960  279.780  26.604   183.180      4.37 R 
 55      77.510  279.780  26.604  -202.270     -4.83 R 
 
R denotes an observation with a large standardized residual. 
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General Linear Model: TM6 Binding versus Temp, pH, dO, DMSO  
 
Factor  Type   Levels  Values 
Temp    fixed       3  22, 24, 26 
pH      fixed       3  5.0, 5.5, 6.0 
dO      fixed       3  30, 40, 50 
DMSO    fixed       2  Present, Absent 
 
 
Analysis of Variance for TM6 Binding, using Adjusted SS for Tests 
 
Source     DF   Seq SS   Adj SS  Adj MS     F      P 
Temp        2   200.51    16.93    8.46  0.23  0.795 
pH          2   322.38    93.53   46.77  1.27  0.288 
dO          2   357.18   631.05  315.53  8.60  0.001 
DMSO        1    55.28    49.67   49.67  1.35  0.250 
Temp*DMSO   2   275.99   339.09  169.55  4.62  0.014 
pH*dO       4   452.83   341.64   85.41  2.33  0.068 
pH*DMSO     2   453.37   172.95   86.47  2.36  0.105 
dO*DMSO     2   179.50   179.50   89.75  2.45  0.096 
Error      54  1982.26  1982.26   36.71 
Total      71  4279.30 
 
 
S = 6.05875   R-Sq = 53.68%   R-Sq(adj) = 39.10% 
 
 
Term            Coef  SE Coef      T      P 
Constant      6.9435   0.7817   8.88  0.000 
Temp 
22             1.723    2.583   0.67  0.508 
24            -1.619    2.583  -0.63  0.533 
pH 
5.0            0.140    1.226   0.11  0.910 
5.5            1.591    1.405   1.13  0.263 
dO 
30            -3.828    1.226  -3.12  0.003 
40            -1.941    1.108  -1.75  0.086 
DMSO 
Present       0.8740   0.7513   1.16  0.250 
Temp*DMSO 
22   Present  -4.643    1.751  -2.65  0.010 
24   Present   3.056    1.115   2.74  0.008 
pH*dO 
5.0 30         3.476    2.546   1.37  0.178 
5.0 40         0.440    1.931   0.23  0.821 
5.5 30        -3.897    1.799  -2.17  0.035 
5.5 40        -3.477    2.075  -1.68  0.100 
pH*DMSO 
5.0 Present   -2.409    1.396  -1.73  0.090 
5.5 Present    3.452    1.598   2.16  0.035 
dO*DMSO 
30 Present    -1.109    1.396  -0.79  0.431 
40 Present    -2.069    1.113  -1.86  0.068 
 
 
Unusual Observations for TM6 Binding 
 
Obs  TM6 Binding      Fit  SE Fit  Residual  St Resid 
  6      60.6500  30.6173  3.2470   30.0327      5.87 R 
 
R denotes an observation with a large standardized residual. 
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A5. Response surface regression analysis for RSM DoE (Minitab
®
 output data) 
Response Surface Regression: WT binding versus Temp, pH, dO, DMSO1  
 
The following terms cannot be estimated, and were removed. 
 
DMSO1*DMSO1 
 
 
The analysis was done using coded units. 
 
Estimated Regression Coefficients for WT binding 
 
Term           Coef  SE Coef       T      P 
Constant    -47.039   24.446  -1.924  0.063 
Temp        -24.282   11.583  -2.096  0.044 
pH           38.203   10.137   3.769  0.001 
dO           -9.841   12.207  -0.806  0.426 
DMSO1         3.557    9.621   0.370  0.714 
Temp*Temp    14.641   17.706   0.827  0.414 
pH*pH        57.073   21.012   2.716  0.010 
dO*dO        46.972   17.652   2.661  0.012 
Temp*pH     -48.646   14.327  -3.395  0.002 
Temp*dO      51.063   16.233   3.146  0.003 
Temp*DMSO1   21.934   15.234   1.440  0.159 
pH*dO       -34.651   13.004  -2.665  0.012 
pH*DMSO1    -33.166   11.262  -2.945  0.006 
dO*DMSO1      3.757   12.307   0.305  0.762 
 
 
S = 53.5882    PRESS = 207603 
R-Sq = 73.29%  R-Sq(pred) = 43.20%  R-Sq(adj) = 63.07% 
 
 
Analysis of Variance for WT binding 
 
Source          DF  Seq SS  Adj SS   Adj MS       F      P 
Regression      13  267884  267884  20606.5    7.18  0.000 
  Linear         4   85983   51639  12909.9    4.50  0.005 
    Temp         1   19259   12621  12620.6    4.39  0.044 
    pH           1   35281   40788  40788.3   14.20  0.001 
    dO           1   12583    1866   1866.4    0.65  0.426 
    DMSO1        1   18860     393    392.5    0.14  0.714 
  Square         3   32897   38252  12750.7    4.44  0.010 
    Temp*Temp    1    7566    1964   1963.6    0.68  0.414 
    pH*pH        1   17886   21187  21187.5    7.38  0.010 
    dO*dO        1    7445   20334  20333.6    7.08  0.012 
  Interaction    6  149004  149004  24834.0    8.65  0.000 
    Temp*pH      1   32019   33107  33106.9   11.53  0.002 
    Temp*dO      1   54971   28416  28415.6    9.90  0.003 
    Temp*DMSO1   1   14899    5953   5953.4    2.07  0.159 
    pH*dO        1   20916   20390  20390.0    7.10  0.012 
    pH*DMSO1     1   25933   24904  24904.3    8.67  0.006 
    dO*DMSO1     1     268     268    267.5    0.09  0.762 
Residual Error  34   97638   97638   2871.7 
  Lack-of-Fit    8   95599   95599  11949.9  152.43  0.000 
  Pure Error    26    2038    2038     78.4 
Total           47  365522 
 
 
Unusual Observations for WT binding 
 
Obs  StdOrder  WT binding      Fit  SE Fit  Residual  St Resid 
  7         7     421.300  333.633  32.779    87.667      2.07 R 
 17        17       2.410  121.894  27.182  -119.484     -2.59 R 
 31        31     462.960  333.633  32.779   129.327      3.05 R 
 41        41      10.230  121.894  27.182  -111.664     -2.42 R 
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R denotes an observation with a large standardized residual. 
 
 
Estimated Regression Coefficients for WT binding using data in uncoded units 
 
Term            Coef 
Constant     4134.36 
Temp        -22.4126 
pH          -990.099 
dO          -61.7212 
DMSO1        90.1532 
Temp*Temp    3.66037 
pH*pH        228.292 
dO*dO       0.469716 
Temp*pH     -48.6460 
Temp*dO      2.55317 
Temp*DMSO1   10.9670 
pH*dO       -6.93021 
pH*DMSO1    -66.3327 
dO*DMSO1    0.375654 
 
  
TEMP*TEMP REMOVED ONLY 
 
Response Surface Regression: WT binding versus Temp, pH, dO, DMSO1  
 
The following terms cannot be estimated, and were removed. 
 
DMSO1*DMSO1 
 
 
The analysis was done using coded units. 
 
Estimated Regression Coefficients for WT binding 
 
Term           Coef  SE Coef       T      P 
Constant    -36.111   20.473  -1.764  0.086 
Temp        -23.371   11.478  -2.036  0.049 
pH           39.056   10.038   3.891  0.000 
dO           -9.605   12.149  -0.791  0.435 
DMSO1         3.509    9.577   0.366  0.716 
pH*pH        56.942   20.916   2.722  0.010 
dO*dO        45.002   17.412   2.585  0.014 
Temp*pH     -49.926   14.179  -3.521  0.001 
Temp*dO      49.963   16.105   3.102  0.004 
Temp*DMSO1   21.661   15.161   1.429  0.162 
pH*dO       -36.773   12.690  -2.898  0.006 
pH*DMSO1    -34.365   11.118  -3.091  0.004 
dO*DMSO1      5.616   12.045   0.466  0.644 
 
 
S = 53.3456    PRESS = 200786 
R-Sq = 72.75%  R-Sq(pred) = 45.07%  R-Sq(adj) = 63.41% 
 
 
Analysis of Variance for WT binding 
 
Source          DF  Seq SS  Adj SS   Adj MS       F      P 
Regression      12  265920  265920  22160.0    7.79  0.000 
  Linear         4   85983   52711  13177.7    4.63  0.004 
    Temp         1   19259   11798  11798.3    4.15  0.049 
    pH           1   35281   43077  43077.3   15.14  0.000 
    dO           1   12583    1779   1778.7    0.63  0.435 
    DMSO1        1   18860     382    382.0    0.13  0.716 
  Square         2   24790   36288  18144.2    6.38  0.004 
    pH*pH        1   19287   21091  21091.3    7.41  0.010 
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    dO*dO        1    5503   19010  19010.3    6.68  0.014 
  Interaction    6  155148  155148  25858.0    9.09  0.000 
    Temp*pH      1   33235   35284  35283.7   12.40  0.001 
    Temp*dO      1   50320   27389  27388.6    9.62  0.004 
    Temp*DMSO1   1   15084    5809   5809.1    2.04  0.162 
    pH*dO        1   26804   23895  23895.1    8.40  0.006 
    pH*DMSO1     1   29087   27188  27187.8    9.55  0.004 
    dO*DMSO1     1     619     619    618.7    0.22  0.644 
Residual Error  35   99601   99601   2845.7 
  Lack-of-Fit    9   97563   97563  10840.3  138.28  0.000 
  Pure Error    26    2038    2038     78.4 
Total           47  365522 
 
 
Unusual Observations for WT binding 
 
Obs  StdOrder  WT binding      Fit  SE Fit  Residual  St Resid 
  7         7     421.300  332.662  32.610    88.638      2.10 R 
 17        17       2.410  115.599  25.977  -113.189     -2.43 R 
 31        31     462.960  332.662  32.610   130.298      3.09 R 
 41        41      10.230  115.599  25.977  -105.369     -2.26 R 
 
R denotes an observation with a large standardized residual. 
 
 
Estimated Regression Coefficients for WT binding using data in uncoded units 
 
Term            Coef 
Constant     1653.14 
Temp         162.980 
pH          -934.920 
dO          -56.4675 
DMSO1        99.1231 
pH*pH        227.767 
dO*dO       0.450021 
Temp*pH     -49.9259 
Temp*dO      2.49817 
Temp*DMSO1   10.8307 
pH*dO       -7.35469 
pH*DMSO1    -68.7304 
dO*DMSO1    0.561647 
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A6. Patent application for PMAS work showing claims (application number GB 
1312343.5, authors, Bawa Z, Bill R.M., Campbell D, Mahomed A and Tighe B.J.) 
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A7. Oral presentation at Aston University Post-graduate research day (June 2012). 
Awarded 1
st
 prize. 
Improving membrane protein production 
in yeast -
the effect of induction phase growth rates on the 
functional yield of adenosine 2a receptor produced in 
P. pastoris
by
Zharain Bawa
 
They play pivotal roles in all cellular processes
They mediate a wide variety of processes 
e.g. cell-cell interactions
They are ubiquitous
~30% of all proteins in all cells are membrane proteins
They are already key drug targets
The majority of prescription pharmaceuticals on the market 
are targeted to membrane proteins, particularly
G protein-coupled receptors (GPCRs)
Human adenosine 2a receptor (hA2aR)
Membrane proteins play a disproportionately 
large role in health and disease
 
263 
 
Membrane proteins: Drug discovery 
challenges
To enable further drug discovery in a rational manner
Structure 
Function
Biochemistry
This is proving to be challenging because:
Membrane proteins rely on the membrane to retain their   
structure and function
Low abundance
 
Hosts for membrane protein production
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Yeast – Pichia pastoris
Eukaryote: similar to mammalian 
cells
Rapid cell growth, high yields and 
cheap
Grow on methanol
Protein structures resolved which 
have contributed to the drug 
discovery pipeline
The Biochemist 2010 32:5 pg15
 
Pichia pastoris and making GPCRs
Genetically engineered to over-produce the protein we want by simply 
changing the type of feed (carbon source)      induction
x 
B
io
m
a
ss
GLYCEROL FEED METHANOL FEED
INDUCTION
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Aim
To explore the influence of the methanol feeding rate on the production 
of hA2aR in P. pastoris
x 
B
io
m
a
ss
METHANOL FEED RATE:
FAST OR SLOW?
 
How? By using Bioreactors
Bioreactors used to control process conditions such as temperature, 
pH, aeration and addition of carbon source – not possible in shake 
flasks
 
266 
 
35 L Bioreactor at AstraZeneca Facility
Control 
software
Mass Spec for 
off gas 
analysis
35 L 
Bioreactor 
vessel
Pumps for 
feeds, acid, 
base and anti-
foam
Me
 
Cell biomass increases with lower methanol feed 
rate (µLow). Final biomass of µLow is double the 
final biomass of µHigh
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A low methanol induction feed rate has an overall positive 
effect on cell biomass and hA2aR production
µHigh
µLow
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The presence of glycerol does not repress production
of hA2aR
Cultivation phase Age (h) µlow µhigh µlow µhigh
IIIA 42.2 4.4 (0.1) 4.4 (0.2) 0 (0) 2.9 (0.1)
IIIB 44.4 7.1 (0.6) ** 4.0 (0.0) 1.1 (0.2) 4.2 (0.2)
IV 66.4 4.5 (0.2) * 3.8 (0.1) 0 (0) 1.1 (0.2)
V 88.9 5.0 (0.2) ** 3.1 (0.1) 0 (0) 0 (0)
Bmax estimate (pmol mg 
-1) Residual glycerol  (g L -1)
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Baseline hA2aR production is present during glycerol
phase in another cultivation at Aston
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This is also true for another protein, Green 
Fluorescent Protein (GFP)
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Discussion Part 1 
µLow cultivation gave overall high biomass and high hA2aR 
yields
µLow showed low amounts of residual methanol in cultivation  
(< 3 g L-1) from feeding the cells slowly
µHigh showed increasing amounts of residual methanol           
(~ 80 g L -1) from feeding the cells quickly
 
Discussion Part 2
In literature, soluble proteins tend to increase during low feeding 
rates and biomass only increases during high feeding rates
Different to what we found: low feeding rate gave high hA2aR 
AND biomass
Suggests other factors influence production of membrane 
proteins
Maybe more important to increase biomass? More cells = more 
membranes = more membrane proteins to be inserted
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Discussion Part 3
hA2aR production was detected when glycerol present in 
cultivation
Unexpected as glycerol represses protein production
This was the same for GFP as well
Unusual and potentially controversial finding
 
Conclusion
Applying a slow methanol feed strategy 
to yeast (P. pastoris) is critical for 
maximum GPCR yields
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